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Abstract
A cost-effectiveness modelling study of strategies to reduce
risk of infection following primary hip replacement based
on a systematic review
Nicholas Graves,1* Catherine Wloch,2 Jennie Wilson,3
Adrian Barnett,1 Alex Sutton,4 Nicola Cooper,4
Katharina Merollini,1 Victoria McCreanor,1 Qinglu Cheng,1
Edward Burn,1 Theresa Lamagni2 and Andre Charlett2
1School of Public Health and Social Work, Queensland University of Technology, Brisbane,
QLD, Australia
2Public Health England, Colindale, UK
3College of Nursing, Midwifery and Healthcare, University of West London, London, UK
4Department of Health Sciences, University of Leicester, Leicester, UK
*Corresponding author n.graves@qut.edu.au
Background: A deep infection of the surgical site is reported in 0.7% of all cases of total hip arthroplasty
(THA). This often leads to revision surgery that is invasive, painful and costly. A range of strategies is
employed in NHS hospitals to reduce risk, yet no economic analysis has been undertaken to compare the
value for money of competing prevention strategies.
Objectives: To compare the costs and health benefits of strategies that reduce the risk of deep infection
following THA in NHS hospitals. To make recommendations to decision-makers about the cost-effectiveness
of the alternatives.
Design: The study comprised a systematic review and cost-effectiveness decision analysis.
Setting: 77,321 patients who had a primary hip arthroplasty in NHS hospitals in 2012.
Interventions: Nine different treatment strategies including antibiotic prophylaxis, antibiotic-impregnated
cement and ventilation systems used in the operating theatre.
Main outcome measures: Change in the number of deep infections, change in the total costs and
change in the total health benefits in quality-adjusted life-years (QALYs).
Data sources: Literature searches using MEDLINE, EMBASE, Cumulative Index to Nursing and Allied
Health Literature and the Cochrane Central Register of Controlled Trials were undertaken to cover the
period 1966–2012 to identify infection prevention strategies. Relevant journals, conference proceedings
and bibliographies of retrieved papers were hand-searched. Orthopaedic surgeons and infection prevention
experts were also consulted.
Review methods: English-language papers only. The selection of evidence was by two independent
reviewers. Studies were included if they were interventions that reported THA-related deep surgical site
infection (SSI) as an outcome. Mixed-treatment comparisons were made to produce estimates of the
relative effects of competing infection control strategies.
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Results: Twelve studies, six randomised controlled trials and six observational studies, involving 123,788
total hip replacements (THRs) and nine infection control strategies, were identified. The quality of the
evidence was judged against four categories developed by the National Institute for Health and Care
Excellence Methods for Development of NICE Public Health Guidance (http://publications.nice.org.uk/
methods-for-the-development-of-nice-public-health-guidance-third-edition-pmg4), accessed March 2012.
All evidence was found to fit the two highest categories of 1 and 2. Nine competing infection control
interventions [treatments (Ts) 1–9] were used in a cohort simulation model of 77,321 patients who had a
primary THR in 2012. Predictions were made for cases of deep infection and total costs, and QALY outcomes.
Compared with a baseline of T1 (no systemic antibiotics, plain cement and conventional ventilation) all other
treatment strategies reduced risk. T6 was the most effective (systemic antibiotics, antibiotic-impregnated
cement and conventional ventilation) and prevented a further 1481 cases of deep infection, and led to the
largest annual cost savings and the greatest gains to QALYs. The additional uses of laminar airflow and body
exhaust suits indicate higher costs and worse health outcomes.
Conclusions: T6 is an optimal strategy for reducing the risk of SSI following THA. The other strategies that
are commonly used among NHS hospitals lead to higher cost and worse QALY outcomes. Policy-makers,
therefore, have an opportunity to save resources and improve health outcomes. The effects of laminar air
flow and body exhaust suits might be further studied if policy-makers are to consider disinvesting in
these technologies.
Limitations: A wide range of evidence sources was synthesised and there is large uncertainty in
the conclusions.
Funding: The National Institute for Health Research Health Technology Assessment programme and the
Queensland Health Quality Improvement and Enhancement Programme (grant number 2008001769).
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Plain English summary
Patients who undergo total hip replacement surgery are at risk of developing a deep infection in thesurgical site. Risks are low, but the consequences are potentially serious, especially for older and frail
people. Patients often need costly revision surgery, which can be painful and reduces their quality of life;
for some, the result is permanent disability.
A range of strategies is available to reduce the risk of infection following surgery, including injected
antibiotics, antibiotic-impregnated cement to fix the artificial hip, different types of ventilation systems in
operating theatres and operator body exhaust suits. These strategies can be used on their own or in
combinations. This research is about the changes to cost and health benefits of different combinations of
strategies designed to reduce infection risk following surgery.
Our results suggest that a combination of injected antibiotics, antibiotic-impregnated cement and
conventional theatre ventilation systems without exhaust body suits is the best strategy for reducing the
risk of infection following hip replacement surgery. It is also the most likely strategy to be cost-effective.
The results suggest that expensive laminar airflow ventilation systems and body exhaust suits used in many
operating theatres lead to higher costs and higher infection risk, and so should not be used.
DOI: 10.3310/hta20540 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 54
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Graves et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xix

Scientific summary
Background
Total hip arthroplasty (THA) is common in the UK, and demand is rising as the population ages. There are
risks with THA, and deep infection of the surgical site is reported in 0.7% of all cases. This uses up scarce
health-care resources and impacts on the patients’ quality of life. Deep infections often lead to revision
surgery, which is invasive, painful and costly. A range of strategies is employed in NHS hospitals to reduce
the risk of deep infection following THA. However, no economic analysis has been undertaken to compare
the value for money of competing prevention strategies. This information will enable policy-makers to
identify a cost-effective approach to managing the risks of infection among patients who have a primary
THA in NHS hospitals.
Objectives
To compare the costs and health benefits of strategies to reduce the risk of deep infection following THA in
NHS hospitals. To make recommendations to decision-makers about the cost-effectiveness of the alternatives.
Methods
An evidence synthesis exercise was completed and an economic decision-analytic model used to assess the
cost-effectiveness of nine different treatment strategies to reduce the risk of surgical site infection (SSI)
following THA carried out in NHS hospitals. Only deep infections were included. Superficial infections were
excluded because they are relatively easy to treat and are not associated with severe or long-term effects
for the patient.
Data sources and extraction
Literature searches using MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature and
the Cochrane Central Register of Controlled Trials, were undertaken to identify infection prevention
strategies in the period 1966–2012. Relevant journals, conference proceedings and bibliographies of
retrieved papers were hand-searched. Orthopaedic surgeons and infection prevention experts were also
consulted. The search was limited to English-language papers. The selection of evidence was conducted by
two independent reviewers and discrepancies were resolved. The patient, intervention, comparison and
outcome framework revealed the population consisted of patients undergoing total hip replacement (THR);
the intervention was infection control strategies to prevent THR-related SSI; the comparison was infection
control strategies compared with other control strategies in the mixed-treatment comparison network; and
the outcome was the number of THR-related SSIs. Studies were included if they were interventions that
reported THA-related deep SSI as an outcome. Antibiotic prophylaxis, antibiotic-impregnated cement and
ventilation systems used in the operating theatre were indicated. The key outcome variables evaluated were
total number of THRs performed and the total number of deep SSIs diagnosed following the THR procedures.
Data synthesis
A mixed-treatment comparison was used to synthesise evidence of effectiveness of nine different
treatment strategies, treatments (Ts) 1–9. The statistical method allowed estimates of the relative
effectiveness of each treatment in a network to be compared. Judgements based on existing evidence
were made regarding the size of the treatment effect. T1 was the reference for comparison and included
no antibiotic prophylaxis, plain cement and conventional ventilation without laminar airflow system.
This was trialled against eight other treatments.
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Economic modelling
We used a Markov model with health states to describe the treatment paths a patient could follow if they
developed a deep SSI after THA. These were debridement, antibiotics and implant retention, a one-stage
revision, the two stages of a two-stage revision and permanent resection. Also included were states for no
infection, deep infection and successful treatment. All states in the model were mutually exclusive and had
‘cost’ and ‘quality-of-life’ tariffs attributed to them. The probability of patients transitioning between states
over time was assigned. Costs and quality-adjusted life-years (QALYs) for each cycle were calculated for
each competing treatment strategy. The model was run for 5 years until all patients had transitioned
through the model. Total cost and QALYs across all cycles were summed for each treatment. Data to
inform model parameters were taken from relevant NHS databases that were linked together. It would not
be possible to run a prospective clinical trial to address the same research question.
Results
Twelve studies, of which six were randomised controlled trials and six were observational studies, involving
123,788 THRs and nine infection control strategies, were identified. The quality of the evidence was
judged against four categories developed by the National Institute for Health and Care Excellence’s
Methods for Development of NICE Public Health Guidance (http://publications.nice.org.uk/methods-for-the-
development-of-nice-public-health-guidance-third-edition-pmg4). All evidence was found to fit the two
highest categories of 1 and 2.
A cohort of 77,321 patients who had a primary THR in 2012 was simulated for conditions relevant to T1
(no systemic antibiotics, plain cement and conventional ventilation). All other treatment strategies reduced
risk and resulted in fewer cases of deep infection with T6 (systemic antibiotics, antibiotic-impregnated
cement and conventional ventilation) the most effective. T6 prevented a further 1481 cases of deep
infection and led to the largest annual cost savings of –£8,325,277 (95% uncertainty interval
–£17,981,040 to £5,765,832). The mean gains to health benefits measured by QALYs were greatest at
147 QALYs gained (95% uncertainty interval 585 to 1157 QALYs gained). Based on this analysis, T6 is the
optimal decision, with the highest probability of being cost-effective, at 32%. Other treatments that
include laminar airflow (T7) and the additional use of body exhaust suit (T9) are common among NHS
trusts, yet lead to both high costs and lower health outcomes (£5,053,528 higher costs and 23 fewer
QALYS for T7 vs. T6; and £9,106,352 higher costs and 84 fewer QALYS for T9 vs. T6).
Conclusions
The modelling results indicate that the combination of systemic antibiotics, antibiotic-impregnated cement
and conventional operating theatre ventilation (T6) is the most effective strategy for reducing the risk of
SSI following THA. It was associated with the greatest prevention of cases of SSI, the largest cost saving
and gains to QALYs. Other strategies that are commonly used among NHS hospitals lead to higher
cost and worse QALY outcomes. There are opportunities to save resources and improve health outcomes.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research and the Queensland Health Quality Improvement and Enhancement
Programme (grant number 2008001769).
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Chapter 1 Background and study objectives
In the UK, the incidence of primary total hip arthroplasty (THA) is 722 per 100,000 operations and thenumber of all hip procedures performed in 2012 was 86,488.1,2 Surgical site infections (SSIs) following
THAs have been reported to occur in 0.7% of patients,3 but this reflects only 1 year post surgery. Infections
are likely to lead to a prolonged hospital stay, increased mortality and reduced quality of life as well as
additional expenditures by health services and patients.4–6 A common consequence of infection is revision
surgery, which is very costly and negatively affects the quality of life of patients for a prolonged period.
Numerous approaches to preventing these infections exist, but practices vary and the cost-effectiveness of
alternative strategies is largely unknown. Systematic reviews of some infection prevention measures have
been undertaken, yet they do not address the related questions of which strategies or combination of
strategies are most effective in reducing infection risk and what decision-makers should do if they wish to be
efficient in the resource-constrained NHS.7–10 This research is about understanding competing infection
prevention methods relevant for THA in the NHS. Using an economic decision model, the cost-effectiveness
of each strategy and bundles of strategies are estimated. If a strategy can decrease the incidence of
infection following hip arthroplasty, costs could be saved and health outcomes improved. Extra infection
prevention does, however, incur additional costs. The change to total costs and health outcomes for each
strategy needs to be estimated and presented in a cost-effectiveness framework, and the results then
interpreted for decision-making.
Hip replacements are procedures in which the hip joint is partially or totally replaced by an artificial
prosthesis. This can be a primary replacement or a revision of a previous replacement that has failed.
The hip joint is a ball-and-socket joint, with the femoral head (top of the femur) sitting in the acetabular cup
of the pelvis. The three major components of an implant for THA are the stem, head and cup (Figure 1).
Partial replacements involve the replacement of the stem and/or head only, but not the acetabular
component. Major revisions involve the removal of the diseased or fractured joint and replacement with a
full artificial prosthesis.
FIGURE 1 Hip arthroplasty components.
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1
Incidence of infections and revisions among hip replacements
Data from 235 NHS and independent sector treatment centres are shown in Table 1. The information was
submitted as part of the Public Health England (PHE) national surveillance of SSI service.3 Data were
reported on 549,495 procedures and SSIs organised into 17 surgical categories from April 2008 to May
2013. Fifty-six per cent of hospitals that perform total hip replacement (THR) contributed data for patients
who underwent hip prosthesis surgery. They show a low cumulative incidence of SSI of 0.7% within 1 year
of hip prosthesis surgery. No clear trend was detected in the incidence over the 5-year period (Figure 2).
The National Joint Registry (NJR)11 collects data that quantify some of the long-term consequences of deep
infection, such as revisions. In 2012, 10,040 hip revision procedures were recorded, of which 12% were a
result of infection, compared with 11% in 2011.1 The burden of revision operations lies primarily with NHS
hospitals, which carried out 83% of revision procedures, compared with 15% in independent sector
hospitals. These statistics contrast with primary hip replacements, 69% of which were carried out in NHS
hospitals and 27% in independent hospitals. Patients who had a revision operation were also less fit than
patients undergoing primary hip replacement, with one-third of patients for revision surgery being
identified as grade 3 under the American Society of Anaesthetists scoring system.1
TABLE 1 Surgical site infection incidence by surgical category within NHS hospitals in England participating in the
PHE National SSI Surveillance Service between April 2008 and March 2013
Surgical
category
Number of
operations
Number of
hospitals
Number of
inpatients
Inpatient and
readmissions,
n (%)
Median
time to
infection
(days)
Incidence
density/1000
inpatient days
Abdominal
hysterectomy
5073 29 31 77 (1.5, 95% CI
1.2 to 1.9)
9 1.3 (95% CI
0.9 to 1.9)
Bile duct, liver
and pancreatic
surgery
2124 6 121 137 (6.5, 95% CI
5.4 to 7.6)
8 4.9 (95% CI
4.1 to 5.9)
Breasta 5081 20 7 52 (1.0, 95% CI
0.8 to 1.3)
13 0.7 (95% CI
0.3 to 1.5)
Cholecystectomy 887 6 31 37 (4.2, 95% CI
3.0 to 5.7)
7 4.6 (95% CI
3.1 to 6.6)
CABG 29,144 23 936 1275 (4.4, 95% CI
4.1 to 4.6)
12 3.2 (95% CI
3.0 to 3.4)
Cardiac
(non-CABG)a
6497 11 59 83 (1.3, 95% CI
1.0 to 1.6)
12 0.7 (95 % CI
0.6 to 0.9)
Craniala 2832 4 17 45 (1.6, 95% CI
1.2 to 2.1)
19 0.7 (95% CI
0.4 to 1.2)
Gastric 1154 8 29 31 (2.7, 95% CI
1.8 to 3.8)
8 2.6 (95% CI
1.7 to 3.8)
Hip prosthesis 170,158 199 577 1240 (0.7, 95% CI
0.7 to 0.8)
14 0.5 (95% CI
0.5 to 0.6)
Knee prosthesis 182,566 193 377 1096 (0.6, 95% CI
0.6 to 0.6)
16 0.4 (95% CI
0.3 to 0.4)
Large bowel 16,734 49 1518 1772 (10.6, 10.1
to 11.1)
8 8.3 (95% CI
7.9 to 8.7)
Limb amputation 2217 19 60 73 (3.3, 95% CI
2.6 to 4.1)
10 1.8 (95% CI
1.4 to 2.3)
Reduction of
long bone
fractureb
13,640 37 91 167 (1.2, 95% CI
1.1 to 1.4)
16 0.8 (95% CI
0.6 to 1.0)
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TABLE 1 Surgical site infection incidence by surgical category within NHS hospitals in England participating in the
PHE National SSI Surveillance Service between April 2008 and March 2013 (continued )
Surgical
category
Number of
operations
Number of
hospitals
Number of
inpatients
Inpatient and
readmissions,
n (%)
Median
time to
infection
(days)
Incidence
density/1000
inpatient days
Repair of neck of
femurb
74,311 130 905 1149 (1.5, 95% CI
1.5 to 1.6)
14 0.7 (95% CI
0.7 to 0.8)
Small bowel 3572 20 211 230 (6.4, 95% CI
5.7 to 7.3)
8 4.9 (95% CI
4.3 to 5.7)
Spinalb 26,249 27 127 283 (1.1, 95% CI
1.0 to 1.2)
14 0.9 (95% CI
0.8 to 1.1)
Vascular 7256 30 147 203 (2.8, 95% CI
2.4 to 3.2)
11 2.2 (95% CI
1.8 to 2.5)
Total 549,495 811 5244 7950
CABG, coronary artery bypass grafting; CI, confidence interval.
a Introduced in April 2010.
b Introduced in July 2008.
Source: Elgohari S et al. Crown copyright and reproduced with the permission of PHE under delegated authority from the
Controller of HMSO.
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FIGURE 2 Trends in the annual cumulative incidence of SSI (%) in the orthopaedic surveillance categories,
with lower and upper 95% CIs, within NHS hospitals in England. (a) Repair of neck of femur; (b) hip prosthesis;
(c) reduction of long bone fracture; and (d) knee prothesis. Source: Elgohari et al.3 Crown copyright and
reproduced with the permission of Public Health England under delegated authority from the Controller
of HMSO. (continued )
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Definitions and diagnosis of infection
We excluded superficial infections from this analysis as they are generally easy to treat and do not present
serious risks for patients. Reducing deep incisional and organ/space infections is the primary focus.
Definitions used have been taken from the Surgical Site Infection Surveillance Service (SSISS) of PHE
(formerly the Health Protection Agency).3
Deep incisional infection
This is defined as infection involving the deep tissues, such as fascia and muscle layers. Infections are
recorded if they arise within 30 days of surgery if no implant is in place or within 1 year if an implant is in
place and the infection appears to be related to the surgical procedure. At least one of the following
criteria must also be met.
l Criterion 1: purulent drainage from the deep incision, but not from the organ/space component of the
surgical site.
l Criterion 2: the deep incision yields organisms from the culture of aseptically aspirated fluid or tissue,
or from a swab and pus cells are present.
l Criterion 3: a deep incision that spontaneously dehisces or is deliberately opened by a surgeon when
the patient has a least one of the following symptoms or signs: fever (> 38 °C), localised pain or
tenderness unless the incision is culture negative.
l Criterion 4: an abscess or other evidence of infection involving the deep incision that is found by direct
examination during reoperation, or by histopathological or radiological examination.
l Criterion 5: diagnosis of a deep incisional SSI by an attending clinician.
2.5
(c)
2.0
1.5
1.0
SS
I i
n
ci
d
en
ce
 (
%
)
0.5
0.0
20
04
/5
20
05
/6
20
06
/7
20
07
/8
20
08
/9
20
09
/1
0
20
10
/1
1
20
11
/1
2
20
12
/1
3
Inpatient/readmission
Inpatient
Readmission
Year
1.4
(d)
1.2
1.0
0.8
0.6
0.4
SS
I i
n
ci
d
en
ce
 (
%
)
0.2
0.0
20
04
/5
20
05
/6
20
06
/7
20
07
/8
20
08
/9
Year
20
09
/1
0
20
10
/1
1
20
11
/1
2
20
12
/1
3
Inpatient/readmission
Inpatient
Readmission
FIGURE 2 Trends in the annual cumulative incidence of SSI (%) in the orthopaedic surveillance categories,
with lower and upper 95% CIs, within NHS hospitals in England. (a) Repair of neck of femur; (b) hip prosthesis;
(c) reduction of long bone fracture; and (d) knee prothesis. Source: Elgohari et al.3 Crown copyright and
reproduced with the permission of Public Health England under delegated authority from the Controller of HMSO.
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Organ/space infection
This is defined as a SSI involving any part of the anatomy, such as an organ or space other than the
incision, opened or manipulated during the surgical procedure. Infections are recorded if they occur within
30 days of surgery if no implant is in place or within 1 year if an implant is in place and the infection
appears to be related to the surgical procedure. At least one of the following criteria must also be met.
l Criterion 1: purulent drainage from a drain that is placed through a stab wound into the organ/space.
l Criterion 2: the organ/space yields organisms from the culture of aseptically aspirated fluid or tissue,
or from a swab and pus cells are present.
l Criterion 3: an abscess or other evidence of infection involving the organ/space that is found by direct
examination, during reoperation, or by histopathological or radiological examination.
l Citerion 4: diagnosis of an organ/space infection by an attending clinician.
These definitions are broadly comparable with both those used by the US Centers for Disease Control and
Prevention, which implement the National Nosocomial Infections Surveillance System,12 and those used by
the European Centre for Disease Control Health Care Associated Infection – Net Consortium.13
Aetiology, microbiology and risk factors
Pathogens that cause SSI may be derived from the patient’s own microbial flora on their skin or body,
from the skin or mucous membranes of operating personnel, or from the operating room environment
(instruments or equipment used during the procedure and airborne particles). Occasionally, micro-organisms
from a distant infection in the body can establish a SSI by attaching to a prosthesis or other implant left in
the operative site.14
Practices to prevent SSI are primarily aimed at minimising the number of micro-organisms introduced into
the operative site via these routes. Procedures aimed at removing micro-organisms that normally colonise
the patient’s skin include preoperative showering and disinfection of the skin at the surgical site; personnel
involved in the operation disinfecting their hands and wearing sterile clothing to minimise the risk of
introducing their own microbial flora into the wound; and air ventilation systems to minimise the risk of
airborne contamination of the incision or instruments.12 Prophylactic antibiotics are used to prevent
micro-organisms introduced to the operative site multiplying, and surgeon technique in minimising tissue
damage is important to enhancing the patients’ defences against infection.15,16 Wound dressings are used
to prevent access of micro-organisms into the incision postoperatively.12
Gram-positive micro-organisms are responsible for over half of SSIs that occur following orthopaedic
surgical procedures, with Staphylococcus aureus being the most common pathogen (PHE SSI report 201317 –
there are other SSISS reports18 that detail the distribution of pathogens causing SSIs in orthopaedics in the
English data).
Diagnosis and treatment
The decision regarding the selection of an adequate treatment strategy for SSI after a hip replacement
should be well planned and made by a team of orthopaedic surgeons and infectious disease/microbiology
specialists. The goal is not only to eradicate infection but also to preserve function of the hip joint.19
As a number of different treatment options exist, individual circumstances have to be taken into
consideration before treatment can begin. The main factors that influence the treatment and its success
are the nature of the organism, site of infection, local factors relating to the bone and tissue condition,
the time of infection onset and the patient’s general health status.19–21
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The first step should be diagnosis of the infection and its microbiological properties, especially when
antibiotics are considered for treatment.20 Only after the virulence and antimicrobial susceptibility of the
organism and immune status of the host have been assessed can an appropriate antibiotic agent be
selected.22 There is no set approach for diagnosing SSIs or prosthesis-related infections, but a physical
examination and a discussion of the patient’s history and symptoms should always be incorporated.22
The following list of strategies can be regarded as a gold standard, but in practice a combination of only
some of these individual strategies is pursued.21,23,24
l Imaging [e.g. standard radiography (X-ray), contrast autography, computerised tomography,
ultrasonography, magnetic resonance imaging].
l Laboratory [e.g. repeated measurement of leucocyte count in the synovial fluid (found in the cavities
between joints to reduce friction)].
l Histopathology (e.g. testing for neutrophils in tissue specimen).
l Microbiology (e.g. swabs from pre- or intraoperative specimen or from removed fragments of
the implant).
Once the diagnosis and type of infection has been established, the treatment options are surgical
debridement with retention of the prosthesis, revision surgery, lifelong suppressive antibiotics or
permanent resection.19,25,26
Surgical debridement
If an infection manifests early in the post-operative period, debridement in combination with antibiotic
therapy and retention of the prosthesis is a potentially successful treatment option. The success rate
described in studies varies greatly from 2.8% to 100%, but more recent estimates suggest that this is
closer to 80%.27 The criteria proposed for the use of this technique are a duration of symptoms of
< 1 month, infection with staphylococci or streptococci, no loosening of the prosthesis and no evidence of
poor soft-tissue integrity as a result of prior surgical procedures.28 The debridement should be performed
as early as possible after the onset of symptoms of infection to avoid treatment failure, ideally within
2–5 days.27,29,30 As this treatment avoids major revision surgery to replace the joint, it is particularly
advantageous for elderly patients.31
Revision surgery
Revision surgery can be performed as either a one- or a two-stage revision, each combined with
antimicrobial therapy. In a one-stage revision, all infected tissue is removed and the prosthetic components
are exchanged in the same operation. Even though this method gives good results in > 80% of patients
and permits early mobility, the patient faces the risk that any remaining bacteria may reinfect the newly
implanted prosthetic device. It is generally accepted that a one-stage revision should be used only if bone
grafting is not required, there is no fistula present, the infection is not a result of difficult or resistant
bacteria, debridement was extensive enough that others would not be able to repeat the procedure and
antibiotic cement is used.30
A two-stage revision involves the resection of all infected tissue and the removal of the prosthesis, after
which the patient undergoes antibiotic treatment for a period usually ranging from 6 weeks to several
months, until the infection is under control.27,28,30 The patient’s movement is limited during that time and it
can be very painful. In the second stage a new prosthesis is inserted in a reimplantation arthroplasty.28,32
For this technique to be used, the patient must have adequate bone stock and minimal comorbidities
that might otherwise affect their suitability for multiple surgical procedures.30 Two-stage revisions are a
common treatment for chronic infections in the USA, with studies showing consistently high cure rates of
> 90% and a good prognosis of relapse-free survival.22 However, this method is expensive, can result in
significant skeletal defects, demands long hospitalisation periods, and can result in severe functional
impairment and sometimes death.28,30
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Lifelong suppressive antibiotics
Lifelong suppression of the infection with antibiotics is infrequently used in practice, but might be the only
option for morbid, bedridden or inoperable patients.33 Antibiotic therapy without implant removal has an
estimated failure rate of > 90%,34 as it only eases the symptoms without eliminating the infection.19
Permanent resection
Permanent resection of the prosthesis, also known as Girdlestone resection, can be seen as a last resort
after all other treatment options, including revision surgery, have failed.35 This salvage technique is seen as
acceptable for patients who are not fit for further revision operations because of poor bone stock or a high
risk of recurring infection.36 Other indications include poor quality of soft tissue, infection with multiple or
resistant organisms, poor general health or high complexity of reconstruction arthroplasty.37 The main purpose
of the Girdlestone procedure is to reduce pain, as overall quality of life and patient satisfaction may not be
improved because of substantially worse functional outcomes.19,35,36 Patients are often left with a stiff joint and
limited mobility, limb shortening as a result of bone loss and scar tissue, and a requirement for a walking aid.37
Impact on patients and costs to health services
Deep SSIs are associated with substantial costs. Direct costs include a prolonged hospital stay, hospital
readmission, outpatient visits, reoperation, additional antibiotic treatment, radiological and laboratory tests,
home visits by health services and medication costs, as well as additional mortality and morbidity. Indirect costs
include lost productivity of the patient and their family but could also comprise the damage to a clinician’s or
hospital’s reputation or loss of staff morale.38 Other consequences of SSIs are a serious impact on the quality
of life and mental state of the generally elderly patients having to face further major surgery. Orthopaedic SSI
has been reported to increase the mortality risk by 50% and the hospital stay by, on average, 11.5–14 days
and to double the rehospitalisation rates.4,5,39 A UK study by Vanhegan et al.40 compared the costs of
revision operations for aseptic loosening, dislocation, deep infection and periprosthetic fracture. Clinical,
demographic and economic data were collected for 305 consecutive-revision THRs in 286 patients in a single
tertiary referral unit. The authors found that the mean inpatient stay for patients with deep infection was
significantly longer. Mean total costs were £21,937 in deep infection cases, compared with £11,897, £18,185
and £10,893 for aseptic, dislocation and periprosthetic cases, respectively. A recent cost-analysis study in
France found that costs of septic revisions were 3.6 times higher following a THA than following a primary
THA, mainly because of longer hospitalisation periods and rehabilitation after hospital discharge.41
The treatment or revision of an infected joint can be very time-consuming and resource intensive.42,43
Costs of SSIs usually increase with the depth of infection (i.e. superficial infections incur fewer costs than deep
infections).38 The economic burden of SSI after hip arthroplasty was reported to increase health-care costs by
more than 300%, but dollar estimates differ widely, from US$400 to US$60,000 per SSI treated.5,38,41,44,45
Apart from obvious reasons for the wide range of estimated costs, such as severity of infection or differing
hospital fees in different countries, there is no consistent methodology used to calculate costs of infection.46
The measurement of cost requires identifying the quantity of resource use and the unit costs or prices for
using the resources.47 However, in this context not only costs attributed to the occurrence of infections and
related resources are relevant. The implementation of additional infection prevention will also incur costs,
details of which are important for an accurate representation of cost outcomes. Often cost savings
resulting from infection prevention programmes are overstated, making them appear more desirable
than they actually are. Using hospital accounting methods rather than an economic approach biases the
results in this context; they include fixed costs, such as wages, which are not affected by the incidence or
control of infection.48 Similarly, costs of infection are overstated when total hospital costs and total length
of stay of infected patients are compared with uninfected patients. Patients who are more susceptible to
infection often display severe cases of illness and are thus likely to incur higher costs throughout their
hospital stay. Only costs incurred after the onset of infection should be attributed to infections.49
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For the economic evaluation in this project, the costs of infection prevention interventions are direct costs
of implementation and continuous use of each strategy. Ultraclean air surgery, for example, would require
the installation of specialised air handling systems. These capital costs would be valued by calculating the
equivalent annual costs that integrate opportunity costs, as well as depreciation of the investment.47 These
costs, along with resource costs, such as additional electricity consumption per procedure or increased
staffing requirements, would have to be taken into consideration. Each of the competing infection
prevention strategies may be associated with different costs. The cost estimates for the occurrence of
infection include direct in-hospital and post-discharge costs. Direct in-hospital costs can be measured as
treatment costs, resource consumption and extra mortality and morbidity resulting from infection, whereas
direct post-discharge costs are measured as out-of-pocket costs for patients and the use of primary care
services. Treatment costs refer to the different treatment alternatives described in the model.
Current general infection prevention measures in the NHS
Guidelines on infection prevention precautions have been developed for NHS professionals to ensure the
safety of patients and health-care personnel, as well as those who visit the health-care environment.
General infection prevention measures include hand hygiene, respiratory hygiene, personal protective
equipment, occupational exposure, management of care equipment, safe care of linen, control of
environment and safe waste disposal.
l Hand hygiene: good hand hygiene is very important for reducing the transmission of infectious agents.
l Respiratory hygiene: respiratory hygiene has been added to the guidelines to reduce the risk of an
influenza pandemic.
l Personal protective equipment: the use of gloves, gowns, masks or goggles is essential for the health
and safety of both patients and those caring for them.
l Occupational exposure management: health-care staff must report incidents of exposure to infectious
agents or needle-stick injuries and deal with incidents promptly.
l Management of care equipment: care equipment needs to be carefully managed to limit the risk of
contamination with micro-organisms.
l Safe management of linen: appropriate handling of soiled fabric/linen is important to avoid
transmission of micro-organisms.
l Control of environment: the term ‘environment’ refers to any general horizontal or frequently touched
surfaces in the environment. Routine cleaning is required to minimise transfer of micro-organisms from
the environment to patients/clients.
l Safe waste management: disposing of waste appropriately can minimise the risk of transmitting
micro-organisms.
Specific guidelines on control of SSIs are available in UK, providing advice on the preoperative,
intraoperative and postoperative phase (Table 2).50–52
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Current cost-effectiveness evidence
The following databases were searched for relevant cost-effectiveness evidence: PubMed, Health
Technology Assessment Database, NHS Economic Evaluation Database, MEDLINE, Academic Search Elite,
Australia/New Zealand Reference Centre, Cumulative Index to Nursing and Allied Health Literature and
EconLit. Searches were initially based on applicable medical subject headings/subject terms for research
undertaken in this field (‘Arthroplasty, Replacement, Hip’, ‘Surgical wound infection’, ‘Decision Support
Techniques’, ‘Models, economic’, ‘Costs and Cost Analysis’). In order to make the searches more specific,
and to find further references, individual search terms were combined with medical subject headings
(‘infection’, ‘cost-effectiv*’, ‘intervention’, ‘control, ‘antimicrobial’, ‘prophylaxis’, ‘antibiotic’, ‘cement’,
‘gentamicin’, ‘pre-operative’, ‘showering’, ‘antisep*’, ‘skin preparation’, ‘hair’, ‘nutrition’, ‘sterile’, ‘gown’,
‘surgical attire’, ‘mask’, ‘ultra-clean air’, ‘laminar’, ‘operating room’, ‘oxygen’, ‘suction drain’, ‘patient
warming’, ‘UV radiation’, ‘wound dressing’, ‘surveillance’).
Studies were screened for relevance using the eligibility criteria outlined in Table 3.
TABLE 2 Surgical site infection prevention measures
Preoperative phase Intraoperative phase Postoperative phase
Preoperative showering Hand decontamination Changing dressings
Hair removal Incise drapes Postoperative cleansing
Patient theatre wear Sterile gowns Topical antimicrobial agents for
wound healing by primary intention
Staff theatre wear Gloves Dressings for wound healing by
secondary intention
Staff leaving the operating area Antiseptic skin preparation Antibiotic treatment of SSI and
treatment failure
Nasal decontamination Diathermy Debridement
Mechanical bowel preparation Maintaining patient homeostasis Specialist wound care services
Remove hand jewellery, artificial
nails and nail polish
Wound irrigation and intracavity lavage
Antibiotic prophylaxis Antiseptic and antimicrobial agents
before wound closure
Wound dressings
TABLE 3 Eligibility criteria used to select relevant cost-effectiveness evaluations
Inclusion criteria Exclusion criteria
Published between January 1995 and
July 2014
Partial economic evaluations (cost or effectiveness study)
Economic evaluation of infection prevention
strategy for THA
No comparator
Evaluation based on decision model Procedure other than hip arthroplasty (e.g. knee, shoulder, general surgery)
Assessment of adult population Economic evaluation of infection diagnosis/treatment
Language is English Prevention of transfusion-associated infection (e.g. human
immunodeficiency virus infection, hepatitis)
Accessible in full
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Searches were limited to match these criteria as much as possible; for example, searches were restricted to
the relevant time frame and English language only.
Studies were selected in a four-step process, illustrated in Figure 3. First, all titles in the selected search
results (n= 199) were screened for inclusion. Titles not meeting the eligibility criteria at this stage
were excluded (n= 133), for example because the study focus was on a different type of surgical
procedure, such as knee or shoulder arthroplasty, or had a different objective, such as prevention of
thromboembolism. Second, the abstracts of relevant studies (n= 66) were screened for inclusion.
The most common reasons for exclusion were partial economic analysis, especially cost analysis, or studies
for infection treatment or diagnosis rather than control. If decisions about inclusion were unclear, full
articles were retrieved and reviewed. Studies were included if they met all of the above-described criteria.
References of eligible studies (n= 4) and excluded literature reviews (n= 3) were hand-searched for further
relevant studies.
Description of cost-effectiveness evidence
The literature searches resulted in five cost-effectiveness evaluations matching the inclusion criteria.53–57
However, two studies were conducted by the same author group: one was a cost-effectiveness evaluation
and the second was a systematic review with a cost-effectiveness evaluation.53 As the same decision
problem and decision model were used in both these publications, only the more recent and updated
article was included.55 The characteristics of the remaining four studies are summarised in Table 4.
Articles retrieved in
initial search
(n = 199)
Excluded (n = 133)
• Not about infection prevention
• Not orthopaedic
Excluded (n = 3)
• Literature review
Hand-searched references (n = 286)
• Relevant reference, n = 1
Excluded (n = 59)
• Not an economic evaluation
• Only partial economic evaluation
• Assessment of infection 
   diagnosis/treatment
Articles reviewed and
screened for inclusion
(n = 66)
Full economic evaluations
(n = 4)
Full economic evaluations
(n = 5)
FIGURE 3 Review process of articles retrieved in the medical literature.
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TABLE 4 Characteristics of retrieved cost-effectiveness evidence
Characteristic
Study
Cummins et al. (2009)54 Elliott et al. (2010)55 Courville et al. (2012)56 Merollini et al. (2013)57
Research
question
Is the use of antibiotic-
impregnated bone
cement in primary THA
cost-effective when
compared with cement
without antibiotics?
Is there a threshold of
MRSA prevalence at
which switching to routine
glycopeptide-based
antibiotic prophylaxis
becomes cost-effective?
Is preoperative nasal
mupirocin treatment
cost-effective in
preventing SSI in total hip
and knee arthroplasty?
Are strategies claiming
to reduce the risk of SSI
in hip arthroplasty
cost-effective?
Patient cohort Patients undergoing
primary THA for
the treatment of
osteoarthritis (not
fracture); baseline
average age: 68 years
Patients undergoing
primary THA
Patients with end-stage
hip or knee osteoarthritis
for whom THA and TKA
were recommended
because of failed medical
management
Patients undergoing
THA; baseline age:
65 years
Perspective Unclear (USA) Cost perspective of the
UK NHS and Personal
Social Services
Societal perspective, but
limited to costs and
effects directly affecting
the target population
Health services
perspective
Comparators Antibiotic-impregnated
cement vs.
polymethylmethacrylate
bone cement without
antibiotics
Vancomycin vs.
cephalosporin vs.
combination of
vancomycin and
cephalosporin
Preoperative nasal
screening and mupirocin
treatment vs. preoperative
mupirocin treatment vs.
no treatment or screening
Antibiotic prophylaxis vs.
antibiotic-impregnated
cement and antibiotic
prophylaxis vs. laminar
air operating rooms and
antibiotic prophylaxis vs.
no antibiotic prophylaxis
Time frame Model cycles until all
hypothetical patients are
in a death state
Unclear (possibly during
hospitalisation)
Within 1 year of the
primary operation
30 years
Outcome
measure
Rate of revision because
of infection and rate of
all revisions
Rates of superficial/deep
MRSA infection/
non-MRSA infection
ICER QALYs and cost related
to infection prevention
strategies
Findings ICER for antibiotic-
impregnated cement:
US$37,355/QALY
gained. Antibiotic-
impregnated cement
dominated standard
bone cement
If the MRSA infection
rate is ≥ 0.25% and the
rate of infections with
cephalosporin prophylaxis
is ≥0.2%, combined
antibiotic prophylaxis is
optimal
The treat-all and
screen-and-treat
strategies both had
lower costs and greater
benefits than the
no-treatment strategy
Antibiotic prophylaxis and
antibiotic-impregnated
cement dominated the
other three strategies
(no antibiotic prophylaxis,
antibiotic prophylaxis,
antibiotic prophylaxis and
laminar air operating
rooms)
ICER, incremental cost-effectiveness ratio; MRSA, meticillin-resistant Staphylococcus aureus; QALY, quality-adjusted
life-year; TKA, total knee arthroplasty.
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Cummins et al.54 evaluated the cost-effectiveness of using antibiotic-impregnated bone cement in primary
THA compared with standard bone cement. They used the rate of revisions and, in particular, revisions
resulting from infection as primary outcome measures in their Markov model. The cohort simulation showed
that parameters with the greatest influence on model results were costs of cement and baseline age. If
revision resulting from infection was the primary outcome measure, the incremental cost-effectiveness ratio
(ICER) for the use of antibiotic cement was US$37,355 per quality-adjusted life-year (QALY) gained. When
the outcome measure was the rate of all revisions, antibiotic-impregnated cement was more effective and
less costly than standard bone cement. The study demonstrated that antibiotic-impregnated cement was
cost-effective for a relatively young patient group (< 71 years) and for a low cost of cement (<US$650).
As most THA patients in the USA are older, the authors concluded that the use of antibiotic-impregnated
cement as a control measure is of limited use in the US setting unless the price is reduced.
Another economic evaluation, by Elliott et al.,55 focused on the control of meticillin-resistant
Staphylococcus aureus (MRSA) infections using different antibiotic prophylaxis strategies, prior to surgery.
Primary hip arthroplasty was used by way of example in the decision-analytic model and it was assumed
that all patients received some form of antibiotic prophylaxis: non-glycopeptide, glycopeptide or a
combination. The choice of agent has different implications: glycopeptides (e.g. vancomycin) are known to
actively fight resistant strains but pose a risk of increasing bacterial resistance; and non-glycopeptides
(e.g. cephalosporins) are routinely used but do not represent an effective barrier to MRSA infection.
The aim of the study was to investigate whether or not routine glycopeptide-based prophylaxis would be
cost-effective beyond a certain threshold prevalence of MRSA. Assuming a threshold of £30,000 per QALY
gained, the authors found that, for hip arthroplasty, prophylaxis with cephalosporin alone was optimal at a
0.0% MRSA SSI rate or if the MRSA SSI rate was ≥ 0.2% and the rate of other infections was ≤ 0.1%,
and vancomycin alone was to be preferred where the MRSA SSI rate was ≤ 0.15% and the rate of other
infections was ≤ 0.1%. Combined administration of cephalosporin and vancomycin was optimal where the
MRSA SSI rate was ≥ 0.25% and the non-MRSA SSI rate was ≥ 0.2%. The authors noted high levels of
uncertainty and concluded that more work was needed to fully understand the mechanisms of antibiotic
resistance and how it affects the effectiveness of glycopeptides.
A study by Courville et al.56 examined the cost-effectiveness of preoperative nasal mupirocin treatment in
patients with total hip or knee arthroplasty. Three strategies were compared in a decision tree model:
preoperative screening for all patients and treatment with mupirocin for patients testing positive for
S. aureus; preoperative administration of mupirocin to all patients and no screening; and neither preoperative
treatment nor screening. The main outcome, costs and health benefits, was assessed within 1 year of the
primary operation. Courville et al.56 found that both treat-all and screen-and-treat strategies had lower costs
and greater benefits than the no-treatment strategy. The result is robust, even if the cost of mupirocin was
over US$100 and the cost of SSI ranged between US$26,000 and US$250,000. Treating all patients remains
the best strategy when the prevalence of S. aureus carriers and SSIs is varied across plausible values as well as
when the prevalence of mupirocin-resistant strains is high. Owing to imperfect sensitivity of the screening
test, the authors suggested that the treat-all approach is the most likely to decolonise S. aureus-colonised
patients to prevent deep SSI.
A cost-effectiveness analysis by Merollini et al.57 evaluated different strategies claiming to reduce the risk of
SSI in hip arthroplasty in Australia. The baseline strategy, antibiotic prophylaxis, was compared with no
antibiotic prophylaxis, the combination of antibiotic prophylaxis and antibiotic-impregnated cement, and
the combination of antibiotic prophylaxis and laminar air operating rooms, in a Markov model.58 The
model showed that stopping the routine use of antibiotic prophylaxis would increase costs by over
AU$1.5M and result in a loss of 163 QALYs. In both baseline and uncertainty analysis, the combination
of antibiotic prophylaxis and antibiotic-impregnated cement was both less costly and showed greater
health benefits than the other strategies. As a result, the authors recommended the use of antibiotic
prophylaxis combined with antibiotic-impregnated cement, but recommend against the use of laminar
air operating rooms to reduce both the costs and the risk of SSI.
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Quality assessment
The quality of eligible studies was assessed on aspects of structure, data and consistency, using a checklist
adapted from Philips et al.59 (Table 5).
The structural quality of all four economic evaluations was high, although Cummins et al.54 failed to
clearly state the perspective of the evaluation and Elliott et al.55 did not clearly define the time horizon.
Dimensions of data quality were fulfilled by most studies, but two, by Cummins et al.54 and Elliott et al.,55
failed to provide sources of data for at least one parameter. Owing to their importance for the quality of
model, input parameters were assessed in more detail.
Model parameters were ranked using a hierarchy developed by Cooper et al.60 for evaluating decision model
parameters. Using this hierarchy, evidence levels range from 1 to 6, with higher numbers indicating better
quality. The quality of baseline clinical data, treatment effect, costs and utilities is summarised for the
economic evaluation by Cummins et al.54 in Figure 4 and for Elliott et al.55 in Figure 5. If the evidence used
did not match the specified description of evidence, the next most suitable category was chosen. Neither of
the studies commented on the assessments of internal consistency of the decision model. Therefore, it is
unclear whether or not the mathematical logic of the model has been evaluated in these publications.
Figure 4 shows that the quality of baseline clinical data used by Cummins et al.54 was medium to high, low
for treatment effect and high for cost estimates, whereas the quality of utilities used ranged from low to high.
Cummins et al.60 derived baseline infection rates from the Norwegian Arthroplasty Registry, which can be
classed as a recent ‘reliable administrative database covering patients solely from another jurisdiction’,60
representing a quality score of 3.60 Baseline surgical mortality was assumed to be the same for primary
THA and revision surgery, and was also taken from the Norwegian Arthroplasty Registry. Underlying
mortality was informed by recent US life tables, earning a quality score of 2. Owing to a lack of
high-quality data, the clinical effectiveness (treatment effect) of antibiotic-impregnated bone cement was
derived from a non-analytic study and is, therefore, classified as low quality. Cost parameters assigned to
primary THA, increased cost of aseptic revision and revision resulting from infection were adopted from
TABLE 5 Quality assessment of existing cost-effectiveness evidence
Dimension of quality
Study
Cummins et al.
(2009)54
Elliott et al.
(2010)55
Courville et al.
(2012)56
Merollini et al.
(2013)57
Structure
Statement of decision problem Yes Yes Yes Yes
Statement of perspective No Yes Yes Yes
Definition of comparators Yes Yes Yes Yes
Statement of model assumptions Yes Yes Yes Yes
Illustration of model structure Yes Yes Yes Yes
Appropriate time horizon Yes Unclear Yes Yes
Data
Data identification process transparent Yes Yes Yes Yes
Sources of all data given in detail No No Yes Yes
Quality of model input parameters see Figure 4 see Figure 5 see Figure 6 see Figure 7
Assessment of uncertainty Yes Yes Yes Yes
Identification of key parameters Yes Yes Yes Yes
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recently published cost calculations of high quality from the same jurisdiction. The quality of data for the
extra costs of using antibiotic cement was also high, as these estimates were based on original figures
from the authors’ institution. Utility parameters for primary THA and aseptic revision were of high quality,
adopted from a study designed for the patient group of interest. The utility for aseptic revision, on the
other hand, was estimated by the authors as no published estimate was found, representing the lowest
level of data quality according to the classification system used. It was unclear how disutility was
measured, as no reference was stated and no measurement method was described. However, the results
of the Markov model showed that, in the sensitivity analysis, disutility values had no effect on the model.54
Figure 5 shows that the quality of baseline clinical data used by Elliott et al.55 was high. The quality of
treatment effect data was rated as medium, whereas cost parameters data were a mix of high and low
quality and utility inputs data were of low quality. Elliott et al.55 used a possible range of infection rates for
their baseline estimate, based on two different high-quality sources from the literature. Mortality estimates
for superficial and deep SSIs were informed by a recent case series from the same jurisdiction. Underlying
mortality rates were taken from UK life tables, which are high-quality data. As no treatment effect
describing antibiotic prophylaxis for MRSA prevalence was available in the orthopaedic setting, results from
a cardiac clean surgery trial were used instead. Using data from a randomised controlled trial (RCT)
conducted in a different setting may compromise the credibility of model outcomes but, in this case, as
both procedures are clean surgery, the most appropriate ranking for this input is 4. Different costs for
antibiotic prophylaxis and treatment costs of superficial, deep MRSA and non-MRSA infections were
derived through personal communication with the British Medical Association and Royal Pharmaceutical
Society of Great Britain, all representing high-quality data inputs. Recent UK case series and a previously
published economic evaluation informed costs of barrier nursing and inpatient days, and administration
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costs were set at local NHS contract costs. The reference specified for wound exploration costs did not
describe any costs but stated that this strategy can be used to treat infections and hence this parameter
was classed as low quality.61 QALYs for infected joints were derived from a previous study that used expert
opinion and was therefore given the lowest quality categorisation.55,62
Figure 6 shows that the baseline clinical data used by Courville et al.56 was a mix of low and high quality:
the quality of treatment effect data was medium, cost parameters data were of high quality and utility
inputs data were a mix of low and medium quality. For the base case, Courville et al.56 used the S. aureus
colonisation rate from their local population of patients with total joint arthroplasty. This is high quality
according to the Cooper et al.60 classification system. However, the specificity and sensitivity of the screening
test for S. aureus were estimated based on personal communications and unpublished data in the original
source. The treatment effect of mupirocin in reducing SSIs was derived from a meta-analysis that included
both RCT and before-and-after trials for patients undergoing different surgical procedures and is therefore
ranked at level 3 for quality. The probabilities of SSI among mupirocin-treated carriers and untreated
non-carriers were sourced from a single case–control study, representing medium quality. The quality of
data for costs of screening tests and treatment was high, being based on fees from the authors’ medical
centre. Similarly, the costs of primary total joint arthroplasty and revisions were estimated from published
papers where cost calculations were based on reliable data sources in the USA, and were therefore also of
high quality. Utility scores for primary total knee replacement, septic knee revision and THA were based on
previous studies using the time trade-off method. The quality of utility data for septic hip revision was
classified as low, having been taken from the expert opinion estimates used by Cummins et al.54
Figure 7 shows that the quality of baseline clinical data used by Merollini et al.57 was mostly high and that
treatment effect data were of medium to high quality, whereas cost parameters data were a mix of high
and low quality and utility inputs data were a mix of low and medium quality. Merollini et al.57 sourced the
occurrence of deep infection and other transition probabilities from high-quality hospital records in
Queensland, Australia. Mortality probabilities for deep infection were taken from a retrospective review of
surveillance data in the UK, which is classified as medium quality. Mortality probabilities for revision surgery
were calculated based on data from the Australian Orthopaedic Association National Joint Replacement
Registry by Merollini et al.,57 giving a quality score of 1. The quality of underlying mortality probabilities
was also high, as Australian life tables were used. The clinical effects of antibiotic prophylaxis and
antibiotic-impregnated cement were taken from meta-analyses and are therefore classified as high quality.
A large cohort study provided medium-quality data on clinical effect on laminar air systems in operating
theatres. Costs of antibiotic prophylaxis and ultraclean air systems were based on expert opinion and
conservative estimates by the authors, and are therefore of low quality. On the other hand, the cost
assigned to the additional use of antibiotic cement was obtained through personal communication with
the Prince Charles Hospital in Brisbane, QLD, Australia, which is classified as high quality. Utility scores for
patients with no infection, revision operations and successful treatments were derived from a study that
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estimated quality of life using the 15D health-related quality-of-life (HRQoL) survey (a 15-dimensional,
standardised questionnaire) and an observational study (using the Short Form questionnaire-36 items) that
was referred to estimate utility for deep infection. However, the utility of permanent and temporary
resection was based on expert opinion and was therefore classified as low-quality evidence.
Related economic evidence
As the literature review of cost-effectiveness analyses of infection prevention in hip arthroplasty resulted in
only four eligible studies, related economic evaluations were examined. Findings of these studies could be
of relevance even if they did not match the specified inclusion criteria. Most of these studies were excluded
because they focused on infection prevention other than hip arthroplasty procedures, did not use a
decision model, explored the cost-effectiveness of infection treatment or only focused on cost or
effectiveness aspects.
An economic evaluation was published by a Swedish group in 199963 but was excluded as it did not report
the use of a decision model and did not investigate health outcomes. Persson et al.63 assessed the economics
of preventing revisions following THA. The risk of revision because of aseptic loosening was calculated for
different types of cement, and the risk of revision resulting from deep infection was assessed for no
prophylaxis or different combinations of systemic antibiotics, gentamicin-impregnated cement, surgical
enclosure and exhaust-ventilated suits. Although the Swedish Arthroplasty Register was used to measure
most parameters, weighted average costs for proportions of one-stage and two-stage revision were
retrieved from a single Swedish hospital. The authors estimated the expected health-care costs for each
infection prevention strategy and then compared the alternatives in terms of their rate of revision and costs.
Dominated strategies were excluded (e.g. strategies with higher costs at the same rate of revision). The
results showed that every combination with exhaust-ventilated suits resulted in an increased rate of revision.
This led the authors to the conclusion that this strategy should never be used as a preventative measure.
Effective strategies were systemic antibiotics only, systemic antibiotics in combination with antibiotic cement
and, lastly, systemic antibiotics, antibiotic cement and surgical enclosures.64 The last was the most effective
strategy, with revision rates resulting from deep infection of 0.19% and an average cost of prophylaxis of
US$331 for each primary THA performed (based on 100 operations performed per year).64 These additional
costs, especially of a surgical enclosure, were not offset by the cost savings because of infection prevention
and the cost-effectiveness of different strategies varied with the number of THAs performed per year.
For orthopaedic departments already using antibiotic prophylaxis and antibiotic-impregnated cement,
the extra use of a surgical enclosure would cost US$314,000 for each deep infection avoided.
Another related full economic evaluation by Fisman et al.28 used a Markov decision model to compare the
clinical effectiveness and cost-effectiveness of two management strategies: surgical debridement with
retention of the prosthesis or two-stage exchange arthroplasty for infected THA. The model results were
assessed and reported for a 65- and 80-year-old patient cohort. This study fulfilled all criteria for a good
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economic evaluation,47 but the authors noted the need of RCTs to evaluate management strategies for
infected hips in order to increase the quality of model parameters. The results were highly dependent on
the annual relapse rate after debridement for each treatment strategy as well as on the age at the initial
diagnosis of infection. Debridement and retention resulted in a better cost-effectiveness ratio in all cohorts
and increased the life expectancy by 2.2–2.6 quality-adjusted life-months.
A systematic review of effectiveness and cost-effectiveness of antimicrobial prophylaxis in THA was
performed by Glenny and Song.65 The authors assessed the quality of all studies available and performed
different meta-analyses in order to combine effectiveness outcomes and evidence of a number of
antimicrobial agents and routes of administration.28 A total of 25 RCTs were included; the overall
conclusion was that antimicrobial prophylaxis is effective for the control of surgical wound infections in
total joint arthroplasty and the efficacy of most treatment regimens studied was similar.
Numerous partial economic evaluations exist, focusing on cost or effectiveness aspects only rather than
cost-effectiveness (a reason for exclusion in the review). Many of these were related to costs of antibiotic
prophylaxis as a control measure or treatment costs of infection in orthopaedics.42,43,66–75
D’Angelo and Ogilvie-Harris71 reviewed nine cases of septic arthritis following arthroscopic procedures on
the knee or shoulder in terms of their costs and the possible monetary benefits of antibiotic prophylaxis.
Although they mentioned a cost–benefit analysis, this cannot be interpreted in the sense of an economic
evaluation because their estimates did not reflect individual preferences (welfarism) nor did they include a
cost–benefit ratio or single outcome measure.
The most relevant cost analysis was published by Lidwell72 in 1984. He estimated additional costs of
antibiotic prophylaxis, ultraclean air and body exhaust suits used individually in joint replacements, and put
these costs in context with cost savings associated with these preventative measures. The conclusion was
that overall cost savings were achieved for the hospital if antibiotic prophylaxis or clean-air techniques
were used.72
Arens et al.42 estimated the substantial economic burden for hospitals treating infections after joint
replacements as a result of inappropriate reimbursement. They argued that the high economic burden
justified a sound cost evaluation by health insurers and more research in infection prevention.42 Bozic and
Ries43 focused on measuring the impact of deep infection after THA on surgeon and hospital resource
utilisation by analysing clinical and economic data of 25 infected patients. The results were increased total
medical costs for revisions resulting from infection (2.8 times higher than revisions resulting from aseptic
loosening), significantly more hospitalisations, prolonged hospital stay, more operations, more outpatient
visits, more outpatient charges and more complications than for THA without complication or revision
because of aseptic loosening.43 A British study by Edwards et al.73 evaluated data on hip fracture patients
regarding infection risk factors and costs for deep or superficial wound infections, and found significantly
increased treatment costs and length of stay, with doubled operative costs and quadrupled ward costs for
deep infection. Iribarren et al.74 and Kurtz et al.75 also reported higher hospital charges and an increased
length of stay because of periprosthetic infection or SSI after total hip or knee arthroplasty.
Klouche et al.41 performed a retrospective cost analysis using hospital data from approximately 500 hip
arthroplasties performed in a French hospital.41 Treatment costs of infected hips after THA included
preoperative tests, medicosurgical management during the hospital stay, orthopaedic rehabilitation,
antibiotic therapy after revision because of infection and home-based hospitalisation costs.41 They found
that in their institution, the average hospital stay was 7.5 days for primary THA and 30.6 days for revisions
because of infection.41
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Vanhegan et al.40 compared the costs of revision operations for aseptic loosening, dislocation, deep
infection and periprosthetic fracture. Clinical, demographic and economic data were collected for 305
consecutive revision THRs in 286 patients in a single tertiary referral unit. They found that the mean
inpatient stay for patients with deep infection was significantly longer and mean total costs were £21,937
in deep infection cases, compared with £11,897, £18,185 and £10,893 for aseptic, dislocation and
periprosthetic cases, respectively.40
Research goals and objectives
The economic paradigm is that enhanced infection prevention in NHS hospitals will change cost and health
outcomes. Costs will rise with more aggressive infection prevention programmes, but savings will accrue
when cases of infection are prevented. Infection prevention strategies will either increase or decrease total
costs depending on their cost and effectiveness. Health outcomes will only improve as infection-related
morbidity and mortality risk are avoided. The goal of this research is to assess the cost-effectiveness of
infection prevention strategies for hip replacements performed in NHS hospitals.
The information generated will address a gap in the scientific knowledge about how the risks of infection
following THR should be managed. The major benefit of this work will be that infection prevention
arrangements for THR will be improved and this will improve NHS efficiency.
There are five tasks:
1. Synthesise evidence on the effectiveness of strategies to reduce risk of infection after primary hip
replacement (see Chapters 2 and 3).
2. Design a decision-analytic model to predict cost and health outcomes from infection prevention
strategies (see Chapter 4).
3. Identify, select and synthesise the remaining evidence required to update the model (see Chapters 5
and 6).
4. Evaluate the model and characterise uncertainty among the predictions of cost-effectiveness
(see Chapter 6).
5. Interpret the findings with the needs of policy-makers in mind (see Chapters 7 and 8).
A formal modelling framework will be used and updated with existing data. This will inform decision-making
for infection prevention and risk reduction. This represents an advance on the existing research in which
either the effectiveness or cost-effectiveness of single interventions to manage risks is studied in isolation.
Answering the research questions with a prospective clinical trial would be too complex and costly,
and unlikely to survive review by an ethics committee.
BACKGROUND AND STUDY OBJECTIVES
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Chapter 2 Synthesis of effectiveness
evidence methods
The purpose of this chapter is to report the methods used to synthesise current effectiveness evidenceand quantify the relative effectiveness of infection prevention strategies for reducing the risk of SSI
following THR. Sections of this chapter have been published open access in Zheng et al.9 under the terms
of the Creative Commons Attribution Non-Commercial (CC BY-NC 3.0) licence. We focus on key infection
prevention strategies with clinical and cost implications for the prevention of THR-related infection. These
are antibiotic prophylaxis, antibiotic-impregnated cement and laminar airflow operating systems, and were
chosen based on national clinical infection prevention guidelines in the UK,76 the National Institute for
Health and Care Excellence (NICE) publication on Surgical Site Infection – Prevention and Treatment of
Surgical Site Infection50 and through elicitation of expert opinion.
Mixed-treatment comparison models
We used a mixed-treatment comparison (MTC) model for the evidence synthesis, as it allows coherent
judgement to be made on which of multiple treatments is the most effective and produces estimates of
the relative effects of each treatment compared with every other treatment in a network.77,78 A MTC
enables simultaneous comparison of multiple treatments from trials that individually do not compare all
treatment options under consideration.78,79
A MTC is achieved by pooling direct and indirect evidence on each relative treatment effect from all trials
in the evidence network for comparison.77 The model assumes that the relative effect of one treatment
compared with another is the same across the entire set of trials for the fixed-effect analysis,80 and the
odds ratios (ORs) in each trial are different, but form a single common distribution that is the same across
all sets of the trials for the random-effects analysis.77,79 It is under such an assumption that models have
been developed to simultaneously synthesise all available evidence using an extended meta-analysis model
without breaking randomisation.79,81
Regression-based methods have been developed to fit MTC models.82–85 The basic model specification for
MTC methods is an extension of the Bayesian specification for standard pairwise meta-analysis of binary
data using a logistic regression model:86
logit(pj,k) =

µjb for baseline treatment b; b = A, B, C . . .
µjb + δ jbk for treatment k; k>A, B, C . . . ,
(1)
where pjk is the probability of the event for treatment k in trial j; µjb is the log-odds of the event for the
reference (baseline) treatment b in trial j. The study effects µjb are treated as unrelated nuisance
parameters.77 δjbk is the trial specific log-OR of treatment k relative to the reference treatment b in trial j
(k> b signifies that k is numerically after b).
The random-effects model
The trial-specific log-odds δjbk are assumed to be normally distributed with mean dbk and a between-study
variance τ2 as specified below:
δ jbk ∼ Normal (dbk, τ2) where dbk=d jk−d jb. (2)
τ2 accounts for the random effect resulting from between-study variation.
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The fixed-effects model
When the between-study variance τ2= 0, the above random-effects model is reduced to a fixed-effects model:86
δ jbk = dbk. (3)
If A is treated as the overall MTC reference (baseline) treatment, then the effects of treatment B, C, D, . . . K
relative to A, dAB, dAC, dAD . . ., dAK are considered to be basic parameters and dAA= 0. All other parameters that
define treatment effect of one treatment relative to another in the model are called functional parameters.77
These functional parameters are derived from the basic parameters under the assumption that both direct and
indirect evidence estimate the same underlying treatment effect on each pairwise comparison:77
dBC = dAC− dAB (4)
dBD = dAD − dAB . . . (5)
dCD = dAD− dAC . . . (6)
dXY = dAY − dAX. (7)
The full random-effects model
The full random-effects model takes into account the correlation structure induced by multiarm trials.81
Multiarm trials on treatments A, X and Y, for example, induce a covariance between δjAX and δjAY. Under
the assumption of homogeneous variance in these trials, this covariance is reduced81,84 and is completely
accounted for in the model for any multiarm trials.
τ2=2. (8)
The choice of baseline treatment has no impact on the comparisons made.77 This covariance is accounted
for by formulating a correlation structure for any number of arms by decomposition of a multivariate
normal distribution as a series of conditional univariate distributions:86
x1
⋮
xp
0
@
1
A∼N µ1⋮
µp
0
@
1
A,
τ2 τ2=2 ⋯ τ2=2
τ2=2 τ2 … τ2=2
⋮ ⋮ ⋱ ⋮
τ2=2 τ2=2 ⋯ τ2
0
BB@
1
CCA
0
BB@
1
CCA, (9)
with the conditional univariate distributions being:
x1j
x1
⋮
xi−1
0
@
1
A∼N µi + 1i Σ i−1j=1(x j − µj), (i + 1)2i τ2
 
. (10)
Evidence search strategy
There is a wide range of infection prevention measures in current clinical practice, yet we focused on
key infection prevention strategies with critically important clinical and health-care cost implications.
These strategies include antibiotic prophylaxis, antibiotic-impregnated cement and laminar airflow systems.
We followed the systematic review guidelines as outlined in the Quality of Reporting of Meta-Analyses
statements87 and the guide to the methods of technology appraisal by NICE88 for the evidence synthesis.
The first stage of the literature search used existing systematic reviews on antibiotic prophylaxis,
antibiotic-impregnated cement and laminar airflow systems to locate relevant studies for inclusion in the
current evidence synthesis. The second-stage literature search was designed to update existing systematic
reviews by identifying new primary interventions for inclusion in the evidence synthesis. The major
electronic databases searched included MEDLINE (via EBSCOhost), EMBASE, Cumulative Index to Nursing
and Allied Health Literature and the Cochrane Central Register of Controlled Trials.
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Relevant journals, conference proceedings and bibliographies of retrieved papers were hand-searched.
Orthopaedic surgeons and infection prevention experts were also consulted. Owing to language resource
constraints, the search was limited to only English-language papers. The selection of evidence was
conducted by two independent reviewers and discrepancies were resolved by consensus. The search terms
and electronic search strategies used can be found in Appendix 1.
Definition of the outcome measure
The outcome measure used for the current evidence synthesis was deep SSI following primary THR. Failure
to use objective criteria to define SSIs has been shown to substantially affect reported SSI rates.89 For this
review process, which included international evidence, we relied on the definition used in the Guideline for
Prevention of Surgical Site Infection by the US Centers for Disease Control and Prevention.12 This definition
is described in Chapter 1.
Inclusion criteria
Studies were included if all of the following applied:
1. They were primary interventions with THR-related deep SSIs reported as an outcome.
2. Antibiotic prophylaxis, antibiotic-impregnated cement or laminar airflow system was a trial arm.
3. Antibiotic delivery methods were specified (systemically, via cement or both).
4. The type of ventilation system used in the operating theatre was indicated; otherwise, a conventional
ventilation system was assumed.
Some studies defined early deep infection as those requiring a revision procedure within 6 months of the
initial operation and used revision rates as early deep infection rates. Given that deep infections that
developed within this time frame were most likely caused by bacterial contamination at the time of
surgery, studies that only reported revision rates resulting from primary THR-related infection were
also included.
Exclusion criteria
Studies were excluded if any of the following applied:
1. Only superficial infection following THR was reported as an outcome measure, or superficial and deep
infection were treated as one outcome measure without separating one from the other.
2. Only joint replacement-related infection was reported as an outcome measure without separating
THR-related infection from knee replacement-related infection.
3. The outcome measure was revision not caused by SSI.
We treated antibiotic prophylaxis as one intervention arm without differentiating between types, doses and
durations of the administration of different antibiotic regimens. This is because there is no convincing
evidence to suggest that one type of antibiotic regimen is more effective than another, that extending the
duration of an antibiotic regimen beyond 24 hours postoperatively further reduces THR-related SSIs, or
that single-dose or short-term administration is not as effective as long-term administration.65 Therefore,
primary interventions that compared different types, doses or durations of antibiotic regimens were treated
as one-arm trials and excluded from the network meta-analysis, as MTC relies on there being at least
one comparison of two arms that can become part of the connected network.79 The process used for the
literature search is shown in Figure 8.
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The first-stage search through existing systematic reviews
The second-stage search: updating the existing systematic reviews
10 (from the first-stage search)  +  2 (from the second-stage search) = 12
10
Antibiotic-impregnated 
cement
Six trials (Parvizi et al., 
200891)  +  22 trials (Block
 and Stubbs, 200592)
Ventilation systems
 (laminar airflow) 17 trials 
(Whitehead et al., 200893)
Antibiotic prophylaxis
25 trials (Glenny and Song, 
199990)  +  26 trials
 (AlBuhairan et al., 20087)
196 (CINAHL) 140 (EMBASE)15 (Cochrane Central Register of Controlled Trials)289 (MEDLINE)
640
459
54
4
3
181 (duplicates)
405 (THR-related SSI was not an 
outcome measure)
50 (reviews/letters/abstracts/
commentaries, etc.)
1 (not separating superficial from
 deep infection)
1 (comparing different antibiotics)
2
25 + 26 + 6 + 22 + 17 = 96 26 duplicates
60 (reasons for exclusion listed 
in Appendix 2)
FIGURE 8 Two-stage literature search flow chart. CINAHL, Cumulative Index to Nursing and Allied Health
Literature. Reproduced from Zheng H, Barnett AG, Merollini K, Sutton A, Cooper N, Berendt T, et al. Control
strategies to prevent total hip replacement-related infections: a systematic review and mixed treatment
comparison. BMJ Open 2014;4:e003978.9 This is an Open Access article distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt,
build upon this work non-commercially, and license their derivative works on different terms, provided the original
work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/.
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Data extraction
Data were extracted by two independent reviewers and consensus was reached. The key data extracted
from the included studies for the evidence synthesis included the total number of THRs performed and the
total number of deep SSIs diagnosed following the THR operations in each trial; information regarding
the use of antibiotic prophylaxis and its delivery mode, for example systemically, via cement or both;
information about the ventilation system used in the operating theatre; and special surgical clothing used,
for example exhaust body suits. Where information regarding the use of the type of cement, antibiotic
impregnated or plain, was unavailable, plain cement was assumed. If a study reported both early and late
deep infection as outcome measures, the former was chosen over the latter in line with the Centers for
Disease Control and Prevention definition of SSI.12
Quality assessment
We conducted a quality assessment of the included studies. The method for quality grading was adapted
from NICE’s Methods for the Development of NICE Public Health Guidance (Third Edition)93 and NHS
Centre for Reviews and Dissemination guidance.94 Each study was categorised by study type and graded
based on the extent to which the potential sources of bias were minimised. The type of study coupled with
the quality evaluation decided the level of evidence. The level of evidence table was based on the checklist
of NICE’s Methods for the Development of NICE Public Health Guidance (Third Edition) that was adapted
from the Scottish Intercollegiate Guidelines Network. We also assessed the internal validity of the included
studies against the critical appraisal criteria based on the checklists of NICE’s Methods for the Development
of NICE Public Health Guidance (Third Edition) and NHS Centre for Reviews and Dissemination guidance.
Quality scores were allocated to the included studies using quality scoring systems adapted from that used
by the Cochrane Musculoskeletal Injuries Group for RCTs and by Tooth et al.95 for observational studies
(see Tables 62–66 in Appendix 3 and see Table 6 for results of the quality assessment).
The choice of reference treatment and testing the
statistical approach
We chose treatment (T) 1 to be ‘no antibiotic prophylaxis, plain cement and conventional ventilation
without laminar airflow system’. This was the reference treatment as it was trialled against the highest
number of other infection prevention strategies. The choice was made to minimise correlations that may
otherwise be induced between mean treatment effects for each pair of treatments compared. A number
of issues required investigation and the use of some diagnostics: variation in follow-up among the studies,
model fit and deviance, and consistency. The models were fitted within a Bayesian framework using
WinBUGS (MRC Biostatistics Unit, Cambridge, UK) and relevant code by Dias and colleagues.77 The
absolute and relative treatment effects and the ranking of infection prevention strategies were generated
and analysed.
Complementary log–log link to model variation in follow-up durations
The main model used for the evidence synthesis is a binomial likelihood, logit link random-effects model,
adjusting for multiarm trials. This model did not account for the variation in follow-up durations. Given
that THR-related SSIs tended to occur soon after the operation, the use of the logit link MTC models was
justified. However, as there was significant variation in the duration of follow-up in the included studies,
we conducted a sensitivity analysis using the following complementary log–log link that models the effect
of follow-up duration on the number of events occurring, taken from Dias et al.77
δik = cloglog(pik) = log(f i) + log(ψ i, bk) = log(f i) + µl + δi, bkI<k≠1>, (11)
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where φik is the event rate with respect to follow-up duration fi and δi,bk the treatment effects representing
log-hazard ratios:
Ifug =
n 1 if u is true
0 otherwise.
(12)
Modelling the baseline effect
In order to estimate absolute effects of infection prevention strategies, we modelled a baseline effect using
an absolute natural history model within a Bayesian framework:
θik = µi (13)
µi e N(m, δ2m), (14)
where θik is a trial-specific baseline effect (µ) in trial i in arm k. The trial-specific baselines are drawn from a
distribution (a normal distribution assumed) of effects with a common mean and variance. Vague priors
are put on the mean and variance: m∼N(0, 1002), and δm∼Uniform(0, 5).
Assessing model fit and deviance
We used the posterior mean of the residual deviance and the deviance information criterion (DIC) to assess
the goodness of fit of MTC models.77 The posterior mean of the residual deviance, Dres, is defined as the
deviance for the fitted model minus the deviance for the saturated model.77 Each unconstrained data point
i has a contribution Di to the residual deviance:
Dres = Σi Di. (15)
It is expected that each data point should contribute approximately 1 to the posterior mean deviance.77,96
Therefore, under the null hypothesis that the model adequately fits the data, Dres would have a mean
equal to the number of unconstrained data points for a perfectly fitted model.77,96 The DIC is defined as:
DIC = Dres + pD, (16)
where pD denotes the effective number of parameters, which is the sum of the leverages of each individual
observation, defined as the relative influence that each observation has on its own fitted value.
pD = Dres− D^, (17)
where D is the deviance calculated at the posterior mean of the model parameters or of the fitted values for
each data point (the predicted number of events estimated from the model) when non-linearity exists
between the likelihood and the model parameters.97 The DIC provides a measure of model fit that penalises
model complexity. Lower DIC values suggest a better-fitted model.97 When the model fit was poor, we
explored how each data point affected the model fit by plotting Di (each data point’s contribution to Dres)
against its contribution to pD (leverage).97 These summaries were displayed in a plot of leverage versus dri for
each data point, where dri = ±
ﬃﬃﬃ
D
p
i with sign given by the difference between the posterior mean of the
predicted and observed values for observation i. Curves of the form x2+ y= c with c= 1, 2, 3 and 4 were
plotted as they represented the lines of each contribution to DIC. Points lying on such parabolas each
contributed an amount c to DIC, with points lying outside the line c= 3 identified as contributing to the
model’s poor fit.
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Checking consistency by node splitting
The underlying assumption of MTC models is that direct and indirect sources of evidence estimate the
same underlying treatment effect across the MTC network. However, patient populations may differ in
their responsiveness to infection prevention strategies. We therefore examined the consistency of the MTC
models by using node splitting. Node splitting is based on splitting sources of information about a node in
a directed acyclic graph, which represents the dependency structure of a model.77 It allows the conflict
between the inferences on a node from different sources of information to be examined.77 We assessed
the inconsistency between the direct and indirect evidence for each treatment effect by splitting the
information in the model into direct and indirect information.77 Given that only pairs of treatments
that are part of a closed loop have both direct and indirect evidence available,84 and there can be no
inconsistency in multiarm trials,77 only five pairwise comparisons that formed two independent three-way
loops (see Figure 9, T3, T4 and T1, and T9, T8 and T7) in the evidence network needed to be checked for
consistency (see Appendix 4).
Two posterior distributions were obtained from the mean treatment effect dXY: one based on studies
comparing treatment X and Y directly, with mean dDirXY , and another indirectly with mean d
Ind
XY from a MTC
meta-analysis of all the remaining indirect evidence.
The inconsistency parameter was:
ωXY = d
Dir
XY − d
Ind
XY . (18)
A test of the null hypothesis showed that ωXY= 0 would provide evidence of consistency.77 We used the
posterior mean of the residual deviance Dres and the DIC to compare the full MTC model with the model
where a particular node was split. A reduction in Dres or DIC for the split model would suggest an
inconsistency between the different sources of evidence for a treatment. We also plotted each point’s
contribution to the DIC to identify which point in the data contributed to the poor model fit and how their
contribution changed when different nodes were split.77
Addressing heterogeneity
Between-study variability in intervention effects is broadly termed ‘heterogeneity’. It can be induced by
clinical diversity in terms of patient population, intervention or setting, or by variability in study design and
risk of bias. The former is commonly known as clinical heterogeneity and the latter as methodological
heterogeneity. We attempted to address both forms of heterogeneity with metaregression and
bias adjustment.
Metaregression on patient subgroup effects
Among the risk factors known to affect SSIs are patient age, sex and previous surgery. As the included
trials did not report sex-specific THR-related SSIs (nor significant variation in patient mean age), we focused
our attention on previous surgery as a potential covariate interacting with treatment effects and conducted
a metaregression using the following subgroup random-effects model:77
θik = logit(pik) = µi + (δik + βXi)Ifk≠1g, (19)
where θik is the linear predictor in arm k of trial i, µi the trial-specific baseline effects in trial i, and xi is the
trial-level covariate for trial i, which represents a patient subgroup:
xl =

0 if trial i did not report patient group with previous surgery
1 if trial i reported patient group with previous surgery
; (20)
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δ is the trial-specific log-ORs of the SSIs in the intervention compared with the control for the patient
group with no previous surgery reported, and β measures the change in the log-ORs for previous surgery.
The trial-specific log-ORs have a common distribution: δi ∼ N(d, σ2).77
d, β and σ are given independent priors in the Bayesian framework: d, β∼N(0,1002) and σ∼Uniform(0,5).77
Metaregression on follow-up duration effects
Given the significant variation in follow-up durations of included studies, we conducted a metaregression
on follow-up duration as a potential risk of bias for intervention effects using a centred covariate model:
θik = µi + (δik + β(xi−x))IfK≠1g, (21)
where xi is a follow-up duration covariate in trial i and x is the mean covariate value. The intervention
effects were estimated at the mean covariate value, and uncentred and transformed to produce mean
intervention effects at a given covariate value z:
d− β(x − z). (22)
Estimating and adjusting for bias in the mixed-treatment comparison network
With the assumption that the mean and variance of study-specific biases are the same for each treatment
in the MTC network, it is possible to simultaneously estimate treatment effects and bias effects in a
single analysis, and thus to produce treatment effects that are based on the entire body of data, including
both low- and high-quality studies, and also adjust for bias.
We used the following model to estimate and adjust for bias of mixed-quality studies (RCTs and
observational studies) contained in the MTC network:
θik = µi + (δik + βikxi)Ifk≠1g, (23)
where xi= 1 if study i is of low quality (observational) and considered to be at risk of bias and zero for
RCTs; βik is the trial-specific bias of the treatment in arm k relative to the treatment in arm 1 of trial i.
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Chapter 3 Results of synthesis of effectiveness
evidence
Description of the evidence and interventions
From the 12 studies identified by the process shown in Figure 8, six were RCTs98–103 and six were
observational studies.104–109 They included 123,788 THRs and nine infection prevention strategies, as shown
in the MTC network (Figure 9). The data from the included papers are shown in Table 6.
The quality of evidence summarised in Table 6 was variable, with quality score between 11 and 21
(see Tables 65 and 66 in Appendix 3 for the scoring tools used). Five of the six RCT studies99–103 provided
no information on random sequence generation, four100–103 provided no information on blinding assessors
and only one98 reported prior calculation of the sample size. The statistical power for most RCTs was
generally low. Only one98 RCT reported primary analysis based on all randomised cases, whereas the rest
did not report intention to treat. Of the six observational studies, three105,108,109 identified and adjusted for
confounding variables, one106 reported that cases and control groups were comparable on diagnostic
confounding factors and two108,109 described and included in the analysis the outcomes of the patients
who withdrew. Three studies101,108,109 used objective measures to assess the outcomes and were adequately
powered with large sample size ranging from 10,905 to 51,485.
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Effectiveness outcomes
For every strategy in the connected network a relative effect was estimated against another infection prevention
strategy using an OR of SSI. We chose ‘no systemic antibiotics, plain cement and conventional ventilation’ as the
reference strategy (T1), as it was compared with the greatest number of other strategies.
Thirty-six relative effects involving nine infection prevention strategies were estimated in the MTC network
using models that did and did not adjust for duration of follow-up (Table 7). The results from both models
were almost identical, as were estimates of the model fit; therefore, the differences in follow-up duration
had little effect on the effectiveness of the infection strategies. Therefore, we report the results of the
model without adjustment for follow-up from now on. The 36 ORs for all pairwise comparisons are
presented in the forest plot in Figure 10. The probability and median rank of a strategy being the most
effective strategy is shown in Table 8. The models were fitted in a Bayesian framework using WinBUGS
and code by Dias et al.110
TABLE 7 Odds ratios with 95% credible intervals of all infection prevention strategies
Treatment
Treatment
T1 T2 T3 T4 T5 T6 T7 T8
T2 0.31 (0.12
to 0.65)
T3 0.26 (0.03
to 0.95)
0.92 (0.11
to 3.39)
T4 0.25 (0.06
to 0.66)
0.84 (0.28
to 1.97)
1.93 (0.20
to 7.58)
T5 0.38 (0.09
to 1.12)
1.28 (0.38
to 3.38)
3.28 (0.27
to 14.15)
1.96 (0.37
to 6.54)
T6 0.13 (0.03
to 0.35)
0.44 (0.13
to 1.13)
1.12 (0.09
to 4.62)
0.67 (0.12
to 2.12)
0.43 (0.09
to 1.24)
T7 0.27 (0.03
to 0.93)
0.90 (0.13
to 3.14)
2.47 (0.11
to 10.22)
1.41 (0.14
to 5.35)
0.88 (0.09
to 3.10)
1.96 (0.52
to 5.37)
T8 0.52 (0.03
to 2.12)
1.77 (0.11
to 7.20)
5.78 (0.10
to 21.12)
2.89 (0.12
to 11.73)
1.71 (0.08
to 6.93)
3.72 (0.38
to 13.75)
2.26 (0.22
to 8.48)
T9 0.74 (0.05
to 2.69)
2.49 (0.20
to 9.11)
13.15 (0.18
to 27.4)
4.11 (0.22
to 14.92)
2.44 (0.15
to 8.62)
5.00 (0.73
to 16.87)
3.14 (0.42
to 10.41)
2.53 (0.23
to 10.41)
Model fit statistic (posterior mean
residual deviance) 34.3a
Model fit statistic (DIC)
180.6
Heterogeneity (between-study
deviation) 0.62
a Compared with 32 data points. Note that model fit is considered to be adequate if posterior mean residual deviance is
approximately equal to the total number of data points.97
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FIGURE 10 Forest plot of ORs of SSI for infection prevention strategies (random effects). Reproduced from
Zheng H, Barnett AG, Merollini K, Sutton A, Cooper N, Berendt T, et al. Control strategies to prevent total hip
replacement-related infections: a systematic review and mixed treatment comparison. BMJ Open 2014;4:e003978.9
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The five infection prevention strategies associated with a statistically significant reduction in THR-related SSI
compared with the reference strategy (T1) were:
1. T6 with an OR of 0.13 [95% credible interval (CrI) 0.03 to 0.35]; systemic antibiotics, antibiotic-impregnated
cement and conventional ventilation
2. T4 with an OR of 0.25 (95% CrI 0.06 to 0.66); systemic antibiotics, plain cement and laminar airflow
3. T3 with an OR of 0.26 (95% CrI 0.03 to 0.95); no systemic antibiotics, plain cement and laminar airflow
4. T7 with an OR of 0.27 (95% CrI 0.03 to 0.93); systemic antibiotics, antibiotic-impregnated cement and
laminar airflow
5. T2 with an OR of 0.31 (95% CrI 0.12 to 0.65); systemic antibiotics, plain cement and
conventional ventilation.
Statistically non-significant reductions in THR-related SSI compared with the reference strategy, T1, were:
l T5 with an OR of 0.38 (95% CrI 0.09 to 1.12); no systemic antibiotics, antibiotic-impregnated cement
and conventional ventilation
l T8 with an OR of 0.52 (95% CrI 0.03 to 2.12); systemic antibiotics, antibiotic-impregnated cement,
conventional ventilation and body exhaust suit
l T9 with an OR of 0.74 (95% CrI 0.05 to 2.69); systemic antibiotics, antibiotic-impregnated cement,
laminar ventilation and body exhaust suit.
When T7 was compared with T6, the OR of SSI was 1.96 (95% CrI 0.52 to 5.37), suggesting that laminar
airflow could increase infection risk. Similarly, when T8 was compared with T6, the OR was 3.72 (95% CrI
0.38 to 13.75), suggesting that body exhaust suits may also increase infection risk, at least where there is
conventional ventilation. There was no high-quality evidence that antibiotic-impregnated cement without
systemic antibiotics was more effective in reducing infection than plain cement and systemic antibiotics
(T2 vs. T5; OR 1.28, 95% CrI 0.38 to 3.38). All comparisons and interpretations are summarised in Table 9.
TABLE 8 Probability of each infection prevention strategy being the most effective
Infection prevention strategies Probability Median rank (95% CrI)
T1 0.00 9 (7 to 9)
T2 0.00 6 (3 to 8)
T3 0.24 3 (1 to 8)
T4 0.06 4 (1 to 8)
T5 0.02 6 (2 to 8)
T6 0.47 2 (1 to 5)
T7 0.08 3 (1 to 8)
T8 0.10 5 (1 to 9)
T9 0.02 7 (2 to 9)
CrI, credible interval.
Reproduced from Zheng H, Barnett AG, Merollini K, Sutton A, Cooper N, Berendt T, et al. Control strategies to prevent total
hip replacement-related infections: a systematic review and mixed treatment comparison. BMJ Open 2014;4:e003978.9
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Model fit and evidence consistency
The model fit statistics indicate that the fit was less than adequate (see Table 7). This was confirmed by
diagnostic plots that showed infection prevention strategies T2 and T5 of study 4102 and the T1 strategy of
study 10109 were outliers contributing to the inadequate model fit (Figure 11).
Curves of the quadratic function were plotted as they represented the lines of each contribution to DIC.
Points lying outside the line c= 3, were identified as contributing to the inadequate model fit. The plot
shows the first and second arms, strategies T2 and T5, of study 4102 are outliers contributing to the
inadequate model fit.
After exclusion of both the first and second arms of study 4102 (T4 and T1, and T4 and T2, respectively),
the model fitted the data well and the heterogeneity was significantly reduced, but the results were little
changed (Figure 12).
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FIGURE 11 Leverage vs. deviance residual superimposed on curves y= –x2+ c, where c= T1, T2, T3 and T4,
representing the amount contributed to DIC. Reproduced from Zheng H, Barnett AG, Merollini K, Sutton A,
Cooper N, Berendt T, et al. Control strategies to prevent total hip replacement-related infections: a systematic
review and mixed treatment comparison. BMJ Open 2014;4:e003978.9 This is an Open Access article distributed in
accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others
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A further sensitivity analysis was undertaken that removed the first arm of study 10109 (T1 and T10) (Figure 13).
After excluding study 10109 from the network, all the remaining data points lay below the quadratic curve with
c= 3, suggesting that the contribution of the remaining data points to the DIC was unimportant, which in
turn would improve the model fit.
Following these sensitivity analyses, infection prevention strategy T6 remained dominant, with the highest
probability (64%) and highest median rank of being the most effective strategy (Table 10).
The MTC results are shown in Table 11. The sensitivity analysis that excluded studies 4102 and 10109 from the
MTC network showed that model fit was improved; the DIC was reduced from 180.6 to 141.8.
The posterior mean residual deviance was also reduced from 34.3 to 25.3. Heterogeneity measured in
between-study standard deviation across the MTC network also reduced from 0.63 to 0.43.
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FIGURE 12 Sensitivity analysis excluding the first and second arms of study 4102 (T4 and T1, and T4 and T2,
respectively). Leverage vs. deviance residual superimposed on curves: y= –x2+ c, where c= T1, T2, T3 and T4,
representing the amount contributed to DIC. Reproduced from Zheng H, Barnett AG, Merollini K, Sutton A,
Cooper N, Berendt T, et al. Control strategies to prevent total hip replacement-related infections: a systematic
review and mixed treatment comparison. BMJ Open 2014;4:e003978.9 This is an Open Access article distributed in
accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others
to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different
terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/3.0/.
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FIGURE 13 Sensitivity analysis by further excluding the first arm of study 10109 (T1 and T10). Leverage vs. deviance
residual superimposed on curves: y= –x2+ c, where c= T1, T2, T3 and T4, representing the amount contributed to
DIC. Reproduced from Zheng H, Barnett AG, Merollini K, Sutton A, Cooper N, Berendt T, et al. Control strategies to
prevent total hip replacement-related infections: a systematic review and mixed treatment comparison. BMJ Open
2014;4:e003978.9 This is an Open Access article distributed in accordance with the Creative Commons Attribution
Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work
non-commercially, and license their derivative works on different terms, provided the original work is properly
cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/.
TABLE 10 The probability of each infection prevention strategy being the best strategy and its median rank
(sensitivity analyses)
Infection prevention strategies Probability Median rank (95% CrI)
T1 0.00 9 (7 to 9)
T2 0.01 6 (2 to 8)
T3 0.14 4 (1 to 8)
T4 0.05 4 (1 to 7)
T5 0.00 8 (4 to 9)
T6 0.64 1 (1 to 4)
T7 0.05 3 (1 to 7)
T8 0.10 4 (1 to 8)
T9 0.01 6 (2 to 9)
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The direct evidence from all conventional pairwise meta-analyses is presented in Table 12. There was broad
agreement among the direct evidence from conventional pairwise meta-analyses, the direct and indirect
evidence from node splitting and the evidence from the MTC model. Tests for inconsistency between
direct and indirect evidence from node splitting suggested that there was no statistically significant
evidence of inconsistency. The model fit statistics for the node splitting and the MTC models were similar,
implying that there was no conflict between the direct and indirect evidence. It is worth noting that the
95% CrIs for some pairwise comparisons widened greatly following node splitting. This is explained by the
node splitting reducing the evidence available to inform the variance.
A test of interaction between RCTs and observational studies was not statistically significant, suggesting
that combining these study types was not inappropriate (Table 13).
The results were little changed by excluding the RCT by Hill et al.98 (Table 14) or by including the RCT by
Lidwell et al.111 (Table 15).
Strategy T6 (systemic antibiotics, antibiotic-impregnated cement and conventional ventilation) remained
dominant in both these further analyses, with the highest probability of being a cost-effective decision
(63% and 83%, respectively) and highest median rank of being the most effective strategy (see Tables 14
and 15).
TABLE 11 Odds ratios with 95% CrIs of all nine infection prevention strategies (sensitivity analysis)
Treatment
Treatment
T1 T2 T3 T4 T5 T6 T7 T8
T2 0.22 (0.08
to 0.43)
T3 0.20 (0.03
to 0.60)
1.00 (0.15
to 3.21)
T4 0.19 (0.06
to 0.43)
0.87 (0.35
to 1.86)
1.61 (0.23
to 5.78)
T5 0.76 (0.11
to 2.23)
3.39 (0.61
to 10.42)
7.09 (0.48
to 28)
4.80 (0.62
to 16.16)
T6 0.09 (0.02
to 0.25)
0.43 (0.09
to 1.27)
0.63 (0.09
to 1.92)
0.63 (0.09
to 1.92)
0.19 (0.24
to 0.69)
T7 0.33 (0.02
to 0.56)
1.05 (0.11
to 2.90)
3.92 (0.09
to 6.67)
1.74 (0.12
to 4.22)
0.46 (0.03
to 1.43)
1.85 (0.67
to 4.20)
T8 0.83 (0.02
to 1.16)
10.75 (0.09
to 15.88)
43.12 (0.08
to 12.92)
6.84 (0.10
to 8.44)
1.04 (0.03
to 2.83)
3.83 (0.44
to 10.33)
2.05 (0.27
to 6.33)
T9 0.66 (0.03
to 1.44)
3.42 (0.19
to 7.35)
10.32 (0.16
to 16.24)
4.60 (0.20
to 10.58)
1.29 (0.06
to 3.57)
4.72 (1.00
to 10.27)
3.23 (0.58
to 7.56)
2.39 (0.31
to 8.37)
Model fit statistic (posterior mean
residual deviance) 25.3a
Model fit statistic (DIC)
141.8
Heterogeneity (between-study
deviation) 0.43
a Compared with 32 data points. Note that model fit is considered to be adequate if posterior mean residual deviance is
approximately equal to the total number of data points.97
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TABLE 13 Metaregression on subgroup interaction between RCTs and observational studies
Models (10 studies included)
The posterior
mean residual
deviance DIC
β (subgroup interaction
term)
Heterogeneity
(between-study
standard deviation)
The random-effects metaregression
model
24.3 141 1.4 (95% CrI –0.3 to 3.5) 0.4
The random-effects MTC model 25.3 141.8 Not applicable 0.4
TABLE 14 Probability of each infection prevention strategy being the best, excluding Hill et al.98
Treatment Probability of each strategy being the best Median rank (95% CrI)
T1 0.00 8 (5 to 8)
T2 0.01 5 (2 to 7)
T4 0.16 3 (1 to 7)
T5 0.01 7 (3 to 8)
T6 0.63 1 (1 to 4)
T7 0.06 3 (1 to 6)
T8 0.11 4 (1 to 8)
T9 0.02 5 (2 to 8)
TABLE 15 Probability of each infection prevention strategy being the best, including Lidwell et al.111
Treatment Probability of each strategy being the best Median rank (95% CrI)
T1 0.00 9 (7 to 9)
T2 0.00 5 (3 to 7)
T3 0.01 7 (2 to 8)
T4 0.03 4 (1 to 7)
T5 0.00 8 (3 to 9)
T6 0.83 1 (1 to 3)
T7 0.04 2 (1 to 6)
T8 0.09 4 (1 to 8)
T9 0.01 5 (2 to 8)
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Chapter 4 Cost-effectiveness methods
Background
The purpose of this cost-effectiveness study is to evaluate change in cost and health outcomes arising from
each of the identified infection prevention strategies. The main decision-making group in the NHS is NICE,
and it uses cost-effectiveness information to compare the health benefits forgone from competing
configurations of NHS services. This approach meets the social objective of making improvements to health
when the budget for services is fixed. It requires a systematic assessment of the changes to costs and the
changes to health from alternate configurations of services.112
Costs
The change in costs is shown as ΔC and includes the positive costs from implementing an infection
prevention strategy and all the cost savings that arise from the avoided infections, such as reduced length
of stay and revisions. Costs are estimated as quantities of resource used, q, and prices, p. The latter are
estimated using existing market prices or shadow prices. In processes of production, costs can be fixed or
variable. Fixed costs cannot be changed short term and do not vary with fluctuations in productivity or
output, whereas variable costs are flexible and change with productivity levels.47 The sum of both these
costs is the total cost. For the interpretation of costs of competing health-care alternatives we will estimate
the incremental change to total costs. Incremental costs are more helpful for decision-making as they show
the costs of achieving an additional unit of health benefit.113
The perspective for the analysis determines the scope of the costs included, and for this project we assume
only those costs incurred by the NHS are relevant. Private costs are excluded because of the difficulty in
assigning a shadow price to certain items, such as volunteer time.
Costs that occur in the present are usually given more value than future costs and hence are discounted.
To avoid inconsistencies in the conclusions, both costs and benefits arising in the future need to be
discounted, typically at a rate of 3%; this is the rate used for this research. Without discounting,
inconsistencies in the overall allocation of resources could arise, as we would be treating the value of
health care differently compared with economic benefits of other sectors in the economy.47
Health outcomes
The change in health outcomes/effects are shown as ΔE. This summarises the gain in health outcomes
from a decision to adopt a treatment strategy. In this case we use the QALY, which serves as a generic
measure of health outcomes. It is widely used since it allows a combination of both morbidity, measuring
quality of life, and mortality, measuring length of life, into a single score.114
Utility scores describe the quality of life in a certain health state where perfect health is valued 1 and death
0. A QALY is the product of a utility score and the time spent in that health state. In Figure 14 an example
of two competing alternatives with different health outcomes is shown. Alternative A generates two
additional life-years at a utility of 0.8, whereas alternative B offers four additional life-years at a lower
utility of 0.6. The calculation of QALYs below shows that alternative B generates 0.8 extra QALY outcomes
than alternative A. Health benefits are not discounted in this example.
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A widely used method for valuing the utility of different health states is a multiattribute utility scale.115
Examples of instruments using a multiattribute utility scale include the European Quality of Life-5
Dimensions (EQ-5D) questionnaire, developed by the EuroQoL Group, and the Assessment of Quality of
Life and Short Form questionnaire-6 Dimensions.47 These classification systems allow the derivation of
preferences for health states using prescored measurements called utility weights. The utility weights have
been valued previously, by a representative sample of the population for which it is used. The EQ-5D is one
of the most widespread instruments and measures five dimensions – mobility, self-care, usual activities,
pain/discomfort and anxiety/depression – with three levels for each and so defines a total of 243 health
states.115 People with a certain disease or health outcome are asked to respond to a question for each
dimension and their answers are used to determine which health state best fits their condition. The UK
value set generated by Dolan116 for the EQ-5D was used for this project.
Incremental cost-effectiveness
The ICER is shown below as the cost incurred to gain 1 QALY:
ICER =
CT − CC
ET − EC
=
ΔC
ΔE
. (24)
It arises by comparing the costs and health outcomes of novel treatments or health programmes (CT) with
the costs of the baseline comparator (CC). In Table 16 we show hypothetical outcomes of current practice
compared with a novel infection prevention strategy, and how the resulting ICER is calculated.
A decision to adopt a new treatment or service depends on a number of factors, most importantly the
ability and willingness to pay for marginal health benefits. This value is reflected by the ceiling or threshold
ratio, such as £25,000–£35,000, traditionally used by NICE.117 An evidence-based approach to finding a
threshold was presented recently by Claxton et al.,118 who found that values of around £18,000 were
more appropriate. Combined uncertainty in the estimates showed that the probability that the threshold is
< £20,000 per QALY is 0.64 and the probability that it is < £30,000 is 0.92.118 Other factors influencing
health policy decisions are social value judgements, such as equity and efficiency, the level of need in the
community or the severity of a given outcome.117,119
1.0
0.8
0.6
0.4
0.2
0.0Death Life-years
Outcomes
Alternative A: 0.8 × 2 = 1.6 QALYs
Alternative B: 0.6 × 4 = 2.4 QALYs
Net benefit of B over A: 2.4–1.6  = 0.8 QALYs
Perfect health
0 2 4 6
Alternative A
Alternative B
FIGURE 14 Example of a QALY calculation of two alternatives.
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Cost-effectiveness planes are used to summarise results, and Figure 15 shows the ICER from the example
in Table 16. Current practice is at the origin, the x-axis represents the effectiveness and the y-axis
represents the costs associated with the infection prevention alternative. The ceiling ratio in green indicates
the maximum willingness to pay for one extra unit of outcome (i.e. 1 QALY).
Strategies can fall into one of four quadrants describing possible combinations of incremental costs and
benefits. Strong dominance exists for strategies that fall in quadrants II and IV. As infection prevention
alternatives in quadrant IV cost less and are more effective, they should always be accepted and are
described as dominant. On the other hand, strategies falling into quadrant II cost more and give less
benefit. These are described as dominated and should always be rejected by decision-makers. For
strategies in quadrant I or III, the decision is more complex. Strategies falling into quadrant III are less costly
but also have a lower effectiveness, whereas those falling into quadrant I are more costly but return better
health outcomes.120,121 For these cases the ceiling ratio is crucial for making a decision about accepting or
rejecting an alternative strategy. Strategies with an ICER below the ceiling ratio are likely to be accepted,
and those above are likely to be rejected.
The novel strategy in the hypothetical example shows higher incremental costs and benefits than current
practice and lies in quadrant I. At £5000 per QALY gained, it falls below the ceiling ratio and we would
therefore expect the decision-maker to adopt the new treatment strategy.
TABLE 16 Hypothetical outcomes of two alternatives facilitating the calculation of an ICER
Costs (£) QALYs
Current practice 1,800,000 210
Novel strategy 2,000,000 250
Difference 200,000 40
ICER 5000/QALY
III
IVIII
Lower costs
Higher costs
Lower
 effectiveness
Higher
 effectiveness40
£200,000
Ceiling ratio
Novel strategy
FIGURE 15 Cost-effectiveness plane showing an ICER example of a novel strategy in the context of a ceiling ratio.
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Models versus prospective trials
Cost-effectiveness studies can be undertaken either as decision models or alongside prospective clinical
trials. The latter are called ‘piggyback’ economic evaluations, meaning that economic data are collected
alongside trial-specific clinical data. The positive aspects of this approach are low marginal costs of
collecting economic data and the availability of patient-specific data for both costs and outcomes. But the
fact that clinical trials are designed to assess clinical issues, such as treatment effects, can be problematic.
Economic models focus on informing a specific decision, whereas trials never include all treatment
alternatives relevant to a health-care decision and often compare new treatment with a placebo
alternative. Economic models can include all relevant options, represented in a model structure. It is
important to always compare current practice with the alternative of ‘doing nothing’, which can be
simulated in a hypothetical model without randomising real patients.122,123
Randomised trials allocate patients into groups, have relatively small sample sizes and are designed to
capture short to intermediate outcomes. Follow-up of patients usually ends at a clinically significant time
point, often when the efficacy of a treatment or medication is established. But other long-term effects,
such as mortality beyond study end points, may nevertheless play an important role for the implementation
of an alternative. Economic models have the advantage that they can simulate large patient cohorts over
their lifetimes and, therefore, estimate long-term health outcomes without the time and money constraints
of clinical studies.47 Further advantages of models are that they can make indirect comparisons between
alternatives for which no RCT is available. They can also be used to observe how outcomes change when
certain parameters or assumptions are varied.122
Randomised controlled trials are a gold standard measurement of outcomes and may differ from real-
world scenarios. Economic models, on the other hand, synthesise data from different sources, including
RCTs. Therefore, they can integrate data specific to the country of interest, such as particular occurrence
and management strategies of a disease.118 Consequently, RCTs often cannot be generalised, whereas
economic models are better at reflecting real-world settings using real-world data inputs.123
Evidence used in decision models
Decision models employ data from a range of sources to inform the model structure and parameters.
Economic analysis based on data from a single RCT could introduce bias because of the method of
analysis, confounding or patient selection.60,123 In decision models, evidence is commonly required for
model pathways with related probabilities, clinical effect size, baseline clinical data, resource use, costs and
utilities. Possible data sources have been categorised as research based, real world based and reference
based.118,124 Research-based sources of evidence include RCTs, meta-analyses of RCTs, observational studies
and economic models. Examples of real-world data sources are administrative databases, hospital or other
health-care statistics and disease registers. Reference-based data sources refer to established standards in a
decision-making context, such as guidelines, disease classifications or drug formularies.125
Depending on the model component, different data sources might be more suitable than others. For the
assessment of treatment effects, well-conducted clinical trials or systematic reviews of clinical trials
including meta-analyses are favoured.122,126 However, systematic reviews can very rarely be performed for
each single model input because of time and resource constraints. In this case, alternative search
techniques can be used, known as ‘pearl growing’ and ‘berrypicking’, which start with reviewing relevant
studies and studies related to these studies until enough evidence is collected.127,128 Although it is hard to
determine when sufficient evidence has been identified, economic models can be used to establish the
value of collecting more information.129 Furthermore, systematic reviews are not always required or the
ideal source of data.118 Cost and resource use are often informed by local sources, by primary data
collection or routinely collected data, as they can vary greatly in different settings.
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A good model will include the most important events that impact on costs and health outcomes, rather
than all possible events.125 The model structure is typically developed and validated with the help of experts
in the field, and the structure of models can be updated as new evidence becomes available.130
Potential hierarchies of data sources have been developed to facilitate the selection of appropriate
evidence.60 Rankings of data components included in the hierarchy are clinical effect sizes, adverse events
and complications, baseline clinical data, resource use, costs and utilities. For baseline clinical data, for
example, the best available evidence would be a case series or a reliable database specifically developed
for the study of interest, with patients from the jurisdiction of interest. Evidence of poorer quality would be
recent case series not developed for the study or include patients from another jurisdiction. Further down
in the hierarchy are old case series, estimates from RCTs, estimates from previously published economic
analyses and, finally, expert opinion.
It is essential that the best available evidence is used to inform decision models as the results are only as
reliable as the data input with the lowest quality.60 However, the identification of all relevant evidence is
very demanding and most search strategies practised lack uniformity and transparency.124 There are no
clear guidelines on this process and a recent review of modelling guidelines reported inconsistent advice.59
This methodological issue has been recognised and more guidance on searches for model parameters
is anticipated.59,125
Uncertainty in parameters
Model parameters such as probabilities, relative risk, costs and utilities are estimates and their true value is
usually unknown. In order to reduce the risk of bias and improve the usefulness of a model for decision-
making, it is crucial to assess the extent of uncertainty around parameter estimates and its overall effect on
model outcomes. A semi-Bayesian framework is suitable to capture uncertainty in model parameters.131
Instead of using only point estimates the whole distribution of a parameter can be used in probabilistic
sensitivity analyses (PSAs). The first step is to fit distributions around individual model parameters. Some
distributions are more suitable for certain parameters because of their natural features, for example cost
parameters are always positive and skewed, hence gamma distributions are a good fit (Figure 16).
Possible shapes of beta distributions are shown in Figure 17. Beta distributions take values between 0
and 1 and are therefore suited to distributions of probabilities in the model.
Briggs et al.132 summarises the following types of distributions, typically used to fit data likelihood functions
to model parameters (Table 17).
Once distributions are fitted around model parameters a Monte Carlo simulation is used in which values
are drawn randomly for each parameter from the assigned distribution. The model is run multiple times,
each time with new values selected at random. The result is a joint posterior distribution of costs and
effects.133 This output distribution can be plotted on the cost-effectiveness plane illustrating incremental
costs and incremental effectiveness for each of the simulations.
Figure 18 shows the PSA results for the novel infection prevention strategy example. Instead of giving the
results of thousands of simulations, only 10 simulations are illustrated here, for simplification purposes.
The initial ICER is surrounded by possible outcomes generated by the Monte Carlo simulation, represented
by the blue circles. The area of uncertainty forms a cloud of point estimates.
Whether or not a strategy is cost-effective depends on the proportion of the point estimates generated by
the Monte Carlo simulation that fall in the cost-effective part of the plane, under the ceiling ratio line. As
seven point estimates in the example are below the given ceiling ratio, there is a 70% chance that the
novel strategy is cost-effective and, therefore, optimal for decision-makers. However, this approach is only
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FIGURE 16 Examples of gamma distributions.
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FIGURE 17 Examples of beta distributions.
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Novel strategy
FIGURE 18 Example of uncertainty cloud on the cost-effectiveness plane.
TABLE 17 Types of distributions frequently used for model parameters
Parameter Form of data/method of estimation Candidate distribution
Probability (0≤ π≤ 1) Binomial/multinomial: estimated proportion(s).
Time to event: survival analysis
Beta(α,β),α,β> 0
Log-normal(lm,lv),lm,lv> 0
Relative risk (θ> 0) Binomial: ratio of estimated proportions Log-normal(lm,lv),lm,lv> 0
Cost (θ≥ 0) Weighted sum of resource counts: mean Gamma(α,β),α,β> 0
Log-normal(lm,lv),lm,lv> 0
Utility (θ≥ 0) Continuous non-zero: mean Gamma(α,β),α,β> 0
Log-normal(lm,lv),lm,lv> 0
All parameters Any distribution of data Normal(µ,σ2),σ2> 0
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useful when there is one choice compared with a current practice comparator. When multiple options are
available to decision-makers, another interpretation of the results is required.
The concept of incremental net monetary benefit (NMB) is appropriate and represents a single-figure
summary of the outcome measures of cost and health benefits (QALYs).134 It is derived by rearranging the
formula for calculating ICERs and incorporating the ceiling ratio, λ.
ICER =
CT − CC
ET − EC
=
ΔC
ΔE
< λ. (25)
The NMB is calculated by multiplying the ceiling ratio by the average incremental health benefits and,
subsequently, deducting average incremental costs:
NMB = (λ × ΔE) − ΔC. (26)
Employing the NMB simplifies the statistical interpretation of decision model results. The alternative with
the highest mean NMB is the best option for decision-makers as it maximises health benefits under
conditions of scarce resources.135 This may not be the outcome with the highest probability of being the
best decision, and the cause of the discrepancy is worth discussing. Halton et al.136 shows exactly why this
occurs via an example reproduced in Table 18.
These results show that treatment A is optimal only once out of the five simulations from the model
parameters, giving a 20% chance it is the best choice and an 80% chance it is the wrong choice.
Treatment B or remaining with baseline reveals higher chances of being an optimal decision, yet treatment
A has the highest NMB at 126 and so is the best decision if the objective is to maximise health benefits
under conditions of scarce resources. The reason for this apparent contradiction is that the distribution of
NMBs is skewed. There could be a few large outlier values for treatment A that drag the mean NMB
statistic to a higher value; in this case the value of 150 shown twice in Table 18 is fulfilling this. The only
way to interpret the information in Table 18 is to say that treatment A is best, but there is great
uncertainty in this conclusion with an 80% chance it is incorrect. In this case more research might be
required to reduce this uncertainty.135 If the NMB outcome were normally distributed, then the treatment
with the highest probability of being cost-effective would also be the one with the highest NMB.135
The generalisation of the decision rule to multiple comparators implies we choose the option with the
maximum incremental NMB.
TABLE 18 Incremental NMBs for a hypothetical evaluation comparing two novel treatments to standard practice
Baseline Treatment A Treatment B Optimal choice
Simulation 1 140 150 160 B
Simulation 2 100 110 120 B
Simulation 3 110 100 100 Baseline
Simulation 4 100 150 130 A
Simulation 5 130 120 110 Baseline
Average of the incremental NMB 116 126 124 Baseline/A/B= 40%/20%/40%
Reproduced from Halton et al.136 under the Creative Commons Attribution Licence CC BY 2.0 (http://creativecommons.org/
licenses/by/2.0).
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Other sources of uncertainty
In addition to parameter uncertainty, other types of uncertainty should also be considered: uncertainty in
model structure or assumptions, patient heterogeneity and variability. An approach favoured by NICE to
test model assumptions is called scenario analysis and can be performed as part of the PSA. In a scenario
analysis, the model assumptions are varied and the PSA run for each change. The different scenarios are
compared and the most robust one is selected.137 Patient heterogeneity is a type of uncertainty that can be
explained, for example, by different age or sex of patients. Variability, on the other hand, refers to random
differences between patients that cannot be explained, that is, differences occurring by chance.132 In order
to deal with heterogeneity between patient groups, multiple acceptability curves can be employed, for
example for different age groups or according to sex. Decision-makers can subsequently identify which
infection prevention strategies are cost-effective for certain patient subgroups (e.g. 80-year-old males).
A scenario analysis can also be performed for variability, such as different types of hospitals or levels of
surgeon experience, but this depends on the information available.
Markov models
The mechanism of Markov models is explained in this section using a very simple example: a model with
only two health states and a death state. Model health states are mutually exclusive and death is an
absorbing state, because once an individual has entered the state, they must remain there.138 As Markov
models generally start with a cohort of people at risk of a disease, the example starts with a cohort of
patients at risk of developing an infection. The model can capture the probability of patients remaining in
the initial state (‘no infection’) or moving into one of the other health states (‘infection’ or ‘death’). These
transitions occur within a previously defined time period, called a ‘Markov cycle’.132,138 The length of model
cycle depends on the research question but could be hours, days, months or years and can be run for any
period of time, up to the full lifetime of a patient or cohort of patients. In each model cycle individuals
have a certain probability of moving between health states, shown by the arrows in Figure 19.
In this example it is possible for an individual to remain in their current health state, move to the other one
or die in any cycle. The fictional transition probabilities for this example are summarised in a transition
matrix, illustrated in Table 19.
This table is to be read from left to right; for example, the probability of moving from ‘no infection’
(first column) to ‘infection’ (third column) is 0.15, representing 15% of patients. All transition probabilities
sum to 1, as it is not possible to leave the model. As indicated by the ‘0’ in the matrix, transitions from the
death state to other health states are not possible. The transition probabilities in this simplified example are
constant but they can be time dependent and adjusted or varied for different cycles. Commonly, the
probability of dying is adjusted as the mortality rate increases with age.
No infection
No infection
Infection
Infection
Death
Death
Cycle 1
Cycle 2
FIGURE 19 Possible transitions between Markov model health states in a given cycle.
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A Markov trace can be computed using the probabilities in the transition matrix for all model cycles. The
Markov trace for the first five cycles of the example model is shown in Table 20. The model simulation
starts with a cohort of 1000 patients free of infection. Over the five cycles, patients move between health
states in accordance with the transition probabilities specified in Table 19.
The transitions in cycle 1 are straightforward: 800 patients remain without infection (1000 × 0.8), 150
patients developed an infection (1000 × 0.15) and 50 patients die (1000 × 0.05). Cycle 2 becomes more
complex as patients are now moving from both the ‘no infection’ and the ‘infection’ states. The total
number of people without infection in this cycle is the sum of patients moving from both health states in
the previous cycle: (800 × 0.8)+ (150 × 0.6)= 730. Typically, cohort simulations are run until all patients are
absorbed by the ‘death’ state.
Model development and validation
Models do not aim to capture all possible health states found in the real world and should be as simple as
possible while portraying key elements of a given decision and incorporating the best-existing evidence.130
In order to meet these requirements, a thorough understanding of events related to the occurrence of
infection following primary THA was necessary.
The iterative process of developing the model structure required reviewing the literature and consulting
with orthopaedic surgeons and infection prevention experts. Some basic questions helped identify the
fundamental elements of the model.
l What happens to a patient with an infection?
l Does the clinical management depend only on the type and onset of infection or also on other factors?
l Which pathways are important to the decision-making process?
l Can some pathways be left out because of insignificance of cost and quality-of-life outcomes?
TABLE 20 Markov trace for example Markov model
Cycle No infection Infection Death Total
0 1000 0 0 1000
1 800 150 50 1000
2 730 173 97 1000
3 688 170 142 1000
4 652 163 185 1000
5 619 155 226 1000
TABLE 19 Transition matrix showing probabilities of moving between health states
Health states
Transition to
No infection Infection Death Total
No infection 0.80 0.15 0.05 1.00
Infection 0.60 0.35 0.05 1.00
Death 0.00 0.00 1.00 1.00
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The decision model is designed to predict cost and health outcomes of competing infection prevention
strategies from a health services perspective. A Markov model is used to show how a hypothetical cohort
of patients moves between different health states over time. The model simulation ends when all patients
in the cohort are in a ‘dead’ state in order to compare long-term health and cost outcomes. It was not
feasible to include all related outcomes from a societal perspective because of financial and time
constraints. The model drafts were shown to orthopaedic surgeons and orthopaedic infection experts to
validate the model structure. Comments and feedback were taken into account, the literature was
reviewed once more regarding some key questions and the model was refined accordingly.
Model description and comparisons
The model takes the health services perspective. The final model structure is outlined in Figure 20 and was
based on the following assumptions.
l No infection is the primary state for the model.
l Deep SSIs occur within 12 months following a THA.
l Patients remain in the ‘deep infection’ state until they receive treatment.
l Treatment options for patients with deep infection are usually debridement, antibiotics and implant
retention (DAIR), one-stage revision or two-stage revision.
l A last resort option is ‘permanent resection’ which patients will remain in until death.
l Patients either experience successful treatment outcomes or treatment failure.
l Patients move into the ‘successful treatment’ state after treatment for infection.
l If treatment was unsuccessful, patients can undergo further treatment (i.e. move directly into treatment
health states DAIR, one-stage revision, two-stage revision or permanent resection).
The model begins with a cohort of infection-free patients who underwent THA. In each model cycle,
patients can move between health states. Patients remain in the ‘no infection’ state, die or develop an
infection. During the following cycles, all patients diagnosed with a deep infection within 12 months move
to the health state ‘deep infection’. Patients stay in this health state until they receive treatment or die. The
standard treatment options are DAIR, one-stage revision or two-stage revision. A less common treatment
option is permanent resection of the prosthesis, used for severe cases. After the initial treatment for deep
infection, patients are assumed to be infection free and move to the ‘successful treatment’ state. Patients
remain in this health state unless further treatment is required because of recurring or persisting symptoms
of infection. In this case, patients can undergo any of the four treatment options multiple times until the
treatment is successful or until they are absorbed by death or permanent removal of the prosthesis. The
model we have developed will be used to estimate the costs and health outcomes, measured by QALYs,
arising from nine competing approaches to managing risk of SSI among THR.
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Chapter 5 Data linkage
F ive national databases were linked together in order to inform the decision model that will address theaims of this research.
NHS Hospital Episode Statistics
The NHS Hospital Episode Statistics (HES) is a data warehouse containing records of all patients admitted
to NHS hospitals in England. It includes private patients treated in NHS hospitals, patients who were
resident outside England and care delivered by treatment centres, including those in the independent
sector, funded by the NHS. It processes over 125 million admitted patient, outpatient and accident and
emergency records each year. The HES data are designed to enable secondary use (i.e. for non-clinical
purposes). Each HES record contains a wide range of information about an individual patient admitted to
a NHS hospital, including clinical information about diagnoses and operations; information about the
patient, such as age group, sex and ethnicity; administrative information, such as waiting times, and dates
and methods of admission and discharge; and geographical information, such as where patients were
treated and the area in which they live.
A data extract was obtained from the Health and Social Care Information Centre (HSCIC) for a cohort of
patients, with specific Office of Population, Censuses and Surveys, Classification of Surgical Operations and
Procedures (OPCS) codes relating to THR for the financial years 2008–12. The HES records for the episode
of operation were extracted and subsequently all other records of hospital episodes relating to this same
cohort of patients were extracted within the given time period, including critical care data (see Appendix 5).
These included patient identifiers such as NHS number, date of birth and provider number, as well as HSCIC
identifiers ‘encryptedhesid’, ‘epikey’ and ‘susrecid’. The NHS number, date of birth and HSCIC identifiers
were used to link the HES admitted patient care (APC) data to other data sets, including:
l critical care
l patient-reported outcome measures (PROMs)
l the Office for National Statistics (ONS) death registrations
l NJR data from the Healthcare Quality Improvement Partnership
l PHE SSISS data.
Office for National Statistics
The ONS is the UK’s largest independent producer of official statistics and is the recognised national
statistical institute for the UK. It is responsible for collecting and publishing statistics related to the
economy, population and society at national, regional and local levels. It also conducts the census in
England and Wales every 10 years. The ONS plays a leading role in national and international good
practice in the production of official statistics. An extract of ONS mortality data for the cohort of hip
replacement patients described above was obtained from the HSCIC. The extract contained the variables
listed in Appendix 5 and included the identifier ‘encryptedhesid’ to link these records to HES APC.
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Patient-reported outcome measures
Patient-reported outcome measures data sets hold information on the effectiveness of care delivered to
NHS patients, as perceived by the patients themselves. Patients rate their health by scoring the severity or
difficulty in completing certain tasks or routine activities. The tools used are the EQ-5D index and the
EQ-5D visual analogue scale. The Oxford hip score is also collected for those undergoing THR. PROMs
data collection is co-ordinated by NHS England, but delivered by organisations such as hospital trusts that
perform relevant procedures and the HSCIC. An extract of PROMs data was obtained from the HSCIC for
the period 2009–12 for the cohort of hip replacement patients obtained from HES records. The PROMs
extract included the variables listed in Appendix 5, in addition to the identifier ‘epikey’ which was used to
link these records to HES APC.
Surgical Site Infection Surveillance Service
The SSISS holds data on SSIs reported by NHS hospitals and independent sector NHS treatment centres. All
hospitals participating in national SSI surveillance are required to follow the surveillance protocol outlining
the follow-up methods and case definitions. Each hospital collects data prospectively on all eligible patients
in a surgical category over a 3-month period. The follow-up period is set at 30 days for non-implant
procedures and 1 year for implant procedures.
Baseline risks for SSI and rates of revision, by patient characteristics, are available from the surveillance
data. Acute care hospitals in England that participated in mandatory SSI surveillance from 1 April 2004 to
31 March 2014 have contributed data for patients who underwent hip replacement. An extract of hip
replacement data was downloaded from the PHE SSISS database for the period 2008–12. The SSISS
extract contained the variables listed in Appendix 5 and included the identifiers ‘patient name’, ‘NHS
number’ and ‘date of birth’ to link these records to HES APC. When NHS numbers were unavailable, these
data were obtained from the Demographic Batch Service.
National Joint Registry for England, Wales and Northern Ireland
The purpose of the NJR data collection is to provide an early warning system for patient safety issues.
Furthermore, in an effort to continue to improve quality and cost-effectiveness of care, the high-quality
data collected about joint replacement surgery in the UK are used to report on, and monitor, patient
outcomes and to support research. NJR data from 2008 to 2012 were provided by the Healthcare Quality
Improvement Partnership and included the variables listed in Appendix 5. The patient identifiers, NHS
number and date of birth were used to link these records to HES APC.
Data linkage and pseudonymisation
The data sets were linked to the HES APC data set using the patient identifiers and HSCIC identifiers
described above for each data set. Prior to analysis the data were anonymised to reduce the chance of
disclosure by transforming NHS number and HSCIC identifiers to new identification numbers that bore no
relationship to the originals. Data, such as date of birth, were ‘blurred’ by calculating age in whole years,
rounded down, or time intervals between two incidents in units larger than days, generating a new code
for providers/institutions to distinguish between but not identify institutions. All patient identifiers were
then removed from the linked data set. Access to the data was restricted to a finite number of named
individuals. The data linkages are shown in Figure 21.
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There are large numbers of data in HES and ONS data sets that have little value for this project, as they do
not relate to THR. The identification of a cohort of patients by the HSCIC, using OPCS codes for THR, has
reduced this to a minimum.
In Figure 21, the dark-green section (A) is where we focus our efforts, as these patients can potentially be
linked across HES, PROMs, NJR, SSISS and ONS mortality data sets. The HES APC data included 316,208
distinct NHS numbers. The mid-green section (B) includes a subset of 276,858 patients of interest from
HES who are not linked to PROMs data, as PROMs data were not available prior to 2009; however, they
can potentially be linked to the NJR and SSISS. Whether or not they can be linked to ONS data will depend
on their mortality status. The light-green section (C) is a subset of 3117 NJR and 57,017 SSISS patients
who were unable to be linked to HES inpatient data. The dark-blue section (D) represents a hypothetical
subset of patients whose data are present in PROMs and link to NJR and SSISS databases, but who cannot
be linked to HES.
Only about 65% of patients in SSISS had a NHS number. This increased to 80% after tracing by the
Demographics Batch Service. The light-blue section (E) represents patients with SSISS data for whom a
missing NHS number could not be traced and, therefore, whose record could not be linked to other data
sets. The NHS number could not be traced for 36,096 patients (19.23% of 187,673) patients in the SSISS
data extract. The final linked data sets may, therefore, be compromised if missing data from patients in
sections C, D and E were excluded for non-random reasons (e.g. if these patients were different in some
way to the included patients in their demographics, treatment pathways or prognosis).
HES A PROMs A
NJR B
NJR C
NJR DPROMs D SSISS D
SSISS E
SSISS C
SSISS B
ONS
Mortality
A
NJR A SSISS A
FIGURE 21 Data linkage of national data sets.
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Chapter 6 Model parameters and results
Transition probabilities
We simulated a cohort of 77,321 patients who had a primary THR in 2012.11 A rate of deep infection to
reflect risks under strategy T1 (no systemic antibiotics, plain cement and conventional ventilation) for a
time period of 2.5 years was estimated by Lidwell et al.111 This study of 8055 operations for replacement of
hips (84%) and knees (16%) was undertaken in 19 hospitals in England, Scotland and Sweden between
1974 and 1979. The conditions relevant to T1 were met for 1161 of these procedures and there were
39 cases of deep infection. The rate of infection under T1 conditions for 2.5 years was therefore 3.4%.
To adjust this for a 12-month follow-up appropriate to this model, we used information from Ong et al.139
Ong et al.139 evaluated the incidence of early-onset (< 2 years) and late-onset (> 2 years) deep joint
infection after primary THA for the period 1997–2006. At 1 year post surgery 66.7% of all deep infections
had been identified. This information was used to predict risks of infection for 12 months following
primary surgery under conditions of T1 for the model.
We accounted for the fact that 32.9% of patients had a cemented hip replacement11 and so the
remainder would have an uncemented procedure. The impact was to change the numbers or individuals in
the cohort who would have incurred costs and gained health benefits from any strategy that included
antibiotic-impregnated cement (T5–9).
The average risks among the cohort of 77,321 patients under conditions of T1 were used to predict 1887
cases of deep infection for 12 months following primary THR (95% uncertainty interval 1253–2621 cases).
These patients then progressed through treatment pathways shown in Figure 20, which is a Markov model
that simulates patients daily. We used the information described in Chapter 5 to estimate the probabilities
of progressing through all model states for 5 years. A major advantage of accessing original data is that
treatment probabilities are time dependent. A hypothetical cohort of patients will move through the model
proportionally to the real patient data. It is not necessary to assume constant transitions, for example
average yearly transitions. Accurate ‘real-world’ transitions between model health states can be used and
the model cycle length adjusted to reflect this. Transition probabilities were calculated for each cycle for
the occurrence of deep infection, first treatment with DAIR, one-stage revision, the first stage of a
two-stage revision followed by the second stage two-stage revision and permanent resection, and further
treatment if the initial treatment failed. Each simulation continued until every simulated patient had died.
The means of the daily transition probabilities are shown in Table 21.
All patients started in the ‘primary’ state. Deep infections and their subsequent treatments were identified
using the International Classification of Diseases, Tenth Edition (ICD-10) codes listed in Appendix 6, and
the presence of a subsequent revision procedure listed in Appendix 7. All deep infections must have
occurred within 12 months of the primary THR, in accordance with SSISS follow-up periods. The ICD-10
codes listed in Appendix 6 were used to identify infections leading to any of the treatment strategies.
Revision resulting from deep SSI could be performed on one or more components of the prosthesis.
ICD-10 organism codes were used to indicate the presence of infection but not the severity of infection,
such as deep or superficial (see Appendix 8). The probability of death was taken from UK life table data for
the years 2010–12 and was downloaded from the ONS website (see Appendix 9). Each patient’s starting
age was randomly selected from the distribution of ages of primary THRs in the hip data. To acknowledge
the uncertainty in the transition probabilities we randomly sampled probabilities using a beta distribution
for each simulation. Hence our simulations include uncertainty about the parameter estimates as well as
stochastic uncertainty. The plot of daily death probability by age is shown in Figure 22.
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Effectiveness evidence
Estimates of the clinical effectiveness of the competing infection prevention strategies are available from
the material included in Chapters 2 and 3. Descriptions of the strategies are provided in Table 22.
Probability ratios are the estimated probabilities of deep infection for strategies T2–9 divided by the
probability of deep infection for T1. The simulations were conducted using Queensland University of
Technology’s high-performance computer. Probability ratios of deep infection using T1 as the reference
strategy are shown in Figure 23. The vertical lines in blue show a probability ratio of 1 (i.e. no change in
probability of infection compared with T1). The probability ratio for deep infection for T2 compared with
T1 has a mode near to 0.5.
The descriptive statistics for the probability ratios are shown in Table 23.
The probability ratio for deep infection for T2 compared with T1 has a mean of 0.46. Therefore, the
average reduction in deep infection for this strategy is around half of the probability of deep infection
for T1.
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FIGURE 22 Plot of daily death probabilities by age.
TABLE 22 Nine treatment strategies used to reduce risk of SSI in primary THR
Treatment strategy Details
T1 No systemic antibiotics, plain cement and conventional ventilation
T2 Systemic antibiotics, plain cement and conventional ventilation
T3 No systemic antibiotics, plain cement and laminar airflow
T4 Systemic antibiotics, plain cement and laminar airflow
T5 No systemic antibiotics, antibiotic-impregnated cement and conventional ventilation
T6 Systemic antibiotics, antibiotic-impregnated cement and conventional ventilation
T7 Systemic antibiotics, antibiotic-impregnated cement and laminar airflow
T8 Systemic antibiotics, antibiotic-impregnated cement, conventional ventilation and body exhaust suit
T9 Systemic antibiotics, antibiotic-impregnated cement, laminar ventilation and body exhaust suit
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FIGURE 23 Probability ratios of deep infection using T1 as the reference strategy. (a) T2 vs. T1; (b) T3 vs. T1;
(c) T4 vs. T1; (d) T5 vs. T1; (e) T6 vs. T1; (f) T7 vs. T1; (g) T8 vs. T1; and (h) T9 vs. T1.
TABLE 23 Probability ratios for the probability of deep infection for T2–9 relative to T1
Treatment
Probability ratios
Mean SD Minimum Maximum
T2 0.46 0.15 0.02 1.30
T3 0.35 0.25 0.00 1.87
T4 0.38 0.18 0.01 1.85
T5 0.51 0.23 0.04 1.74
T6 0.22 0.12 0.01 1.75
T7 0.36 0.23 0.00 1.97
T8 0.50 0.34 0.00 1.98
T9 0.61 0.35 0.00 1.98
SD, standard deviation.
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Membership of model states for 5 years after primary procedure
For the starting cohort of 77,321, the number of patients with deep infection for each of the treatments
T1–9, and their subsequent occupancy of model states, is shown in Table 24.
These results are for the first 5 years following primary procedure and show that T6 prevented the most
cases and had the fewest treatments.
We used the programing software R version 3.0.3 (The R Foundation for Statistical Computing, Vienna,
Austria) for all analyses.
TABLE 24 Means and 95% uncertainty intervals for the number of patients in model
Treatment
Deep
infection
One-stage
revision DAIR
Stage 1 of
two-stage
revision
Stage 2 of
two-stage
revision Excision
T1 1887
(1253 to 2621)
925
(587 to 1350)
1077
(684 to 1548)
361
(198 to 566)
342
(18 to 549)
36
(3 to 105)
T2 870
(345 to 1655)
427
(157 to 813)
497
(194 to 953)
166
(55 to 337)
158
(57 to 322)
17
(1 to 52)
T3 670
(90 to 1937)
329
(44 to 1009)
382
(52 to 1146)
128
(17 to 386)
121
(16 to 377)
13
(1 to 49)
T4 721
(192 to 1589)
355
(90 to 769)
412
(110 to 914)
138
(33 to 322)
131
(32 to 308)
14
(1 to 49)
T5 950
(286 to 2059)
466
(142 to 1043)
544
(161 to 1169)
182
(51 to 408)
172
(47 to 388)
18
(1 to 56)
T6 406
(90 to 964)
200
(47 to 473)
230
(51 to 540)
77
(16 to 193)
74
(15 to 177)
8
(1 to 30)
T7 666
(101 to 2017)
327
(48 to 1016)
380
(56 to 1148)
127
(16 to 382)
121
(15 to 371)
14
(1 to 55)
T8 905
(77 to 2499)
446
(35 to 1290)
516
(42 to 1449)
173
(13 to 493)
164
(12 to 494)
18
(1 to 74)
T9 1126
(143 to 2827)
555
(67 to 1405)
642
(86 to 1668)
216
(28 to 566)
204
(25 to 547)
23
(1 to 80)
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Costing treatments
The cost/price year for all estimates is 2012. The positive incremental costs of implementing each strategy
are estimated from unit cost values for each component of the strategy. Unit costs were estimated for
antibiotics used for prophylaxis, antibiotic-impregnated cement, laminar airflow systems and the use of
exhaust body suits.
Antibiotics used for prophylaxis
Hickson et al.140 estimated the most common prophylaxis regimes used by NHS trusts for knee and hip
replacements. There are three regimes used in the absence of a penicillin allergy: flucloxacillin in
combination with gentamicin, cefuroxime alone and teicoplanin in combination with gentamicin. In the
presence of penicillin allergy either teicoplanin or teicoplanin in combination with gentamicin is used.
The regime used and the doses given differs in NHS trusts and so for each regime the average dose across
trusts was estimated under the assumption that the average patient weighs 75 kg. The expected cost for
each regime was based on data from the British National Formulary.141 As hospitals are able to negotiate
discounts with their suppliers, list prices were discounted by 30%. This is in line with other publications142
and variability is accounted for in the PSA. The average costs of regimes in the absence of a penicillin
allergy (Tables 25–27) and in the presence of one (Tables 28 and 29) were calculated. We assumed that
10% of patients were treated as allergic to penicillin.143
This information is used to estimate a weighted average cost for prophylaxis with antibiotics.
TABLE 25 The costs of flucloxacillin used in combination with gentamicin (57 trusts)
Drug Dose
Average number
of doses Average dose List price (£)
Discounted
price (£)
Flucloxacillin Induction 1 1 g 4.90 3.43
Postoperative 1.77 1 g 8.68 6.08
Gentamicin Induction 0.42 160mg 1.64 1.15
0.58 2mg/kg 2.12 1.48
Postoperative 0 0 0 0
Expected cost 17.34 12.14
TABLE 26 The costs of cefuroxime alone (44 trusts)
Drug Dose
Average number
of doses Average dose List price (£)
Discounted
price (£)
Cefuroxime Induction 1 1.5 g 5.05 3.54
Postoperative 0.20 1.5 g 1.03 0.72
Expected cost 6.08 4.26
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Plain and antibiotic-impregnated cement
We assumed that a hip replacement requires 120 g of cement: 40 g for the cup and another 80 g for the
femur. The cement used can either be plain or antibiotic impregnated. It comes in 40-g packets and,
therefore, we assume that three packets will be used for each THR. There are nine types of plain cement
and 12 types of antibiotic-impregnated cement available for use in the NHS. With no data available for the
frequency with which each of these is used, it was assumed that each type of cement was used at a
similar rate. As with the antibiotic prophylaxis, the list prices for cements were discounted by 30%. The
estimated average cost of plain cement and antibiotic-impregnated cement is shown in Tables 30 and 31.
TABLE 27 The costs of teicoplanin in combination with gentamicin (25 trusts)
Drug Dose
Average number
of doses Average dose List price (£)
Discounted
price (£)
Teicoplanin Induction 0.8 400mg 5.86 4.10
0.2 10mg/kg 2.75 1.92
Postoperative 0.32 1.15 g 6.73 4.71
Gentamicin Induction 0.32 160mg 1.25 0.87
0.68 225mg 3.73 2.61
Postoperative 0 0 0.00 0.00
Expected cost 20.31 14.22
TABLE 28 The costs of teicoplanin alone (36 trusts)
Drug Dose
Average number
of doses Average dose List price (£)
Discounted
price (£)
Teicoplanin Induction 0.92 400mg 6.71 4.70
0.08 6mg/kg 0.69 0.48
Postoperative 0.22 850mg 3.46 2.42
Expected cost 10.85 7.60
TABLE 29 The costs of teicoplanin used in combination with gentamicin (91 trusts)
Drug Dose
Average number
of doses Average dose List price (£)
Discounted
price (£)
Teicoplanin Induction 0.93 400mg 6.84 4.79
0.07 10mg/kg 0.90 0.63
Postoperative 0.26 1.15 g 5.55 3.89
Gentamicin Induction 0.36 160mg 1.41 0.99
1.76 2mg/kg 6.43 4.50
Postoperative 0 0 0.00 0.00
Expected cost 21.13 14.79
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TABLE 30 Costs of plain cement
Cement description Supplier
Price (£)
(three packets)
Discounted price (£)
(three packets)
Palacos 1 × 40 g low viscosity (b1) Heraeus Medical GmBH
(Wehrheim, Germany)
113.10 79.17
Palacos R plain 1 × 40 g high
viscosity (b1)
Heraeus Medical GmBH 50.13 35.09
Palacos MV medium viscosity plain
1 × 40 g (b1)
Heraeus Medical GmBH 50.13 35.09
HV bone cement, 40 g DePuy Synthes UK (Leeds, UK) 70.14 49.10
MV bone cement, 40 g DePuy Synthes UK 70.14 49.10
CMW 1 bone cement, 40 g DePuy Synthes UK 122.48 85.73
CMW 2 bone cement, 40 g fast set DePuy Synthes UK 122.48 85.73
HI FATIGUE high viscosity cement,
1 × 40 g
Zimmer Ltd (Warsaw, IN, USA) 182.97 128.08
SIMPLEX P radio opaque, 40-g pack
full dose
Stryker Orthopaedics
(Kalamazoo, MI, USA)
95.98 67.18
Mean 97.50 68.25
TABLE 31 Costs of antibiotic-impregnated cement
Cement description Supplier
Price (£)
(three packets)
Discounted price (£)
(three packets)
Palacos R+ gentamicin 1 × 40 g
high viscosity (b1)
Heraeus Medical GmBH 116.7 81.69
Palacos+ gentamicin 1 × 40 g low
viscosity (b1)
Heraeus Medical GmBH 150.54 105.38
Palacos MV+ gentamicin 1 × 40 g
medium viscosity (b1)
Heraeus Medical GmBH 116.67 81.67
GHV gentamicin bone cement, 40 g DePuy Synthes UK 95.20 66.64
GMV gentamicin bone cement,
40 g
DePuy Synthes UK 93.53 65.47
CMW 1 gentamicin bone cement,
40 g
DePuy Synthes UK 194.84 136.39
CMW 2 gentamicin bone cement,
40 g fast set
DePuy Synthes UK 194.84 136.39
REFOBACIN bone cement r,
2 × 20 g
Biomet Merck Ltd (Warsaw, IN,
USA)
126.18 88.33
HI-FATIGUE bone cement g,
1 × 40 g
Zimmer Limited 195.6 136.92
SIMPLEX AB cement with
tobramycin 40-g pack full dose
Stryker Orthopaedics 177.26 124.08
CEMEX high viscosity with
gentamicin, 1 × 40 g
Ortho Dynamics (Paterson, NJ,
USA)
85.35 59.75
CEMEX medium viscosity green
cement gentamicin, 1 × 40 g
Ortho Dynamics 85.35 59.75
Mean 136.00 95.20
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Conventional ventilation, laminar airflow and body exhaust
suit costs
The only information found regarding the costs of different ventilation systems was published by Evans,8
who acknowledged laminar airflow was historically a high-cost technology. US data144 showed that, in
1974, the costs of installation were US$50,000, which is equivalent to US$232,853 in 2012 prices.
The technology has matured, and Evans8 estimates that the costs of construction and installation of an
exponential laminar airflow system into a new operating room for 2011/12 range from US$60,000 to
US$90,000. A lifetime of 5 years was assumed for the installation. Based on an exchange rate of US$1 to
£0.66 (source OANDA;145 New York, NY, USA), this estimates annual capital costs between £7920 and
£11,880. Using a typical caseload of five surgeries per day for a 5-day week, 50 weeks per year, the mean
cost per case is between £6.33 and £9.50.
The costs of body exhaust suits were based on US prices as no UK data could be found, and prices were
converted to Pounds Sterling as above. The Stryker Steri-Shield system (Stryker, Kalamazoo, MI, USA) was
used as the case study146 and costs were included for the helmet without lights (US$3515), disposable
hoods (US$86 for a pack of 32), power pack and cord (US$750), and charger (US$7000). Based on the
same volume assumptions, the cost per surgical patient would be £7.72 (Table 32).
Incremental per patient cost of infection prevention strategies
The components of and total costs for each infection prevention strategy are shown in Tables 33–41.
It was assumed that plain cement and conventional ventilation would have been used regardless, so these
items attract zero cost.
TABLE 32 Costs of body exhaust suit illustrated
Costs illustrated Cost (US$) Cost (£)
Helmet 3515 2320
Power pack 750 495
Charger 7000 4620
Total fixed cost 11,265 7435
Divided by 1250 cases, volume assumption 9.01 5.95
Variable cost per hood 2.69 1.78
Cost per patient 11.70 7.72
TABLE 33 Cost of T1: no systemic antibiotics, plain cement and conventional ventilation
Costs illustrated Expected cost (£)
Plain cement 0
Conventional ventilation 0
Total 0
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TABLE 34 Cost of T2: systemic antibiotics, plain cement and conventional ventilation
Costs illustrated Expected cost (£)
Systemic antibiotics 10.09
Plain cement 0.00
Conventional ventilation 0.00
Total 10.09
TABLE 35 Cost of T3: no systemic antibiotics, plain cement and laminar airflow
Costs illustrated Expected cost (£)
Plain cement 0.00
Laminar airflow 7.90
Total 7.90
TABLE 36 Cost of T4: systemic antibiotics, plain cement and laminar airflow
Costs illustrated Expected cost (£)
Systemic antibiotics 10.09
Plain cement 0.00
Laminar airflow 7.90
Total 17.99
TABLE 37 Cost of T5: no systemic antibiotics, antibiotic-impregnated cement and conventional ventilation
Costs illustrated Expected cost (£)
Antibiotic-impregnated cement 95.20
Conventional ventilation 0.00
Total 95.20
TABLE 38 Cost of T6: systemic antibiotics, antibiotic-impregnated cement and conventional ventilation
Costs illustrated Expected cost (£)
Systemic antibiotics 10.09
Antibiotic-impregnated cement 95.20
Conventional ventilation 0.00
Total 105.29
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Cost outcomes for each model state
The costs of a patient spending one cycle in each model state is estimated from the linked data set
assembled for this project. Data for patients who went on to develop an infection following a THR were
analysed with information relating to their THR and subsequent treatments for the infection, informing
cost estimates.
Each patient in the data set has OPCS – version 4 (OPCS-4) codes assigned to each of the procedures they
received. OPCS refers to the former Office of Population, Censuses and Surveys, originally responsible
for the classification system, which has since been merged into what is now the ONS. The OPCS-4
classification system is designed to translate operations and surgical procedures into codes for statistical
and epidemiological analysis.147
The NHS mandatory standard for data collection is the OPCS-4 classification system. It is the required
classification system for Admitted Patient Care Commissioning Data Sets and other national data sets
required for secondary use.
TABLE 39 Cost of T7: systemic antibiotics, antibiotic-impregnated cement and laminar airflow
Costs illustrated Expected cost (£)
Systemic antibiotics 10.09
Antibiotic-impregnated cement 95.20
Laminar airflow 7.90
Total 113.19
TABLE 40 Cost of T8: systemic antibiotics, antibiotic-impregnated cement, conventional ventilation and body
exhaust suit
Costs illustrated Expected cost (£)
Systemic antibiotics 10.09
Antibiotic-impregnated cement 95.20
Conventional ventilation 0.00
Body exhaust suit 7.72
Total 113.01
TABLE 41 Cost of T9: systemic antibiotics, antibiotic-impregnated cement, laminar ventilation and body
exhaust suit
Costs illustrated Expected cost (£)
Systemic antibiotics 10.09
Antibiotic-impregnated cement 95.20
Laminar airflow 7.90
Body exhaust suit 7.72
Total 120.91
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Case-mix classifications are used to categorise patients based on their expected health-care resource use,
primarily for the purposes of reimbursing providers. The NHS in England primarily uses Healthcare Resource
Groups (HRGs).148 HRGs are derived from OPCS-4 and ICD-10 codes in patient records and represent
clinical groupings of patient activity.
Each patient’s OPCS-4 codes were assigned to a HRG using the HRG4+ Code to Group spreadsheet,
which is available online.147–149 It was possible to assign a HRG to each OPCS-4 code; however, each HRG
has different levels based on diagnoses scores or complication and comorbidity information. In the absence
of information that would allow us to specify each patient’s HRG level, it was assumed that patients had
intermediate diagnoses and complication/comorbidity.
The HRG costs were taken from the NHS Reference Costs 2012 to 2013.150 HRGs associated with trauma
and orthopaedics for elective inpatients were used. Each model state was associated with an expected cost
calculated as the weighted average of the cost of the treatments received (Tables 42–53).
TABLE 42 Codes used for model state 1: primary THR
Description of treatment OPCS-4 code HRG-4 code
Percentage
of patients
Primary total prosthetic replacement of hip joint using cement W371 HB12 37
Primary total prosthetic replacement of hip joint not using cement W381 HB12 45
Unspecified total prosthetic replacement of hip joint not using
cement
W389 HB12 1
Primary total prosthetic replacement of hip joint NEC W391 HB12 7
Primary hybrid prosthetic replacement of hip joint using cemented
acetabular component
W931 HB12 1
Primary hybrid prosthetic replacement of hip joint using cemented
femoral component
W941 HB11 8
Primary hybrid prosthetic replacement of hip joint using cement NEC W951 HB11 1
Total 100
NEC, not elsewhere classified.
TABLE 43 Costs used for model state 1: primary THR
HRG-4 code Description
National average
unit cost (£)
Lower quartile
unit cost (£)
Upper quartile
unit cost (£)
HB11A Major hip procedures for non-trauma,
category 2, with major CC
10,146.59 7847.75 11,420.82
HB11B Major hip procedures for non-trauma,
category 2, with intermediate CC
6450.12 5674.46 7024.51
HB11C Major hip procedures for non-trauma,
category 2, without CC
6067.55 5465.07 6457.65
HB12A Major hip procedures for non-trauma,
category 1, with major CC
8201.72 6742.72 9259.28
HB12B Major hip procedures for non-trauma,
category 1, with intermediate CC
6459.47 5577.83 7108.78
HB12C Major hip procedures for non-trauma,
category 1, without CC
5880.43 5117.28 6428.14
CC, case-mix costing.
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TABLE 44 Codes for model state 3: one-stage revision
Description OPCS-4 code HRG-4 code
Percentage
of patients
Revision of total prosthetic replacement of hip joint using cement W373 HR07 11
Revision of one component of total prosthetic replacement of hip
joint using cement
W374 HR07 3
Revision of total prosthetic replacement of hip joint not using cement W383 HR07 10
Revision of one component of total prosthetic replacement of hip
joint not using cement
W384 HR07 2
Revision of total prosthetic replacement of hip joint NEC W393 HR07 2
Revision of one component of total prosthetic replacement of hip
joint NEC
W395 HR07 9
Revision of hybrid prosthetic replacement of hip joint using cemented
acetabular component
W933 HR07 1
Revision of hybrid prosthetic replacement of hip joint using cemented
femoral component
W943 HR07 3
Renewal of prosthesis in organ NOC Y032 UZ05a 6
Removal of prosthesis from organ NOC Y037 UZ05a 1
Attention to total prosthetic replacement of hip joint NEC W394 HB12 5
Total 53
NEC, not elsewhere classified; NOC, not otherwise classified.
a UZ05 is an undefined HRG.
TABLE 45 Costs for model state 3: one-stage revision
HRG-4 code Description
National average
unit cost (£)
Lower quartile
unit cost (£)
Upper quartile
unit cost (£)
HR07A Orthopaedic reconstruction with intervention
score of ≤ 43, with diagnosis score of ≤ 22
6212.21 4989.24 7501.67
HR07B Orthopaedic reconstruction with intervention
score of ≤ 43, with diagnosis score of 23–60
7539.30 5878.98 9149.87
HR07C Orthopaedic reconstruction with intervention
score of ≤ 43, with diagnosis score of 61 or
more
8911.37 6933.32 11,123.38
HB12A Major hip procedures for non-trauma,
category 1, with major CC
8201.72 6742.72 9259.28
HB12B Major hip procedures for non-trauma,
category 1, with intermediate CC
6459.47 5577.83 7108.78
HB12C Major hip procedures for non-trauma,
category 1, without CC
5880.43 5117.28 6428.14
HB99Z Other procedures for non-trauma 3532.34 2879.31 4100.53
CC, case-mix costing.
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TABLE 46 Codes for model state 4: DAIR
Description
OPCS-4
code
HRG-4
code
Percentage
of patients
Attention to total prosthetic replacement of hip joint NEC W394 HB12 2
Open debridement and irrigation of joint W801 HB99 49
Open debridement of joint NEC W802 HB99 2
Other specified debridement and irrigation of joint W808 HB99 1
Unspecified debridement and irrigation of joint W809 HB99 2
Debridement of skin NEC S571 JC42 10
Open irrigation of joint NEC W803 HB99 9
Aspiration of joint W901 HB99 6
Total 81
NEC, not elsewhere classified.
TABLE 47 Costs for model state 4: DAIR
HRG-4
code Description
National average
unit cost (£)
Lower quartile
unit cost (£)
Upper quartile
unit cost (£)
HB12A Major hip procedures for non-trauma, category 1,
with major CC
8201.72 6742.72 9259.28
HB12B Major hip procedures for non-trauma, category 1,
with intermediate CC
6459.47 5577.83 7108.78
HB12C Major hip procedures for non-trauma, category 1,
without CC
5880.43 5117.28 6428.14
HB99Z Other procedures for non-trauma 3532.34 2879.31 4100.53
JC42A Intermediate skin procedures, aged ≥ 13 years 1539.88 1077.03 1774.94
CC, case-mix costing.
TABLE 48 Codes for model state 5: stage 1 of two-stage revision
Description
OPCS-4
code
HRG-4
code
Percentage
of patients
Revision of total prosthetic replacement of hip joint using cement W373 HR07 4
Revision of one component of total prosthetic replacement of hip joint using
cement
W374 HR07 3
Revision of total prosthetic replacement of hip joint not using cement W383 HR07 2
Revision of one component of total prosthetic replacement of hip joint not
using cement
W384 HR07 1
Revision of one component of total prosthetic replacement of hip joint NEC W395 HR07 1
Primary excision arthroplasty of joint NEC W572 HB99 1
Removal of prosthesis from organ NOC Y037 UZ05a 9
Attention to total prosthetic replacement of hip joint NEC W394 HB12 1
Total 22
NEC, not elsewhere classified; NOC, not otherwise classified.
a UZ05 is an undefined HRG.
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TABLE 49 Costs for model state 5: stage 1 of two-stage revision
HRG-4
code Description
National average
unit cost (£)
Lower quartile
unit cost (£)
Upper quartile
unit cost (£)
HR07A Orthopaedic reconstruction with intervention score
of ≤ 43, with diagnosis score of ≤ 22
6212.21 4989.24 7501.67
HR07B Orthopaedic reconstruction with intervention score
of ≤ 43, with diagnosis score of 23–60
7539.30 5878.98 9149.87
HR07C Orthopaedic reconstruction with intervention score
of ≤ 43, with diagnosis score of ≥ 61
8911.37 6933.32 11,123.38
HB12A Major hip procedures for non-trauma, category 1,
with major CC
8201.72 6742.72 9259.28
HB12B Major hip procedures for non-trauma, category 1,
with intermediate CC
6459.47 5577.83 7108.78
HB12C Major hip procedures for non-trauma, category 1,
without CC
5880.43 5117.28 6428.14
HB99Z Other procedures for non-trauma 3532.34 2879.31 4100.53
CC, case-mix costing.
TABLE 50 Codes for model state 6: stage 2 of two-stage revision
Description OPCS-4 code HRG-4 code
Percentage of
patients
Revision of total prosthetic replacement of hip joint using
cement
W373 HR07 4
Revision of total prosthetic replacement of hip joint not using
cement
W383 HR07 9
Revision of one component of total prosthetic replacement of
hip joint not using cement
W384 HR07 2
Revision of total prosthetic replacement of hip joint NEC W393 HR07 3
Revision of one component of total prosthetic replacement of
hip joint NEC
W395 HR07 1
Renewal of prosthesis in organ NOC Y032 UZ05a 1
Removal of prosthesis from organ NOC Y037 UZ05a 1
Total 21
NEC, not elsewhere classified; NOC, not otherwise classified.
a UZ05 is an undefined HRG.
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Health benefits: attaching preference-based utilities to each
health state
Despite having EQ-5D data from the PROMs data set, none of the scores was collected close enough in
time to the health events included in the model. We sought an EQ-5D score within 14 days of the date of
infection, or within 3 months of DAIR or one- or two-stage revision. In the absence of these primary data
we used estimates from published sources, and these are shown in Table 54.
These estimates emerged from a reproducible review that was not published, but formed part of a doctor
of philosophy thesis (see Merollini et al.57). The relevant sections have been reproduced in Appendix 10,
and the entire thesis is available online.
TABLE 51 Costs for model state 6: stage 2 of two-stage revision
HRG-4
code Description
National average
unit cost (£)
Lower quartile
unit cost (£)
Upper quartile
unit cost (£)
HR07A Orthopaedic reconstruction with intervention score
of ≤ 43, with diagnosis score of ≤ 22
6212.21 4989.24 7501.67
HR07B Orthopaedic reconstruction with intervention score
of ≤ 43, with diagnosis score of 23–60
7539.30 5878.98 9149.87
HR07C Orthopaedic reconstruction with intervention score
of ≤ 43, with diagnosis score of ≥ 61
8911.37 6933.32 11,123.38
HB12A Major hip procedures for non-trauma, category 1,
with major CC
8201.72 6742.72 9259.28
HB12B Major hip procedures for non-trauma, category 1,
with intermediate CC
6459.47 5577.83 7108.78
HB12C Major hip procedures for non-trauma, category 1,
without CC
5880.43 5117.28 6428.14
HB99Z Other procedures for non-trauma 3532.34 2879.31 4100.53
CC, case-mix costing.
TABLE 52 Codes for model state 7: excision
Description OPCS-4 code HRG-4 code Percentage of patients
Primary excision arthroplasty of joint NEC W572 HB99 100
NEC, not elsewhere classified.
TABLE 53 Costs for model state 7: excision
HRG-4
code Description
National average
unit cost (£)
Lower quartile
unit cost (£)
Upper quartile
unit cost (£)
HB99Z Other procedures for non-trauma 3532.34 2879.31 4100.53
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Cost-effectiveness evaluation
Simulations were made from all prior distributions specified in the model to make 1000 estimates of
the change to total cost and QALYs, arising from a decision to adopt each of the treatments among the
starting cohort of 77,321 patients. The most effective strategy is T6 and the least effective is T9, shown by
the expected change to the number of cases of deep infection (Table 55).
The impacts on cost and QALY outcomes of choosing another treatment compared with T1, with all
parameter uncertainties included, are shown in Figures 24 and 25, respectively.
Costs are lower than T1 for every other treatment except T9. Costs among patients in the cohort are
reduced most for T6, with estimated savings of £8,325,749; however, T9 increases actual costs by
£781,075. The uncertainty in these estimates is large, shown by the error bars in Figure 24. For all
treatments the error bars rise above zero change in cost, indicating a chance that costs will increase as a
result of a decision to adopt a treatment strategy different from T1. The probability that any of the
treatment strategies will be cost saving is high (Table 56).
The change to total QALYs when other treatments are compared with T1 is shown in Figure 25.
TABLE 54 Overview of utility values used in decision model
Parameter description Estimate (variance) (SD) Distribution Source Instrument/method
No infection ≤ 12 months
post THA
0.86 (0.0117) Beta Räsänen et al.151 15D HRQoL
Deep infection 0.40 (0.0514) Beta Cahill et al.152 AQoL
Revision (DAIR, one-stage
revision, two-stage
revision)
0.81 (0.0176) Beta Räsänen et al.151 15D HRQoL
Permanent/temporary
resection
0.6 (95% CI 0.5 to 0.75) Uniform Fisman et al.28 Expert opinion
Successful treatment 0.82 (0.0198) Beta Räsänen et al.151 15D HRQoL
AQoL, assessment of quality of life; CI, confidence interval; SD, standard deviation.
TABLE 55 Expected change to number of cases of deep infection for each treatment
Treatment Number of deep infections Mean reduction in cases
T1 1887 Not applicable
T2 869 1018
T3 670 1217
T4 722 1165
T5 949 938
T6 406 1481
T7 668 1219
T8 906 981
T9 1126 761
DOI: 10.3310/hta20540 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 54
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Graves et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
75
–2
5
–2
0
–1
5
–1
0–50
Cost (£M)
510152025
M
ea
n
M
in
im
u
m
M
ax
im
u
m
T2
–£
7,
22
6,
73
2
–£
16
,0
83
,0
09
£2
,6
31
,7
24
T3
–£
6,
15
2,
87
7
–£
17
,7
83
,3
52
£1
4,
00
0,
13
3
T4
–£
5,
27
1,
04
0
–£
17
,6
77
,1
78
£1
3,
93
7,
46
1
T5
–£
4,
63
4,
64
7
–£
17
,7
37
,5
85
£1
1,
49
2,
02
6
T6
–£
8,
32
5,
27
7
–£
17
,9
81
,0
40
£5
,7
65
,8
32
T7
–£
3,
27
1,
74
9
–£
13
,7
77
,7
61
£2
2,
12
0,
47
7
T8
–£
3,
96
0,
89
7
–£
17
,1
70
,4
51
£1
9,
19
6,
04
6
T9
£7
81
,0
75
–£
12
,2
48
,5
50
£2
2,
94
1,
34
3
FI
G
U
R
E
24
C
h
an
g
e
to
to
ta
lc
o
st
s
fr
o
m
a
d
ec
is
io
n
to
ad
o
p
t
T2
–
9
co
m
p
ar
ed
w
it
h
T1
.
MODEL PARAMETERS AND RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
76
14
00
M
ea
n
M
in
im
u
m
M
ax
im
u
m
T2 10
1
–7
00
11
56
T3 12
4
–7
16
87
5
T4 11
8
–7
56
99
8
T5 89 –7
34
99
9
T6 14
7
–5
85
11
57
T7 12
4
–8
86
11
42
T8 10
6
–6
99
95
5
T9 62 –7
40
10
04
12
00
10
00 80
0
60
0
40
0
20
0
Change to QALY
–2
00
–4
00
–6
00
–8
00
–1
00
0–0
FI
G
U
R
E
25
C
h
an
g
e
to
to
ta
l
Q
A
LY
s
fr
o
m
a
d
ec
is
io
n
to
ad
o
p
t
T2
–
9
co
m
p
ar
ed
w
it
h
T1
.
DOI: 10.3310/hta20540 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 54
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Graves et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
77
This shows that QALYs for the cohort are likely to increase, compared with T1, regardless of the treatment
strategy chosen. The mean change to QALYs is greatest for T6, at 147 QALYS gained, and least for T9
at 62 QALYs gained. There is large uncertainty in these estimates and the probability that treatment
strategies will increase health benefits is moderate (Table 57).
The mean of the joint distributions of the change to costs and QALYs for each strategy, compared with T1,
are shown in Figure 26.
The joint distributions for each comparison are shown in Figures 27–33. For Figures 26–34, T1 is at the
origin of both axes.
TABLE 56 Probability that the adoption of T2–9 will be cost saving compared with T1
Strategy Probability (%)
T2 96
T3 94
T4 94
T5 96
T6 92
T7 83
T8 64
T9 47
TABLE 57 Probability that each strategy increases QALYs
Strategy Probability (%)
T2 65
T3 67
T4 67
T5 62
T6 70
T7 68
T8 66
T9 57
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FIGURE 26 The mean of the joint distributions of the change to costs and QALYs for each strategy compared
with T1.
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FIGURE 27 T2 compared with T1, change to cost and QALY outcomes.
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FIGURE 28 T3 compared with T1, change to cost and QALY outcomes.
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FIGURE 29 T4 compared with T1, change to cost and QALY outcomes.
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FIGURE 30 T5 compared with T1, change to cost and QALY outcomes.
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FIGURE 31 T6 compared with T1, change to cost and QALY outcomes.
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FIGURE 32 T7 compared with T1, change to cost and QALY outcomes.
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FIGURE 33 T8 compared with T1, change to cost and QALY outcomes.
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Interpretation of results for decision-making
To help decision-makers understand these results, we calculated the expected incremental NMB from
adopting each treatment compared with T1. Deriving this statistic is discussed in Chapter 4. It is a linear
measure of the change to QALYs expressed in monetary units less the change to costs, and so it reflects a
net profit or loss for society from any adoption decision.
Positive NMB suggests an adoption decision is a good outcome for society and negative values suggest the
opposite. QALYs were valued at £18,000 each, in line with recent research.118 In Figure 35 the mean
incremental NMB for each treatment option compared with T1 is shown.
Treatment 6 shows the highest expected incremental NMB at £10,964,883 for the cohort and reflects
the large cost savings and the value of the incremental QALYs gained. T9 shows the lowest expected
incremental NMB at £342,619. The large uncertainty in these conclusions remains, with error bars
overlapping for every treatment and all the time crossing zero.
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FIGURE 34 T9 compared with T1, change to cost and QALY outcomes.
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The probability that each treatment is cost-effective and has positive incremental NMBs is shown by Table 58.
The probabilities in Table 58 were calculated by comparing 1000 simulations of the NMB for each
treatment strategy and choosing, for each simulation, the treatment that returned the highest value.
T9 returned the highest NMB value in only 10 out of 1000 simulations, or 1% of the time. Therefore, we
interpret this decision (T9) as having a 99% chance of being incorrect. T6 returned the highest NMB value
32% of the time, making this treatment the most likely to be cost-effective. T6 also prevented the greatest
number of cases of deep infection (see Table 55), saved the most costs and generated the greatest QALY
gains (see Figures 24 and 25).
TABLE 58 Probability that each treatment is cost-effective
Strategy Probability strategy is cost-effective (%)
T2 15
T3 18
T4 10
T5 7
T6 32
T7 6
T8 11
T9 1
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Chapter 7 Discussion
Summary and conclusions
We used a MTC analysis to compare the effectiveness of nine competing strategies for reducing the risk of
infection following THA and applied the results to a Markov model of the treatment pathways for patients
who develop an infection following THA. This enabled an assessment of the costs and health effects of
the nine treatment strategies in a single coherent framework. To evaluate uncertainty in the estimates
of effectiveness and parameters in the Markov model, a Monte Carlo simulation of prior uncertain
parameters was undertaken. The output of the simulation gives an estimate of the probability of
cost-effectiveness of each of the treatment strategies and can be used as a decision-making tool in the
context of the resource-limited NHS.
The results show that, compared with T1, T6 is the strategy that prevents the greatest number of deep
infections following THA. T6 is a treatment of systemic antibiotics, antibiotic-impregnated cement and
conventional ventilation. It prevents an extra 1481 cases of deep infection and leads to the largest annual
cost savings of –£8,325,277 (95% uncertainty interval –£17,981,040 to £5,765,832). The mean gains to
health benefits measured by QALYs are greatest at 147 (95% uncertainty interval –585 to 1157). T6 is the
optimal decision with the highest probability of being cost-effective, at 32%. T2 competed closely with T6,
delivering cost savings of £7,226,732 and QALY gains of 101. The NMB of a decision to adopt T2 was second
highest, at £9,039,481. The only difference between T6 and T2 was the removal of antibiotic-impregnated
cement for the cemented procedures. This suggests that adding antibiotic-impregnated cement is worthwhile.
Two poor treatments for cost and clinical effectiveness outcomes were T9 and T7, which involved adding in
laminar ventilation and a body exhaust suit. The addition of laminar air only (T7) drives costs upwards by
£5,032,528 each year and reduces QALYs by 23. The further addition of a body exhaust suit increases costs
by £9,106,352 and reduces QALYs by 84. This happens because laminar ventilation and body exhaust suits
were found to increase risk of infection.
T6 dominates all other options by both cost and effect. These findings have to be considered against the
limitations of the research method, data used and large uncertainties shown.
Limitations and strengths
As a relatively new evidence synthesis tool, MTC provides a powerful analytical tool that enables all
available evidence, direct and indirect, to be included in an evidence base, synthesised and ranked
according to its relative efficacy with associated probability statements.78 Like any analytical model, MTC is
based on a range of assumptions and the use of non-informative priors within a Bayesian framework.
A key assumption of the MTC model used is that intervention effects are exchangeable across all trials in
the network. In other words, both direct and indirect sources of evidence in each pairwise comparison are
assumed to estimate the same treatment effects across the network of all trials. However, the assumption
is appropriate only provided that the baseline characteristics of patient populations and intervention
protocols are homogeneous. Variation in these parameters inevitably poses certain threats to both the
internal and external validity of MTC models. In order to assess and adjust for the risk of estimation bias,
we assessed the model fit and checked the consistency of intervention effect estimates from direct and
indirect evidence sources. We conducted a metaregression on previous surgery and follow-up duration as
potential sources of heterogeneity. We also estimated and adjusted for bias associated with studies with
mixed quality. We were limited to English-language literature, and this may cause a bias in the results,
but we were unable to describe the size of it or direction it might take. There were limited data available,
and the MTC model was unable to adjust for potential confounders such as case mix, particularly patient
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comorbidity, in different hospital settings, different types of laminar airflow systems used and temporal
changes in clinical practices, infection control technology and patient profiles that may have taken place
over the past several decades. Despite the inherent limitations of MTC models and the limited number of
studies available, the current evidence using MTC has the potential to change our understanding about
the effectiveness of infection prevention strategies or a combination of multiple infection prevention
strategies. This in turn may help contribute to the identification and implementation of evidence-based
best infection prevention strategies for reducing the risk of, and preventing, THR-related SSI.
The baseline risks of infection for T1 were based on the Lidwell et al.111 study, conducted in the 1970s and
reporting 39 cases of deep infection among 1161 patients who had surgery under conditions that were
closely correlated with T1. The 3.4% rate of infection describes 2.5 years, yet the model we ran counted
infection outcomes for 12 months only. The rate of 3.4% was reduced based on US data by Ong et al.,139
who showed that 66.7% of all infections they found over a 9-year period presented in the first 12 months.
Whether or not these assumptions lead to an estimate that reliably describes the baseline risk of infection
for T1 in NHS hospitals is unknown. If this estimate is inaccurate, however, it will not impact on the
conclusions drawn, as the incremental change to outcomes is the key for decision-making. Absolute values
are not particularly relevant.
A large effort was made to include parameter uncertainties in the model, and these large uncertainties can
be seen in the results tables and figures, especially Figures 24, 25 and 35. We assumed that there was no
structural uncertainty arising from the design of the Markov model. We did, however, spend time
consulting with orthopaedic surgeons and infection prevention experts. A process was completed to
identify the events most likely to impact cost and health outcomes while attempting to keep the model as
simple as possible.
A further limitation of the model relates to the data used to inform patient outcomes. PROMs data could
not be linked to the relevant time points for primary THA, deep infection or revision procedures. As a
result, we made use of utility values from a previous review of health outcomes relating to THA, to attach
health benefits to each state in our Markov model. These had been used in a previous model, in an
Australian context. There are no strong reasons to believe that these values are not appropriate to the NHS
setting. A further limitation is the scope of costs included. The data sets that were available for this project
describe only the acute sector, and the costs of primary care, private out-of-pocket expenses and personal
social services costs were excluded. We do feel that the costs of revisions of the primary hip and other
surgical interventions were appropriately quantified and are likely to be the largest component of
total costs.
Perhaps the biggest limitation of our model is the uncertainty regarding the effectiveness of the different
treatment options. The best possible data were sourced and appropriate methods used to interpret them.
A prospective randomised trial to address the research questions addressed here would be impossible; the
cost would be prohibitive and it would not be passed by an ethics committee.
A major strength of this analysis, therefore, is the ability to compare nine different treatment strategies for
the prevention of infection, together, using currently available evidence, without the need for a costly and
time-consuming clinical trial. Large numbers of patient-level data were available, which are routinely
collected in the NHS. This enabled a thorough analysis of THA patient demographics and treatment
strategies as a result of deep infection following THA. Similarly, effectiveness data from a number of trials
were available and were able to be synthesised using MTC techniques into one comparative analysis of all
relevant treatment strategies. In addition, modelling studies have significant advantages over RCTs and
other clinical studies in that they enable estimates of long-term cost and effectiveness of treatments.
Similarly, findings from modelling studies are generalisable as they are not restricted to controlled trial
criteria, and real-world populations are considered.
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Chapter 8 Conclusions and recommendations
The conclusion from this research is that T6 is the best decision for NHS hospitals. More studies could bedone on the effectiveness of laminar airflow systems and body exhaust suits to reduce the large
uncertainties we see in this modelling study. The next steps include education of relevant health-care
professionals about these research findings. Further introduction of new laminar airflow systems into NHS
hospital operating rooms should be carefully considered, as these are expensive and our research shows
that they might harm patients and increase costs. The same applies to the routine use of body
exhaust suits.
The literature revealed some information deficiencies. There were only a small number of studies available
for evidence synthesis and this reduced the statistical power making the CrIs wide for many of the
comparisons. Owing to limited data, the MTC model could not be used to adjust for potential
confounders. Examples of potential confounders are case mix, particularly patient comorbidity in different
hospital settings; different types of laminar airflow systems used (such as horizontal and vertical systems);
changes in clinical practice over time; infection control technology, such as the use of ultra-high airflows in
modern conventional operating theatres; forced air blankets; and patient characteristics that may have
changed over the past several decades.
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Appendix 1 Search terms and strategies used for
updating existing evidence
MEDLINE search strategy and output
Date of search: August 2011.
Date range searched: January 1966 to June 2011.
Search strategy
1. MH “arthroplasty, replacement, hip’ (12,088)
2. MH”Hip prosthesis” (16,064)
3. or/1-2 (23,923)
4. MH “Surgical wound infection” (24,907)
5. MH “prosthesis-related infections” (5875)
6. MH “sepsis+” (78,337)
7. MH “bacterial infections+” (651,285)
8. or/4-7 (718,898)
9. MH “infection control+’ (44,638)
10. infection prevent*/ (33,276)
11. MH “antibiotic prophylaxis” (6889)
12. MH “anti-infective agents+” (427,375)
13. MH “Anti-Bacterial Agents+” (226,839)
14. intravenous antibiotics/ (3008)
15. systemic antibiotics/ (2001)
16. or/9-15 (489,991)
17. MH “bone cements” (7563)
18. Antibiotic cement/ (448)
19. antibiotic bone cement (smart text searching)/ (7715)
20. Antibiotic-impregnated cement (smart text searching)/ (733)
21. Antibiotic-impregnated bone cement (smart text searching )/ (1001)
22. Antibiotic-loaded cement (smart text searching)/ (1129)
23. Antibiotic-loaded bone cement (smart text s)/ (7969)
24. MH “Environment, Controlled+” (218,646)
25. MH “ventilation” (4202)
26. MH “Air conditioning” (2075)
27. MH “operating rooms” (9370)
28. Operating theatre/ (1937)
29. laminar air flow (smart text searching)/ (3374)
30. laminar airflow (smart text searching )/ (244)
31. laminar air flow system (smart text searching) (4345)
32. ultra-clean air (smart text searching )/ (2527)
33. ultra clean air (smart text searching)/ (2527)
34. ultra-clean air system (smart text searching) (4496)
35. conventional operating room (smart text searching)/ (22,235)
36. conventional operating theatre (smart text searching)/ (2777)
37. Turbulent air flow (smart text searching)/ (2613)
38. or/25-38 (256,457)
39. 3 and 8 and 16 (697)
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40. 3 and 8 and 24 (292)
41. 3 and 8 and 39 (87)
42. 40 or 41 or 42 (834)
43. Limit 43 to 2004-2011 (01/01/2004-01/06/2011) (343)
44. Limit 44 to English (289)
Cumulative Index to Nursing and Allied Health Literature
search strategy and output
Date of search: August 2011.
Date range searched: January 1966 to June 2011.
Search strategy
1. MH “arthroplasty, replacement, hip’ (4105)
2. MH “joint prosthesis” (2008)
3. Hip prosthesis (smart text searching) (1894)
4. or/1-3 (5474)
5. MH “Surgical wound infection” (3410)
6. MH “prosthesis-related infections” (529)
7. MH “sepsis+” (7640)
8. MH “bacterial infections+” (39,831)
9. or/5-8 (48,616)
10. MH “infection control+’ (31,116)
11. infection prevent*/ (10,134)
12. MH “antibiotic prophylaxis” (2227)
13. MH “anti-infective agents+” (45,136)
14. Anti-Bacterial Agents (smart text searching)/ (2578)
15. intravenous antibiotics (smart text searching)/ (1301)
16. systemic antibiotics (smart text searching)/ (665)
17. or/10-16 (79,414)
18. MH “bone cements” (804)
19. Antibiotic cement (smart text searching) (96)
20. antibiotic bone cement (smart text searching)/ (610)
21. Antibiotic-impregnated cement (smart text searching)/ (107)
22. Antibiotic-impregnated bone cement (smart text searching )/ (126)
23. Antibiotic-loaded cement (smart text searching)/ (144)
24. Antibiotic-loaded bone cement (smart text s)/ (638)
25. MH “Environment, Controlled+” (4265)
26. MH “ventilation+” (747)
27. MH “Air conditioning” (118)
28. MH “operating rooms” (4319)
29. Operating theatre (smart text searching) (663)
30. laminar air flow (smart text searching) (126)
31. laminar airflow (smart text searching )/ (38)
32. laminar air flow system (smart text searching) (137)
33. ultra-clean air (smart text searching )/ (40)
34. ultra clean air (smart text searching)/ (40)
35. ultra-clean air system (smart text searching) (126)
36. conventional operating room (smart text searching)/ (359)
37. conventional operating theatre (smart text searching)/ (664)
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38. Turbulent air flow (smart text searching)/ (52)
39. or/26-39 (9280)
40. 4 and 9 and 17 (216)
41. 4 and 9 and 25 (59)
42. 4 and 9 and 40 (24)
43. 41 or 42 or 43 (233)
44. Limit 44 to 2004-2011 (01/01/2004-01/06/2011) (196)
45. Limit 45 to English (196)
The Cochrane Central Register of Controlled Trials search
strategy and search output
Date of search: August 2011.
Date range searched: January 1966 to June 2011.
Search strategy
#1. MH “arthroplasty, replacement, hip +”/exp (1254)
#2. MH”Hip prosthesis”/exp (942)
#3. or/1-2 (1949)
#4. MH “Surgical wound infection”/exp (2470)
#5. MH “prosthesis-related infections”/exp (127)
#6. MH “sepsis ”/exp (2684)
#7. MH “bacterial infections”/exp (13,168)
#8. or/4-7 (17,095)
#9. MH “infection control”/exp (1116)
#10. infection prevent*/ (16,554)
#11. MH “antibiotic prophylaxis”/exp (1040)
#12. MH “anti-infective agents”/exp (44,153)
#13. MH “Anti-Bacterial Agents”/exp (18,759)
#14. intravenous antibiotics/ (2375)
#15. systemic antibiotics/ (1220)
#16. or/9-15 / (55,871)
#17. MH “bone cements”/ exp (579)
#18. Antibiotic cement/ (39)
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#19. antibiotic bone cement/ (32)
#20. Antibiotic-impregnated cement/ (7)
#21. Antibiotic-impregnated bone cement/ (7)
#22. Antibiotic-loaded cement/ (3)
#23. Antibiotic-loaded bone cement/ (3)
#24. or/17-23 (601)
25. MH “Environment, Controlled”/exp (1948)
26. MH “ventilation”/exp (52)
27. MH “Air conditioning”/exp (25)
28. MH “operating rooms”/exp (230)
29. Operating theatre/ (402)
30. laminar air flow/ (39)
31. laminar airflow/ (11)
32. laminar air flow system/ (7)
33. ultra-clean air/ (5)
34. ultra clean air/ (6)
35. ultra-clean air system/ (2)
36. conventional operating room/ (184)
37. conventional operating theatre/ (59)
38. Turbulent air flow/ (5)
39. or/25-38 (2697)
40. 3 and 8 and 16/ (58)
41. 3 and 8 and 24/ (9)
42. 3 and 8 and 39/ (11)
43. 40 or 41 or 42/ (59)
44. Limit 43 to 2004-2011 (15)
45. Limit 44 to English (15)
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EMBASE search strategy and search output
Date of search: August 2011.
Date range searched: January 1966 to June 2011.
Search strategy
#1. ‘hip arthroplasty’/exp (32,814)
#2. ‘hip prosthesis’/exp (26,568)
#3. #1 OR #2 (32,814)
#4. ‘surgical infection’/exp (18,425)
#5. ‘prosthesis infection’/exp (2624)
#6. ‘sepsis’/exp (129,060)
#7. ‘bacterial infection’/exp (667,479)
#8. #4 OR #5 OR #6 OR #7 (767,273)
#9. ‘infection control’/exp (55,345)
#10. ‘infection prevention’/exp (31,360)
#11. ‘antibiotic prophylaxis’/exp (16,495)
#12. ‘antiinfective agent’/exp (1,827,014)
#13. ‘antibiotic agent’/exp (833,849)
#14. ‘intravenous’/exp AND ‘antibiotics’/exp (57,368)
#15. systemic AND ‘antibiotics’/exp (70,947)
#16. #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 (1,886,128)
#17. ‘bone cement’/exp (9336)
#18. ‘antibiotic’/exp AND ‘cement’/exp (1532)
#19. ‘antibiotic’/exp AND ‘bone’/exp AND ‘cement’/exp (340)
#20. ‘antibiotic’/exp AND impregnated (1038)
#21. ‘gentamicin bone cement’/exp (343)
#22. ‘antibiotic loaded’ AND ‘cement’/exp (204)
#23. ‘antibiotic loaded’ AND ‘bone’/exp AND ‘cement’/exp (31)
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#24. #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 (10,339)
#25. ‘microclimate’/exp (30,703)
#26. ‘air conditioning’/exp (10,256)
#27. ‘operating room’/exp (15,854)
#28. ‘laminar airflow’/exp (566)
#29. laminar AND ‘air’/exp AND ‘flow’/exp AND system (29)
#30. ‘ultra clean’ AND ‘air’/exp (15)
#31. ultra AND clean AND ‘air’/exp (16)
#32. ‘ultra clean’ AND ‘air’/exp AND system (2)
#33. conventional AND operating AND room (886)
#34. conventional AND operating AND theatre (135)
#35. ‘turbulent flow’/exp (2813)
#36. #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 (49,434)
#37. #3 AND #8 AND #16 (828)
#38. #3 AND #8 AND #24 (226)
#39. #3 AND #8 AND #36 (37)
#40. #37 OR #38 OR #39 (915)
#41. #37 OR #38 OR #39 AND [english]/lim AND [2004-2011]/py (529)
#42. #37 OR #38 OR #39 AND [english]/lim AND [embase]/lim NOT [medline]/lim AND [2004-2011]/
py (140)
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Appendix 2 Excluded studies
TABLE 59 Studies excluded and reasons for exclusion (antibiotic prophylaxis)
Studies excluded from the MTC Reasons for exclusion
Bryan CS, Morgan SL, Caton RJ, Lunceford EM Jr. Cefazolin versus cefamandole
for prophylaxis during total joint arthroplasty. Clin Orthop Relat Res
1988;228:117–22
Without separating THRs from TKRs
Chiu FY, Lin CF, Chen CM, Lo WH, Chaung TY. Cefuroxime-impregnated
cement at primary total knee arthroplasty in diabetes mellitus. A prospective,
randomised study. J Bone Joint Surg Br 2001;83:691–5
Outcome measure was TKR-related
infection
Chiu F-Y, Chen C-M, Lin C-FJ, Lo W-H. Cefuroxime-impregnated cement in
primary total knee arthroplasty: a prospective, randomized study of three
hundred and forty knees. J Bone Joint Surg Am 2002;84:759–62
Outcome measure was TKR-related
infection
Davies AJ, Lockley RM, Jones A, el-Safty M, Clothier JC. Comparative
pharmacokinetics of cefamandole, cefuroxime and cephradine during total hip
replacement. J Antimicrob Chemother 1986;17:637–40
Only compared different types of
antibiotic agents
Davis WA, Kane JG. Antimicrobial prophylaxis for arthroplasty: a comparative
study of cefonicid and cefazolin. Orthopedics 1987;10:1405–9
Only compared different types of
antibiotic agents
DeBenedictis KJ, Rowan NM, Boyer BL. A double-blind study comparing
cefonicid with cefazolin as prophylaxis in patients undergoing total hip or knee
replacement. Rev Infect Dis 1984;6(Suppl. 4):901–4
Only compared different types of
antibiotic agents
Doyon F, Evrard J, Mazas F, Hill C. Long-term results of prophylactic cefazolin
versus placebo in total hip replacement. Lancet 1987;1:860
We included the study by Hill et al.98
instead as it was a long-term follow-up
study (both studies have the same
patient population)
Gunst JP, Deletang S, Rogez JM, Blanloeil Y, Baron D, Dixneuf B. [Prophylactic
antibiotic therapy with cefamandole in total hip surgery replacement using
Charnley’s tent. A randomized study.] Pathol Biol 1984;32:567–9
In French
Heydemann JS, Nelson CL. Short-term preventive antibiotics. Clin Orthop
Relat Res 1986;205:184–7
Without separating THRs from TKRs
Jones RN, Wojeski WV. Single-dose surgical prophylaxis using ticarcillin/
clavulanic acid (Timentin): a prospective, randomized comparison with
cefotaxime. Diagn Microbiol Infect Dis 1987;7:219–23
Without separating THRs from other
joint replacements. The study covered
gastrointestinal, obstetrics and
gynaecology, orthopaedic and other
procedures with limited data for joint
replacements
Jones RN, Wojeski W, Bakke J, Porter C, Searles M. Antibiotic prophylaxis
of 1036 patients undergoing elective surgical procedures. A prospective,
randomized comparative trial of cefazolin, cefoxitin, and cefotaxime in
a prepaid medical practice. Am J Surg 1987;153:341–6
Without separating THRs from other
joint replacements. The study covered
gastrointestinal, obstetrics and
gynaecology, orthopaedic and other
procedures with limited data for joint
replacements
Jones RN, Slepack JM, Wojeski WV. Cefotaxime single-dose surgical prophylaxis
in a prepaid group practice. Comparisons with other cephalosporins and
ticarcillin/clavulanic acid. Drugs 1988;35(Suppl. 2):116–23
Without separating THRs from other
joint replacements. The study covered
gastrointestinal, obstetrics and
gynaecology, orthopaedic and other
procedures with limited data for joint
replacements
Mauerhan DR, Nelson CL, Smith DL, Fitzgerald RH Jr, Slama TG, Petty RW, et al.
Prophylaxis against infection in total joint arthroplasty. One day of cefuroxime
compared with three days of cefazolin. J Bone Joint Surg Am 1994;76:39–45
Only compared two different types of
antibiotic agents
continued
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TABLE 59 Studies excluded and reasons for exclusion (antibiotic prophylaxis) (continued )
Studies excluded from the MTC Reasons for exclusion
Mollan RA, Haddock M, Webb CH. Teicoplanin vs cephamandole for
antimicrobial prophylaxis in prosthetic joint implant surgery: (preliminary results).
Eur J Surg 1992;567:19–21
Without separating THRs from TKRs
Periti P, Stringa G, Donati L, Mazzei T, Mini E, Novelli A. Teicoplanin – its role as
systemic therapy of burn infections and as prophylaxis for orthopaedic surgery.
Italian Study Groups for Antimicrobial Prophylaxis in Orthopaedic Surgery and
Burns. Eur J Surg 1992;567:3–8
Without separating THRs from TKRs
Periti P, Stringa G, Mini E. Comparative multicenter trial of teicoplanin versus
cefazolin for antimicrobial prophylaxis in prosthetic joint implant surgery. Italian
Study Group for Antimicrobial Prophylaxis in Orthopedic Surgery. Eur J Clin
Microbiol Infect Dis 1999;18:113–19
Without separating THRs from TKRs
Ritter MA, Campbell E, Keating EM, Faris PM. Comparison of intraoperative
versus 24 hour antibiotic prophylaxis in total joint replacement. A controlled
prospective study. Orthop Rev 1989;18:694–6
Without separating THRs from TKRs
Soave R, Hirsch JC, Salvati EA, Brause BD, Roberts RB. Comparison of ceforanide
and cephalothin prophylaxis in patients undergoing total joint arthroplasty.
Orthopedics 1986;9:1657–60
Only compared two antibiotic agents
Vainionpää S, Wilppula E, Lalla M, Renkonen OV, Rokkanen P. Cefamandole
and isoxazolyl penicillins in antibiotic prophylaxis of patients undergoing total
hip or knee-joint arthroplasty. Arch Orthopaed Trauma Surg 1988;107:228–30
Only compared two antibiotic agents
Wall R, Klenerman L, McCullough C, Fyfe I. A comparison of teicoplanin and
cefuroxime as prophylaxis for orthopaedic implant surgery: a preliminary report.
J Antimicrob Chemother 1988;21(Suppl. A):141–6
Without separating THRs from TKRs
Wollinsky KH, Oethinger M, Büchele M, Kluger P, Puhl W, Merhkens HH.
Autotransfusion – bacterial contamination during hip arthroplasty and efficacy
of cefuroxime prophylaxis. A randomized controlled study of 40 patients.
Acta Orthop Scand 1997;68:225–30
The purpose of the study was to
examine bacterial contamination
Evrard J, Doyon F, Acar JF, Salord JC, Mazar F, Flamant R. Two-day cefamandole
versus five-day cephazolin prophylaxis in 965 total hip replacements. Report of a
multicentre double blind randomised trial. Int Orthop 1988;12:69–73
Only compared two different types of
antibiotic agents
Wymenga A, van Horn J, Theeuwes A, Muytjens H, Slooff T. Cefuroxime for
prevention of postoperative coxitis. One versus three doses tested in a
randomized multicenter study of 2651 arthroplasties. Acta Orthop Scand
1992;63:19–24
Only compared two different doses of
an antibiotic agent
Suter F, Avai A, Fusco U, Gerundini M, Caprioli S, Maggiolo F. Teicoplanin versus
cefamandole in the prevention of infection in total hip replacement. Eur J Clin
Microbiol Infect Dis 1994;13:793–6
Only compared two different types of
antibiotic agents
Pollard JP, Hughes SP, Scott JE, Evans MJ, Benson MK. Antibiotic prophylaxis in
total hip replacement. Br Med J 1979;1:707–9
Only compared two different types of
antibiotic agents
TKR, total knee replacement.
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TABLE 60 Studies excluded and reasons for exclusion (antibiotic-impregnated cement)
Studies excluded from the MTC Reasons for exclusion
Josefsson G, Kolmert L. Prophylaxis with systematic antibiotics versus
gentamicin bone cement in total hip arthroplasty. A ten-year survey of 1688
hips. Clin Orthop Relat Res 1993;292:210–14
This study had the same patient population
as Jossefson et al.,102 but had a longer
follow-up period
McQueen M, Littlejohn A, Hughes SP. A comparison of systemic cefuroxime
and cefuroxime loaded bone cement in the prevention of early infection
after total joint replacement. Int Orthop 1987;11:241–3
This study did not report the number of
THRs assigned to systemic or cement
antibiotic treatment
Lieberman JR, Callaway GH, Salvati EA, Pellicci PM, Brause BD. Treatment of
the infected total hip arthroplasty with a two-stage reimplantation protocol.
Clin Orthop Relat Res 1994;301:205–12
This study could not be located in the
author’s references
Josefsson G, Gudmundsson G, Kolmert L, Wijkström S. Prophylaxis with
systemic antibiotics versus gentamicin bone cement in total hip arthroplasty.
A five-year survey of 1688 hips. Clin Orthop Relat Res 1990;253:173–8
This study had the same patient population
as Jossefson et al.,102 but had a longer
follow-up period
Pfarr B, Burri C. [Prospective study on the effect of gentamycin-Palacos in
200 total hip prostheses.] Aktuelle Probl Chir Orthop 1979;12:207–10
In German
Wannske M, Tscherne H. [Results of prophylactic use of Refobacin-Palacos in
implantation of endoprostheses of the hip joint in Hannover.] Aktuelle Probl
Chir Orthop 1979;12:201–5
In German
Buchholz HW, Engelbrecht H. [Depot effects of various antibiotics mixed
with Palacos resins.] Chirurg 1970;41:511–5
In German
Buchholz HW, Gartmann HD. [Infection prevention and surgical
management of deep insidious infection in total endoprosthesis.] Chirurg
1972;43:446–53
In German
Buchholz HW, Engelbrecht H, Rottger J, Siegel A. Erkentnisse nach Wechsel
von uber 400 infizierten Huftendoprothesen. Orthop Prax 1977;12:1117–20
In German
Thierse L. [Experiences with Refobacin-Palacos with regard to deep late
infections following hip-joint endoprosthesis surgery. A 4-years’ study
(author’s transl).] Z Orthop Ihre Grenzgeb 1978;116:847–52
In German
Röttger J, Buchholz HW, Engelbrecht E, Siegel A. [Results with
Refobacin-Palacos in the changing of infected prostheses. Results of
prostheses exchange under cover of Refobacin-Palacos in Hamburg.]
Aktuelle Probl Chir Orthop 1979;12:211–13
In German
Chiu FY, Lin CF, Chen CM, Lo WH, Chaung TY. Cefuroxime-impregnated
cement at primary total knee arthroplasty in diabetes mellitus. A prospective,
randomised study. J Bone Joint Surg Br 2001;83:691–5
Outcome measure was TKR-related
infection
Chiu F-Y, Chen C-M, Lin C-FJ, Lo W-H. Cefuroxime-impregnated cement in
primary total knee arthroplasty: a prospective, randomized study of three
hundred and forty knees. J Bone Joint Surg Am 2002;84:759–62
Outcome measure was TKR-related
infection
Persson U, Persson M, Malchau H. The economics of preventing revisions in
total hip replacement. Acta Orthop Scand 1999;70:163–9
An economic evaluation study citing
infection data from Lidwell et al.111
Malchau H, Herberts P, Ahnfelt L. Prognosis of total hip replacement in
Sweden. Follow-up of 92,675 operations performed 1978-1990.
Acta Orthop Scand 1993;64:497–506
Only investigated risk factors for revision
Havelin LI, Espehaug B, Vollset SE, Engesaeter LB. The effect of the type of
cement on early revision of Charnley total hip prostheses. A review of eight
thousand five hundred and seventy-nine primary arthroplasties from the
Norwegian Arthroplasty Register. J Bone Joint Surg Am 1995;77:1543–50
Revision was the outcome measure
Espehaug B, Engesaeter LB, Vollset SE, Havelin LI, Langeland N. Antibiotic
prophylaxis in total hip arthroplasty. Review of 10,905 primary cemented
total hip replacements reported to the Norwegian arthroplasty register,
1987 to 1995. J Bone Joint Surg Br 1997;79:590–5
Only investigated patient-related risk
factors for early revision
Buchholz HW, Elson RA, Heinert K. Antibiotic-loaded acrylic cement: current
concepts. Clin Orthop Relat Res 1984;190:96–108
A semi-review rather than a primary study
continued
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TABLE 60 Studies excluded and reasons for exclusion (antibiotic-impregnated cement) (continued )
Studies excluded from the MTC Reasons for exclusion
Murray WR. Use of antibiotic-containing bone cement. Clin Orthop Relat Res
1984;190:89–95
THRs were not separated from revisions
Lynch M, Esser MP, Shelley P, Wroblewski BM. Deep infection in Charnley
low-friction arthroplasty. Comparison of plain and gentamicin-loaded
cement. J Bone Joint Surg Br 1987;69:355–60
The study could not be connected to the
MTC network
TKR, total knee replacement.
TABLE 61 Studies excluded and reasons for exclusion (ventilation systems in operating theatres)
Studies excluded from the MTC Reasons for exclusion
Charnley J. Postoperative infection after total hip replacement with special
reference to air contamination in the operating room. Clin Orthop Relat Res
1972;87:167–87
Information about the use of antibiotic
was unavailable
Berthelot P, Loulergue P, Raberin H, Turco M, Mounier C, Tran Manh Sung R,
et al. Efficacy of environmental measures to decrease the risk of hospital-
acquired aspergillosis in patients hospitalised in haematology wards.
Clin Microbiol Infect 2006;12:738–44
Outcome was pulmonary aspergillosis
infection
Clark RE, Amos WC, Higgins V, Bemberg KF, Weldon CS. Infection control in
cardiac surgery. Surgery 1976;79:89–96
Outcome measure was cardiac infection
Davidson AI, Smylie HG, Macdonald A, Smith G. Ward design in relation to
postoperative wound infection: part II. Br Med J 1971;1:72–5
Outcome measure was wound infection
in general
Drake CT, Goldman E, Nichols RL, Piatriszka K, Nyhus LM. Environmental air
and airborne infections. Ann Surg 1977;185:219–23
Outcome measure was wound infection
in general
Franco JA, Baer H, Enneking WF. Airborne contamination in orthopedic
surgery. Evaluation of laminar air flow system and aspiration suit.
Clin Orthop Relat Res 1977;122:231–43
THRs were not separated from TKRs,
with culture bacteria being the outcome
measure
Gruenberg MF, Campaner GL, Sola CA, Ortolan EG. Ultraclean air for
prevention of postoperative infection after posterior spinal fusion with
instrumentation: a comparison between surgeries performed with and without
a vertical exponential filtered air-flow system. Spine 2004;29:2330–4
Outcome measure was not THR-related
infection
Lidwell OM, Lowbury EJ, Whyte W, Blowers R, Stanley SJ, Lowe D. Effect of
ultraclean air in operating rooms on deep sepsis in the joint after total hip or
knee replacement: a randomised study. Br Med J 1982;285:10–14
THRs were not separated from TKRs
Millar KJ. The impact of a new operating theatre suite on surgical wound
infections. Aust N Z J Surg 1979;49:437–40
Outcome measure was not THR-related
infection
Oren I, Haddad N, Finkelstein R, Rowe JM. Invasive pulmonary aspergillosis
in neutropenic patients during hospital construction: before and after
chemoprophylaxis and institution of HEPA filters. Am J Hematol 2001;66:257–62
Outcome measure was not THR-related
infection
Sanderson MC, Bentley G. Assessment of wound contamination during
surgery: a preliminary report comparing vertical laminar flow and conventional
theatre systems. Br J Surg 1976;63:431–2
THRs were not separated from joint
replacements
Simsek SY, Bicer Y, Yapici N, Kalaca S, Aydin OO, Camur G, et al. Analysis of
risk factors for sternal surgical site infection: emphasizing the appropriate
ventilation of the operating theaters. Infect Control Hosp Epidemiol
2006;27:958–63
Outcome measure was not THR-related
infection
Wilson L. Large building air conditioning: a case for central systems.
Heat Piping Air Cond 1982;54:61
Irrelevant outcome
Nelson JP, Glassburn AR Jr, Talbott RD, McElhinney JP. The effect of previous
surgery, operating room environment, and preventive antibiotics on
postoperative infection following total hip arthroplasty. Clin Orthop Relat Res
1980;147:167–9
Previous surgery history was suspected to
be a serious confounder, masking true
treatment effect, and no pertinent data
were available to explain the observed
difference in the incidence of infection
by the authors
TKR, total knee replacement.
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Appendix 3 Study quality assessment tools
TABLE 62 Study type
Study
type Studies included
1 Meta-analysis, systematic reviews of RCTs or RCTs including cluster RCTs
2 Systematic reviews of, or individual, non-RCTs, case–control studies, cohort studies, controlled before-and-after
studies, interrupted time series studies and correlation studies
3 Non-analytical studies such as case reports, case-series studies
4 Expert opinion, formal consensus
TABLE 63 Study quality
Study
quality Evaluation
++ All or most of the quality criteria have been fulfilled. Where the criteria have been fulfilled, the conclusions of
the study or the review are thought to be very unlikely to alter
+ Some of the criteria have been fulfilled. Where the criteria have been fulfilled, the conclusions of the study or
the review are thought to be unlikely to alter
– Few or no criteria have been fulfilled. The conclusions of the study are thought to be likely or very likely to alter
TABLE 64 Level of evidence
Level of
evidence Explanation
1++– High-quality meta-analysis, systematic reviews of RCTs or RCTs (including cluster RCTs) with a very low risk of bias
1+ Well-conducted meta-analysis, systematic reviews of RCTs or RCTs (including cluster RCTs) with a low risk of bias
1– Meta-analyses, systematic reviews of RCTs or RCTs (including cluster) with a high risk of bias
2++ High-quality systematic reviews of these types of studies, or individual, non-RCTs, case–control studies,
cost–benefit analysis studies and correlation studies with a low risk of confounding, bias or chance, and a high
probability that the relationship is causal
2+ Well-conducted non-RCT, case–control studies, cohort studies, cost–benefit analysis studies and correlation
studies with a low risk of confounding, bias or chance, and a moderate probability that the relationship is causal
2– Non-RCTs, case–control studies, cohort studies, cost–benefit analysis studies, interrupted time series and
correlation studies with a high risk or chance of confounding bias, and a significant risk that that relationship is
not causal
3 Non-analytical studies (e.g. case reports, case series)
4 Expert opinion, formal consensus
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TABLE 65 Quality score allocation for RCTs
Code Criterion Definition
C1 Random sequence generalisation
Was the assignment to the treatment groups truly
random?
Adequate: sequence generalisation was truly random
(computer-generated, random numbers table or coded
packages)
Inadequate: use of such means as alternation, case
record number, birth date, etc.
Unknown: no details were provided in the paper of
random sequence generalisation
C2 Blinding of subjects
Were patients blinded to treatment allocation?
Adequate: adequate measures were adopted to ensure
patients were blinded to treatment allocation
Inadequate: there was some possibility of disclosure of
treatment allocation
Unknown: no details were provided in the paper of
treatment allocation
C3 Blinding of assessors
Were the assessors of the outcome blinded to
treatment status?
Adequate: actions were taken to blind assessors or
outcomes so that bias is unlikely
Inadequate: there may be some possibility that assessors
or outcomes were not blinded
Unknown: no details were provided in the text
C4 Sample size
Was a priori calculation of sample size undertaken?
Yes
No/not mentioned
C5 Baseline characteristics and comparability
Were the treatment and control groups similar at
baseline in terms of prognostic factors?
Unconfounded: treatment and control groups were
comparable at baseline/or confounding were adjusted
Some degree of confounding: mentioned, but not
adjusted for
Significant potential for confounding or confounding not
discussed
C6 Intention to treat
Were the outcomes of subjects who withdrew
described and included in the analysis (intention to
treat)?
Intention to treat: primary analysis based all randomised
cases
Analysis unmodified: numbers and reasons for withdraw
were indicted but not considered in the analysis
No mention: intention to treat not mentioned
C7 Outcome assessment
Was the assessment of the method of wound
infection defined and applied consistently between
parent groups?
Microbiological diagnosis based on a predefined protocol
Microbiological diagnosis may be included in definite
criteria
Clinical decision with no specific criteria or assessment
methods unstated
C8 Statistical analysis
Was appropriate statistical analysis used?
Appropriate statistical analysis was used
It was unclear whether or not appropriate statistical
analysis was used
Inappropriate statistical analysis was used
Adapted from the quality scoring system used by the Cochrane Musculoskeletal Injuries Group153 for RCTs based on the
Joanna Briggs Institute Reviewer’s Manual.154
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TABLE 66 Quality score allocation for observational studies
Code Criterion Definition
1 Were the patients at a similar point in
their disease progression?
The patients were at a similar point in their disease progression
(3 points)
It was unclear whether or not the patients were at a similar point in
their disease progression (2 points)
The patients were not at a similar point in their disease progression
(1 point)
2 Were confounding variables identified
and their effects adequately adjusted for?
Confounding variables were identified and their effects adequately
adjusted for (3 points)
It was unclear whether or not confounding variables were identified
and their effects adequately adjusted for (2 points)
Confounding variables were not identified and their effects were not
adequately adjusted for (1 point)
3 Was bias minimised regarding the
selection of cases and controls (cases
and control groups comparable on all
the prognostic confounding factors)?
The bias regarding the selection of cases and controls was minimised
(3 points)
The bias regarding the selection of cases and controls was
inadequately addressed (2 points)
The bias regarding the selection of cases and controls was not
addressed (1 point)
4 Were outcomes assessed using objective
measures or criteria (self-recall
questionnaire is not)?
Outcomes were assessed using objective measures or criteria (3 points)
Outcomes were assessed using limited objective measures and criteria
(2 points)
Outcomes were not assessed using objective measures and criteria
(1 point)
5 Was outcome assessment blind to
exposure status?
Outcome assessment was blind to exposure status (3 points)
It was unclear whether or not outcome assessment was blind to
exposure status (2 points)
Outcome assessment was not blind to exposure status (1 point)
6 Was follow-up carried out over a
sufficient period of time (long enough
for the outcome to occur)?
Follow-up was carried out over a sufficient period of time (3 points)
It was unclear whether or not follow up was carried out over a
sufficient period of time (2 points)
Follow-up was carried out over an insufficient period of time (1 point)
7 Were the outcomes of the patients who
withdrew described and included in the
analysis?
The outcomes of the patients who withdrew were described and
included in the analysis (3 points)
The outcomes of the patients who withdrew were unclear nor were
their inclusion in the analysis (2 points)
The outcomes of the patents who withdrew were not included in the
analysis (1 point)
8 Was appropriate statistical analysis used? Appropriate statistical analysis were used (3 points)
It was unclear whether or not appropriate statistical analysis was used
(2 points)
Statistical analysis used was inappropriate (1 point)
Adapted from the quality scoring system used by Tooth et al.95 for observational studies.
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Appendix 4 Primary total hip replacement
OPCS codes
The primary THR OPCS codes are detailed below.
W371 Primary total prosthetic replacement of hip joint using cement.
W378 Other specified total prosthetic replacement of hip joint using cement.
W379 Unspecified total prosthetic replacement of hip joint using cement.
W381 Primary total prosthetic replacement of hip joint not using cement.
W388 Other specified total prosthetic replacement of hip joint not using cement.
W389 Unspecified total prosthetic replacement of hip joint not using cement.
W391 Primary total prosthetic replacement of hip joint not elsewhere classified (NEC).
W398 Other specified other total prosthetic replacement of hip joint.
W399 Unspecified other total prosthetic replacement of hip joint.
W931 Primary hybrid prosthetic replacement of hip joint using cemented acetabular component.
W938 Other specified hybrid prosthetic replacement of hip joint using cemented acetabular component.
W939 Unspecified hybrid prosthetic replacement of hip joint using cemented acetabular component.
W941 Primary hybrid prosthetic replacement of hip joint using cemented femoral component.
W948 Other specified hybrid prosthetic replacement of hip joint using cemented femoral component.
W949 Unspecified hybrid prosthetic replacement of hip joint using cemented femoral component.
W951 Primary hybrid prosthetic replacement of hip joint using cement NEC.
W958 Other specified hybrid prosthetic replacement of hip joint using cement.
W959 Unspecified hybrid prosthetic replacement of hip joint using cement.
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Appendix 5 Process information for the
data linkage
TABLE 67 Hospital Episodes Statistics data APC
HES variable New variable Pseudonymised variable
admincat Retained
endage Retained
startage Retained
dob Deleted
dob_cfl Deleted
ethnos Retained
lopatid Deleted
newnhsno Deleted
encrypted_hesid Deleted
homeadd Deleted
sex Retained
admidate Retained
adm_cfl Retained
elecdate Deleted
elec_cfl Deleted
admimeth Retained
admisorc Retained
firstreg Retained
elecdur Retained
disdate Retained
dis_cfl Retained
disdest Retained
dismeth Retained
bedyear Deleted
spelbgin Retained
epiend Retained
epistart Retained
speldur Retained
spelend Retained
epidur Retained
epiorder Retained
epie_cfl Retained
epis_cfl Retained
continued
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TABLE 67 Hospital Episodes Statistics data APC (continued )
HES variable New variable Pseudonymised variable
epistat Deleted
epitype Retained
provspno Deleted
disreadydate Deleted
diag_01 Retained
diag_02 Retained
diag_03 Retained
diag_04 Retained
diag_05 Retained
diag_06 Retained
diag_07 Retained
diag_08 Retained
diag_09 Retained
diag_10 Retained
diag_11 Retained
diag_12 Retained
diag_13 Retained
diag_14 Retained
diag_15 Retained
diag_16 Retained
diag_17 Retained
diag_18 Retained
diag_19 Retained
diag_20 Retained
cause Retained
opertn_01 Retained
opertn_02 Retained
opertn_03 Retained
opertn_04 Retained
opertn_05 Retained
opertn_06 Retained
opertn_07 Retained
opertn_08 Retained
opertn_09 Retained
opertn_10 Retained
opertn_11 Retained
opertn_12 Retained
opertn_13 Retained
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TABLE 67 Hospital Episodes Statistics data APC (continued )
HES variable New variable Pseudonymised variable
opertn_14 Retained
opertn_15 Retained
opertn_16 Retained
opertn_17 Retained
opertn_18 Retained
opertn_19 Retained
opertn_20 Retained
opertn_21 Retained
opertn_22 Retained
opertn_23 Retained
opertn_24 Retained
opdate_01 Retained
opdate_02 Retained
opdate_03 Retained
opdate_04 Retained
opdate_05 Retained
opdate_06 Retained
opdate_07 Retained
opdate_08 Retained
opdate_09 Retained
opdate_10 Retained
opdate_11 Retained
opdate_12 Retained
opdate_13 Retained
opdate_14 Retained
opdate_15 Retained
opdate_16 Retained
opdate_17 Retained
opdate_18 Retained
opdate_19 Retained
opdate_20 Retained
opdate_21 Retained
opdate_22 Retained
opdate_23 Retained
opdate_24 Retained
operstat Deleted
posopdur Retained
continued
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TABLE 67 Hospital Episodes Statistics data APC (continued )
HES variable New variable Pseudonymised variable
preopdur Retained
classpat Deleted
intmanig Retained
mainspef Retained
tretspef Deleted
domproc Retained
HRGLATE Deleted
HRGLATE35 Deleted
hrgnhs Retained
hrgnhsvn Retained
suscorehrg Retained
sushrg Retained
sushrgvers Retained
susspellid Deleted
procode Deleted
procode3 Deleted
procodet Deleted
protype Retained
susrecid Deleted
epikey Deleted
nhsnum_trans Generated
hesid_trans Generated
susrec_trans Generated
epikey_trans Generated
procode-trans Generated
procode3_trans Generated
procodet_trans Generated
age at operation Generated (whole years,
round down)
HES variable critical care
ccstartdate Retained
ccdisdest Retained
ccdisloc Retained
ccdisdate Retained
susrecid Deleted
susrecid_trans Generated
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
122
TABLE 68 Patient-reported outcome measure data
PROMs variable New variable Pseudonymised variable
PROMS_SERIAL_NO Deleted
PROMS_PROC_CODE Retained
PROMS_PROC_GROUP Retained
PATIENT_DEATH Retained
COMPLETE Retained
Q1_COMPLETE Retained
Q1_COMPLETED_DATE Retained
Q1_ASSISTED Retained
Q1_ASSISTED_BY Retained
Q1_SYMPTOM_PERIOD Retained
Q1_PREVIOUS_SURGERY Retained
GENDER Retained
Q1_LIVING_ARRANGEMENTS Retained
Q1_GENERAL_HEALTH Retained
Q1_DISABILITY Retained
Q1_PROCODE Deleted
Q2_COMPLETE Retained
Q2_COMPLETED_DATE Retained
Q2_ASSISTED Retained
Q2_ASSISTED_BY Retained
Q2_SURGERY_DATE Retained
Q2_ALLERGY Retained
Q2_URINE Retained
Q2_BLEEDING Retained
Q2_WOUND Retained
Q2_READMITTED Retained
Q2_FURTHER_SURGERY Retained
Q2_SATISFACTION Retained
Q2_SUCCESS Retained
Q2_LIVING_ARRANGEMENTS Retained
Q2_GENERAL_HEALTH Retained
Q2_DISABILITY Retained
EQ5D_INDEX_CHANGE Retained
EQ5D_SCALE_CHANGE Retained
Q1_EQ5D_PROFILE Retained
Q1_EQ5D_INDEX Retained
Q1_EQ5D_HEALTH_SCALE Retained
continued
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TABLE 68 Patient-reported outcome measure data (continued )
PROMs variable New variable Pseudonymised variable
Q1_MOBILITY Retained
Q1_SELF_CARE Retained
Q1_ACTIVITY Retained
Q1_DISCOMFORT Retained
Q1_ANXIETY Retained
Q2_EQ5D_PROFILE Retained
Q2_EQ5D_INDEX Retained
Q2_EQ5D_HEALTH_SCALE Retained
Q2_MOBILITY Retained
Q2_SELF_CARE Retained
Q2_ACTIVITY Retained
Q2_DISCOMFORT Retained
Q2_ANXIETY Retained
Q1_EQ5D_SCALE_COMPLETE Retained
Q1_EQ5D_PROFILE_COMPLETE Retained
Q2_EQ5D_SCALE_COMPLETE Retained
Q2_EQ5D_PROFILE_COMPLETE Retained
SCORE_CHANGE Retained
HR_Q1_SCORE Retained
HR_Q1_SCORE_COMPLETE Retained
HR_Q2_SCORE Retained
HR_Q2_PAIN Retained
HR_Q2_SUDDEN_PAIN Retained
HR_Q2_NIGHT_PAIN Retained
HR_Q2_WASHING Retained
HR_Q2_TRANSPORT Retained
HR_Q2_DRESSING Retained
HR_Q2_SHOPPING Retained
HR_Q2_WALKING Retained
HR_Q2_LIMPING Retained
HR_Q2_STAIRS Retained
HR_Q2_STANDING Retained
HR_Q2_WORK Retained
HR_Q2_SCORE_COMPLETE Retained
HESID_MATCHED Retained
HESID_RANK Retained
EPISODE_MATCHED Retained
EPISODE_MATCH_RANK Retained
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TABLE 68 Patient-reported outcome measure data (continued )
PROMs variable New variable Pseudonymised variable
Q2_MATCHED Retained
Q2_MATCH_RANK Retained
STATUS_DATE Retained
MODIFIED_DATE Retained
EQ5D_VERSION Retained
Q1_SCORE_COMPLETE Retained
Q1_LANGUAGE Retained
Q1_SCAN_DATE Retained
Q1_EQ5D_VERSION Retained
Q2_SCORE_COMPLETE Retained
Q2_FORM_VERSION Retained
Q2_LANGUAGE Retained
Q2_SCAN_DATE Retained
Q2_EQ5D_VERSION Retained
STATUS Retained
EPIKEY Deleted
HES_YEAR Deleted
HES_SCHEMA Deleted
procode_trans Generated
epikey_trans Generated
TABLE 69 Office for National Statistics mortality data
ONS variable New variable Pseudonymised variable
dod (Date of death) Deleted
sex Retained
cause_of_death Retained
encrypted_hesid Deleted
hesid_trans Generated
Age at death Generated (whole years, round down)
Time primary to death Generated (whole months, round down)
Time revision to death Generated (whole months, round down)
Time debridement to death Generated (whole months, round down)
Flag: default date used Generated (Y/N)
N, no; Y, Yes.
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TABLE 70 Public Health England SSI data
PHE SSI variable New variable Pseudonymised variable Comment
SurveyDataID Deleted
PatientName Deleted
PatientSurname Deleted
NHSNumber Deleted
SerialNumber Deleted
HospitalCode Deleted
HospitalName Deleted
HospitalOrgCode Deleted
NHSTrustName Deleted
NHSTrustCode Deleted
HPARegion Deleted
ParticipationPeriod Retained
PeriodStartDate Retained
PeriodEndDate Retained
Category Retained
Gender Retained
DateOfBirth Deleted
DateHospitalAdmission Retained
DateOperation Retained
WeightKG Retained
HeightCM Retained
PrimaryIndication Retained
OPCSCode1 Retained
OPCSDescr1 Retained
OPCSCode2 Retained
OPCSDescr2 Retained
OPCSCode3 Retained
OPCSDescr3 Retained
RevisionOfHipProsthesis Retained
surgerytype Retained
AntibioticCement Retained
AntimicrobialProphylaxis Retained
ASAScore Retained
Woundclass Retained
DurationOperation Retained
SurgeonGrade Retained
SurgeonCode Deleted
SurgeonCode2 Deleted
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TABLE 70 Public Health England SSI data (continued )
PHE SSI variable New variable Pseudonymised variable Comment
RiskIndex Retained
ProstheticImplant Retained
MultipleSurgProced Retained
ReasonSurvDiscont Retained
PDDdate Retained Date inpatient surveillance stopped
PDDquestComplete Retained Patient questionnaire completed
PatientReviewed Retained Patient reviewed as part of systematic post
discharge
PDDCompleteDate Retained Date patient questionnaire completed
PatReviewedDate Retained Date of review as part of systematic post
discharge surveillance
PatientPDQGiven Retained Patient given questionnaire
Calculated BMI Retained
Detection Retained
DateOnset Retained
SSIType Retained
SSIIncisionalType Retained
OrganismCode1 Retained
OrganismCode2 Retained
OrganismCode3 Retained
Criteria Deleted
nhsnum_trans Generated
hospitalcode_trans Generated
age at operation Generated (whole years,
round down)
surv_id_trans Generated
ssi_comb recid Generated
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TABLE 71 National Joint Registry data
NJR variable New variable Pseudonymised variable
PrimaryNJRIndexNo Deleted
PrimaryProcedureID Deleted
PrimaryDB Retained
PrimaryLocalID Deleted
PatientForenames Deleted
PatientSurname Deleted
PatientGender Retained
PatientDOB Deleted
AgeAtPrimary Retain and round down
Postcode Deleted
NHSNumber Deleted
PrimaryBMI Retained
PrimaryASA Retained
Joint Retained
Side Retained
PrimaryProcedureType Retained
PrimaryPatientProcedure Retained
Approach Retained
nhstrustcode Deleted
Trust Deleted
Hospital Deleted
organisationcode Deleted
Organisation_Type Retained
LeadSurgeonGrade Retained
FirstAssisitantGrade Deleted
PrimaryOpDate Retained
IndForImp_Osteoarthritis Deleted
IndForImp_AvascularNecrosis Deleted
IndForImp_OtherInflammatoryArthropathy Retained
IndForImp_IndicationOther Retained
IndForImp_Previousinfection Retained
CementComponentType Retained
CementImplantType Retained
StemCentralizerImplantType Delete
StemCentralSectionImplantType Delete
FemoralCanalPlugImplantType Delete
TaperAdapterImplantType Delete
OutcomeType Retained
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TABLE 71 National Joint Registry data (continued )
NJR variable New variable Pseudonymised variable
PrimaryToOutcomeYears Retained
AgeAtDeath Retain and round down
RevisionNJRIndexNo Delete
RevisionProcedureID Delete
RevisionDate Retained
RevisionProcedureType Retained
RevisionPatientProcedure Retained
IndForRevHip_Infection Retained
Laminar_Flow_Theatre Retained
minimally_invasive_surgery_used Deleted
image_guided_surgery_used Deleted
patient_position Retained
incision_approach Retained
surgical_approach Retained
IndForRevHip_Other Retained
IndForRevHip_Other_text Retained
RevisionDB Retained
nhsnum_trans Generated
orgcode_trans Generated
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Appendix 6 International Classification of
Diseases, Tenth Edition T-codes: complications
of surgical and medical care
The ICD-10 T-codes are detailed below.
T845 Infection and inflammatory reaction due to internal joint prosthesis.
T846 Infection and inflammatory reaction due to internal fixation device.
T847 Infection and inflammatory reaction due to other internal orthopaedic prosthetic devices, implants
and grafts.
T857 Infection and inflammatory reaction due to other internal prosthetic devices, implants and grafts.
T814 Infection following a procedure.
T813 Disruption of wound, not elsewhere classified.
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Appendix 7 Treatment path codes/combinations
We are interested only in treatment paths related to deep infection. Revisions that occur for otherreasons are not relevant to the model.
Hierarchy rules (where several procedures occur on the
same date)
Debridement, antibiotics and implant retention plus any other code from section Hip revision codes or
Excision codes. The latter takes precedence ≥ one-stage revision, part of a two-stage or an excision.
One-stage revision and two-stage revision, the latter takes precedence ≥ two-stage revision. However, to
qualify as a two-stage procedure, the code in question must be followed by, or subsequent to, another
relevant code on a different date.
2 × DAIR codes are collapsed into one ≥DAIR.
The ICD-10 code in 3.B.3 (Y831) was used only to corroborate revision procedures and does not indicate a
separate procedure if there are other relevant codes present on the same date. If there are no other
revision codes, Y831 can be used to indicate a revision.
For debridement, antibiotics and implant retention classification
Any code from section Debridement (owing to deep infection) codes. A DAIR may be carried out as part of
another revision procedure on the same date. Where this is the case, the procedure should be classified
accordingly (i.e. not as a DAIR alone).
For one-stage revision classification
Any code from section Hip revision codes. To classify as a one-stage revision, the procedure in question
must not be followed by any other revision procedure. A patient may have several one-stage procedures.
For two-stage revision classification
We used the following codes to identify clear cases of two-stage operations: Y703 – first stage of staged
operation; and Y711 – subsequent stage of staged operation. If these codes are not present, there must
be two revision codes on two different dates and the two stages must occur within 180 days of each
other. If the subsequent procedure does not occur within this time frame (and Y703/Y711 is not present)
the procedures are to be classified as two one-stage operations.
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For stage 1-only classification
We used W572* – primary excision arthroplasty of joint NEC; Y037* – removal of prosthesis from organ
NOC (not otherwise classified); W394^ – attention to total prosthetic replacement of hip joint NEC; and
W954^ – attention to hybrid prosthetic replacement of hip joint using cement NEC (^ may indicate DAIR
or part of a two-stage revision, these codes are often followed by another revision code).
For stage 1 or 2 classification
We used any code from Hip revision codes. These are the same codes used to define a one-stage revision
and so should only be classified as part of a two-stage revision if the rules for the two-stage revision
are satisfied.
For permanent excision classification
We used any code from section Excision codes followed by any other revision or DAIR procedure on a
subsequent date. An excision procedure may be performed as part of a two-stage revision. Where this is
the case, it should be classified as part one of a two-stage revision, not a permanent excision. DAIR may
be performed at the same time as an excision. Where this occurs, patients are to be classified into the
permanent excision category.
Hip revision codes
W373 Revision of total prosthetic replacement of hip joint using cement.
W374 Revision of one component of total prosthetic replacement of hip joint using cement.
W383 Revision of total prosthetic replacement of hip joint not using cement.
W384 Revision of one component of total prosthetic replacement of hip joint not using cement.
W393 Revision of total prosthetic replacement of hip joint NEC.
W395 Revision of one component of total prosthetic replacement of hip joint NEC.
W933 Revision of hybrid prosthetic replacement of hip joint using cemented acetabular component.
W943 Revision of hybrid prosthetic replacement of hip joint using cemented femoral component.
W953 Revision of hybrid prosthetic replacement of hip joint using cement NEC.
Y032* Renewal of prosthesis in organ NOC.
Excision codes
Y037* Removal of prosthesis from organ NOC.
W572* Primary excision arthroplasty of joint NEC.
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Debridement (owing to deep infection) codes
W801* Open debridement and irrigation of joint.
W802* Open debridement of joint NEC.
W808* Other specified debridement and irrigation of joint.
W809* Unspecified debridement and irrigation of joint.
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Appendix 8 International Classification of
Diseases, Tenth Edition organism codes
The ICD-10 organism codes are detailed below.
B951 Streptococcus, group B, as the cause of diseases classified elsewhere.
B954 Other streptococci as the cause of diseases classified elsewhere.
B956 Staphylococcus aureus as the cause of diseases classified elsewhere.
B957 Other staphylococci as the cause of diseases classified elsewhere.
B958 Unspecified staphylococci as the cause of diseases classified elsewhere.
B961 Klebsiella pneumoniae as the cause of diseases classified elsewhere.
B962 Escherichia coli (E. coli) as the cause of diseases classified elsewhere.
B964 Proteus (mirabilis) (morganii) as the cause of diseases classified elsewhere.
B965 Pseudomonas (aeruginosa) (mallei) (pseudomallei) as the cause of diseases classified elsewhere.
B966 Bacteroides fragilis (B. fragilis) as the cause of diseases classified elsewhere.
B968 Other specified bacterial agents as the cause of diseases classified elsewhere.
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Appendix 9 Daily death probabilities from Office
for National Statistics
TABLE 72 Daily death probabilities by age (results for men and women combined)
Age (years) Probability
13 0.0000002
14 0.0000003
15 0.0000004
16 0.0000005
17 0.0000008
18 0.0000009
19 0.0000010
20 0.0000010
21 0.0000010
22 0.0000010
23 0.0000011
24 0.0000011
25 0.0000012
26 0.0000012
27 0.0000013
28 0.0000014
29 0.0000015
30 0.0000016
31 0.0000017
32 0.0000018
33 0.0000019
34 0.0000021
35 0.0000022
36 0.0000024
37 0.0000026
38 0.0000029
39 0.0000031
40 0.0000034
41 0.0000036
42 0.0000039
43 0.0000042
44 0.0000047
continued
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TABLE 72 Daily death probabilities by age (results for men and women combined) (continued )
Age (years) Probability
45 0.0000050
46 0.0000053
47 0.0000056
48 0.0000062
49 0.0000068
50 0.0000073
51 0.0000082
52 0.0000091
53 0.0000099
54 0.0000108
55 0.0000119
56 0.0000132
57 0.0000142
58 0.0000156
59 0.0000170
60 0.0000187
61 0.0000204
62 0.0000221
63 0.0000236
64 0.0000259
65 0.0000282
66 0.0000320
67 0.0000350
68 0.0000378
69 0.0000428
70 0.0000482
71 0.0000527
72 0.0000583
73 0.0000632
74 0.0000708
75 0.0000778
76 0.0000872
77 0.0000972
78 0.0001091
79 0.0001211
80 0.0001365
81 0.0001543
82 0.0001733
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TABLE 72 Daily death probabilities by age (results for men and women combined) (continued )
Age (years) Probability
83 0.0001951
84 0.0002190
85 0.0002443
86 0.0002732
87 0.0003043
88 0.0003379
89 0.0003815
90 0.0004225
91 0.0004581
92 0.0004991
93 0.0005393
94 0.0006037
95 0.0006618
96 0.0007234
97 0.0007765
98 0.0008306
99 0.0008870
100 0.0009455
Source: www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies#tab-data-tables.
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Appendix 10 How evidence was found for
health utilities
Search strategy
The first step was to define key components in order to focus the review. Commonly, these are identified
as the population, interventions and outcomes of interest.155
Population
People aged > 18 years who underwent primary THA surgery in hospital/other acute care setting and
did/did not develop an infection within the 12 months post surgery.
Interventions
No deep SSI ≤ 12 months post primary THA, deep SSI ≤ 12 months post primary THA treated with:
l permanent resection (Girdlestone arthroplasty)
l DAIR
l one-stage revision
l two-stage revision
l no infection (successful treatment) after initial treatment for SSI post THA.
Outcomes
Quality of life (instrument and scores).
The following search terms used were combinations of medical subject headings with relevant keywords.
A librarian with experience in systematic reviews was consulted for advice in regards to search terms
and strategies.
Medical subject headings
‘Arthroplasty, Replacement, Hip’, ‘Arthroplasty, Replacement’, ‘Reoperation’, ‘Infection’, ‘Hip joint –
surgery’, ‘Surgical Wound Infection’, ‘Prosthesis-Related Infections’, ‘Quality of Life’, ‘Mortality’.
Keywords
Quality of life, utility, QoL, QALY, SF-36, SF-12, EQ-5D, infection, surgical site infection, SSI, prosthetic joint
infection, PJI revision, revision arthroplasty, arthroplasty, hip, total hip arthroplasty, hip replacement,
joint replacement, debridement, DAIR, resection, Girdlestone, cost-effectiveness, CEA, CUA, mortality,
death, outcomes.
Databases searched
EBSCOhost: Academic Search Elite; Australia/New Zealand Reference Centre; Cumulative Index to Nursing
and Allied Health Literature; MEDLINE; EconLit; The Cochrane Library; The Cochrane Database of
Systematic Reviews; Database of Abstracts of Reviews of Effectiveness; The Cochrane Central Register
of Controlled Trials; The Cochrane Database of Methodology Reviews; Information about the Cochrane
Collaboration; Health Technology Assessment database; NHS Economic Evaluation Database; and PubMed.
DOI: 10.3310/hta20540 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 54
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Graves et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
143
The following selection criteria were applied for the selection of relevant articles:
Inclusion criteria
Published between January 2000 and July 2012; involving an adult patient group (as defined by study);
assessment of health outcomes related to interventions described above; quality of life reported as Short
Form questionnaire-12 items, Short Form questionnaire-36 items, 15D HRQoL, Short Form questionnaire-6
Dimensions or EQ-5D; language is English; accessible in full (not only abstract).
Exclusion criteria
Procedures related to hip fracture.
Review process
The literature searches retrieved 108 relevant titles, of which all abstracts were reviewed. As a result,
66 articles were excluded and reasons for exclusion of each study were recorded. The most common
reason for exclusion was not reporting quality of life but instead other outcomes after THA like treatment
failure or success rates (Figure 36). The full content of the remaining 42 articles was reviewed and another
18 articles were excluded thereafter. The review revealed a total of 24 papers matching the inclusion
criteria. Of these, 10 reported mortality outcomes, eight reported quality-of-life outcomes and six reported
economic evaluations using both quality-of-life and mortality outcomes. In a next step, the quality of these
studies was assessed and put in hierarchical order.
Selection and review of titles 
(n = 108)
Review of full articles 
(n = 42)
Quality assessment
Reasons for exclusion of articles (n = 66)
• No abstract available, n = 1
• No QoL reported (e.g. other outcomes such as
   treatment success, failure rate, complications), n = 52
• Other QoL measure used (e.g. WOMAC), n = 2
• No hip procedure, n = 6
• Not right time point (QoL before THA), n = 1
• Language not English, n = 4
Reasons for exclusion of articles (n = 18)
• No QoL scores reported (general/other), n = 6
• Other QoL measure used (e.g. Harris hip score,
   Oxford hip score, WOMAC, HUI, Nottingham 
   Health Profile), n = 6
• Not right time point (QoL 12 years post revision), n = 1
• QoL before/after intervention, n = 1
• No mortality rate reported (e.g. general study on
   causes of death), n = 1
• Not referring to hip procedure/interventions 
   specified (e.g. all prosthetic devices), n = 3
Inclusion of articles (n = 24)
• Mortality, n = 10
• QoL, n = 8
• Economic evaluations reporting
   QoL and mortality, n = 6
FIGURE 36 Review process of articles assessing health outcomes. HUI, Health Utilities Index; QoL, quality of life;
WOMAC, Western Ontario and McMaster University Osteoarthritis Index.
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